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ABSTRACT
[^H]-Paroxetine and [^H]-imipramine are known to label with high affinity, a site which is 
associated with the serotonergic transporter in brain and platelets. [^H]-imipramine binding
to platelet membranes appears to be a biological marker in depression, the B^ax of platelet
imipramine binding being significantly decreased in untreated depressed patients by 
comparison with healthy volunteers.
Psychotherapy is claimed to produce significant improvement in depressed subjects without 
the use of drugs. This study aimed to determine whether differences were apparent in 
binding values for [^HJ-paroxetine and [^HJ-imipramine binding in subjects suffering fix)m 
mild depression compared to controls, and how these values changed as the subjects went 
through a period of psychotherapy. In addition, psychiatric state was assessed using the 
BDI, the MAACL and the GHQ-28. Binding levels were then correlated with the scores 
obtained from the self-administered questionnaires to determine the relationship between 
binding and psychological state. Similar data were also collected from a group of nurses, 
who it was predicted would be suffering from a higher level of depression than the general 
population and would remain untreated.
The results from the psychotherapy group indicated that clients entering the study were 
significantly more depressed than controls (BDI P<0.05; MAACL P<0.01 GHQ-28 
(excluding somatic symptoms) P<0.05) and had lower imipramine binding. Furthermore as 
they went through the period of psychotherapy their psychological test scores fell, and 
imipramine binding levels rose, to a level equivalent to the control values. Levels of 
[^H]-paroxetine binding to platelets did not appear to be affected by psychological state, at 
least in these patients. ^
In the group of nurses, both binding measurements were significantly lower than controls 
at most time points throughout the study (P<0.05) indicating lower affect. However 
psychological questionnaires indicated less distress in the nurses group than the control
1
group (particularly BDI and GHQ-28). This is discussed in terms of possible coping 
strategies employed by nurses.
It was not possible to correlate the questionnaire scores with the results from the binding 
assays for clients, controls or nurses. There was no significant evidence of sex differences, 
either in binding parameters or questionnaire scores, and no evidence of seasonality of the 
binding levels. Proposals for future work are suggested.
CHAPTER 1 
INTRODUCTION
Within the many approaches to the explanation and treatment of psychic disorders, it is 
possible to distinguish two broad traditions, often seen in the past, not merely as alternative 
but in actual contradiction with each other. Although the two schools of thought are now 
recognising the values and usefulness of each other to a greater extent, differences and 
prejudices still exist. To simplify, the two views may be presented as follows. On the one 
hand, biological psychiatry is committed to the view that much if not all psychiatric illness 
is the consequence of disordered molecular mechanisms within the brain, and that the 
appropriate treatment is therefore by means of drugs which interact with neurochemical 
systems in such a way as to rectify or alleviate molecular imbalances or deficits. On the 
other hand, the psychotherapeutic tradition seeks to explain psychic distress in terms of 
precipitating events in an individual's past life, whether in the distant past of early infancy 
or childhood trauma, or in the crises of present circumstances and way of living. Therapy 
then involves revealing and coming to terms with past personal history and learning to live 
with or transcend present difficulties. Protagonists of each of the two distinct traditions 
have frequently been sceptical or even hostile to the claims of the other.
Biological psychiatry has been critical of psychotherapy as not conforming to the nonns of 
science to which biomedicine aspires, as being expensive for the patient and dubious in 
outcome. There has been a vigorous polemic in the literature about the significance and 
interpretation of the various outcome studies in psychotherapy which have been undertaken 
in the past two decades, over, for instance, whether psychotherapy is more effective than 
"placebo" treatment - or what constitutes a placebo in the context of the particular 
relationship of therapist to client. Additionally, if psychotherapy is effective, is any one of 
its many varieties more effective than any other? (e.g. Smith et al. 1980; Prioleau et al. 
1983; De Witt et a l . 1983; Aveline 1984; Shepherd 1984; Holden 1986 ).
On the other hand, psychotherapy has criticised biological psychiatry for its reductionist
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philosophy, in which existential distress is perceived as epiphenomenal to mere molecular 
happenings, and has charged it with mistaking symptoms for causes, and ignoring the 
whole person in his or her psychic and social context in favour of the administration of 
drugs which may mask rather than treat a condition - or may even have iatrogenic 
consequences. Again, there is an extensive literature.(e.g. Sedgwick 1982; Hill 1983)
It was the aim of this project to explore the possibility of approaches which might help to 
bridge the gap between these two broad therapeutic traditions. I begin from the position 
that any scientific theory of human behaviour, intentions and actions must assume that 
brain processes on the one hand, and human experiential states (to put it at its most general) 
on the other, must be related. It therefore follows that there are biological (or more 
specifically biochemical) ways in which the brain state of, for example, a depressed person 
differs from that of the same person when "normal" - that is, when not depressed - or from 
the average brain state of a population of undepressed and unanxious people. Hence, in so 
far as psychotherapy modifies a person's experiential state, it must also modify their 
biology and brain state (Rose 1984). In so far as biological psychiatry and psychotherapy 
have similar outcomes in improving a psychically distressed person's condition, their 
effects on that person's biology and brain state are likely to be similar.
Two things follow. If the claims of biological psychiatry are valid, there should be 
biochemical markers for conditions diagnosed as depression, anxiety and the affective 
disorders in general. If the claims of psychotherapy are valid, then psychotherapeutic 
treatment of persons suffering from one of the affective disorders should not merely 
improve their psychic state but should result in changes in the biochemical marker(s) for the 
condition. If such a change, in a marker accepted by biological psychiatry, could be shown 
to occur as a consequence of psychotherapeutic treatment, it would be of considerable 
theoretical and social interest in helping to bridge the gap between "biological" and 
"psychic" modes of accounting for psychic distress, and also between biological psychiatry 
and psychotherapy as modes of treatment for that distress. The outcome of this research 
could therefore be of help in developing and improving rational treatment approaches. 
Furthermore it was hoped that the data would provide longitudinal evidence of biochemical
changes in brain state correlated with psychological changes.
It was not the intention of this research to try and determine whether or not psychotherapy 
was an effective treatment for depression or not, and no placebo control group was 
employed. The definition of placebo as proposed by Shapiro (1964) is as follows "any 
therapeutic procedure (or that component of any therapeutic procedure) which is given 
deliberately to have an effect on a patient, symptom syndrome or disease, but is objectively 
without specific activity for the condition being treated". It would have been extremely 
difficult to provide a useful placebo group for this study for the following reasons. Firstly 
it is very difficult to control for psychotherapy using a placebo pill, not least because the 
patient will know which treatment they are receiving, and the ethical issues of using 
placebo outside a rigorous clinical setting are enormous. It is often said that placebo 
deceives the patient, although providing adequate explanation of the study is given, this 
should not be the case.
Secondly I was only intending to use a very mildly depressed group and knew the sample 
size would be relatively small. Placebo response rates in drug trials of antidepressants are 
very high (around 30-50%) and are greatest in patients with less chronic depression (Khan 
et al 1991). This is due to; the placebo effect per se, the warmth and encouragement of 
medical staff, the assignment of the 'sick role' (which helps relationships with family, 
friends and employers), the faith that both the patient and the physician has in the 
medication and extensive analysis as part of the diagnostic procedure. There is also 
evidence of a dose response' in placebo trials, where the more tablets the patient is given 
the more they improve. Given the small sample size it was not likely to detect a difference 
between effective treatment (around 60-70% with anti-depressants, (Brown 1988)) and 
placebo. Therefore the control sample was chosen as a 'normal* group in whom no change 
was predicted.
The third major problem with using a placebo control is the risk of suicide. Suicidal 
ideation is widely recognised as a common symptom of depression (Blumenthal 1988, 
Montgomery et al 1988; Adam 1985) and is not directly related to the severity of the
depression - in fact a very common time for patients to commit suicide is as they start to 
recover. Various studies have estimated that between 50 to 90% of people who commit 
suicide are suffering from depression and 35-79% of suicide attempters (Review Adam 
1985). The variation in these data is probably largely due to the inaccuracy of retrospective 
analysis.
Several studies in the past have used waiting list patients as controls and in this way 
attempted to compensate for spontaneous remission of the disease. However in this study it 
would have meant clients waiting for one year before receiving any help, and this is 
obviously unethical. Other researchers have used inexperienced therapists working with 
patients to act as controls, however given the complex and delicate nature of the 
therapist/patient interaction this approach is potentially very dangerous.
The group of control subjects used in this study were taken from the Open University and 
were intended to act as a population 'norm'. It was assumed that they would not be 
suffering from any depressive disorder or any significant level of stress. To expand the 
scope of the study it was decided to add a group of nurses, who are known to suffer from 
a higher level of stress and depression than any other members of the health profession 
(Wolfgang 1988a) although stress levels tend to be high in all health professionals (e.g. 
McCue 1986).
Stress is not necessarily negative, it is a natural adaptive response to job and organisational 
demands, constraints or opportunities. But when it becomes too severe it can seriously 
impair the performance of the employee in the work environment and eventually at home. 
The general work stress health model (e.g. House 1981; Katz and Kahn 1978) postulates 
that objective work conditions can lead to perceptions of stress. Perceived stress in turn 
leads to boredom, dissatisfaction and turnover, and to individual strains such as anxiety, 
depression and physical illness. Additionally the stress health model hypothesises that 
internal characteristics (i.e.personal characteristics) and external characteristics (i.e. the 
situation) will have both direct and interactive or moderating effects. A relatively consistent 
link has been established between perceived role stress, satisfaction and psychological
well-being. However attempts to confirm the moderating effects of factors such as social 
support have had only limited success (Bheer and Bhagat 1985; Cohen and Wills 1985). 
Sutton and Kahn (1986) proposed that understanding of events, prediction of events and 
control of events would reduce perceived stress and increase satisfaction and well-being. 
The hypothesis was tested by Tetrick and LaRocco (1987) and whilst some improvements 
were made in levels of perceived stress and satisfaction, there was no change in 
psychological well-being.
The sources of stress in nursing can broadly be considered as threefold. Firstly there are 
the fundamental conflicts; such as being responsible for other peoples lives. Secondly there 
is the issue of stereotypes; idealised stereotypes conflict with unpleasant work and failing to 
cure the patient. Thirdly there is social relevance; nurses are isolated to control the issues 
they symbolise - through professionalism and social isolation (Marshall 1986). More 
specifically the identified stressors are; the death of patients, uncertainty about patient 
treatment, inability to meet patient needs and expectations, looking after dying babies, 
facing staff shortages, communication and interpersonal problems with medical staff and 
supervisors, family and life crises, poor self esteem, insecurity about ones knowledge and 
competence and fear of failure (Anderson and Basteyns 1981; Bailey et al 1980; Barstow 
1980; Boxall and Garcia 1983; Cronin-Stubbs and Velsor-Friedrich 1981; Dewe 1987: 
Fountain 1984; Gray-Toft and Andersson 1981; Ivancevich and Matteson 1980; Marcus’ 
and Popovic 1985; Parkes 1985).
Whether or not different types of nursing are more stressed than others is a well researched 
area from which it is very difficult to draw any conclusions. Parkes (1980;1982) found that 
generally medical wards were more stressful than surgical whereas Ivancevich et al (1982) 
found no significant difference. In another study Cavagnaro (1983) compared stress factors 
of critical care nurses with other units and found they were significantly more stressed than 
anesthetic nurses. However Keanne et al (1985) did not find any significant difference in 
burnout reported by intensive care unit (ICU) versus non-ICU nurses, and Chiriboga and 
Bailey(1986) also found no difference in burnout rate between critical care and non-critical 
care nurses. Studies comparing nurses from cancer units with other units have found
significantly more mood swings, relational problems and difficulties in discussing the 
patients condition than other units (Gray-Toft and Anderson 1986). A study of psychiatric 
nurses (De Leo et al 1982) found that psychiatric nurses were more likely to suffer from 
depression and to a lesser extent anxiety than general nurses. Overall it is not clear whether 
any one type of nursing is more stressful than others, what appears to be more important is 
the working environment (Chiriboga and Bailey 1986). Motowidlo et al (1986) in a pair of 
large studies involving nearly 400 nurses identified interpersonal aspects of job 
performance (e.g. sensitivity, warmth, tolerance) and cognitive/motivational aspects (e.g. 
concentration, composure, perseverance and adaptability) as the factors which most 
significantly correlated with self-reported perceptions of stressful events, subjective stress 
depression and hostility. They identified 45 stressful events for nurses and hypothesised 
that the frequency and subjective intensity of these events leads to depression which in turn 
causes a deterioration of interpersonal and cognitive/motivational aspects of job 
performance. Age appears to be a very important factor in the amount of stress experienced 
by nurses (e.g. Livingstone and Livingstone 1984) the younger the nurse, the more likely 
they are to suffer from stress. Numerof and Abrams (1984) have argued that the citing of 
factors such as feelings of insecurity, to account for nursing stress rests largely on 
anecdotal evidence. They list age, role status, time since graduation, job tenure, area of 
nursing and interpersonal needs as the most important factors in job stress. The majority of 
work on nurses has focused generally on stress rather than looking directly at depression, 
however it is well established that stress and depression are closely associated.
GENERAL HYPOTHESES
In view of the the general concepts discussed above, the hypotheses for this research 
were:-
a) Clients in psychotherapy and nurses would be more depressed than controls at the start 
of the study, and this would be detectable both by psychological questionnaires and by one 
or more biochemical marker(s).
b) That as the study progresses the scores from the psychological questionnaires and the 
biochemical marker(s) will improve for the clients such that their values approach similar
8
levels to the controls.
c) That the nurses scores on psychological questionnaires and biochemical markers will not 
improve over the time course of the study.
CHAPTERS
DEPRESSION: THE DISORDER AND OPTIONS FOR TREATMENT 
How is depression defined?
Everyone has at some time in their lives felt "depressed", this is a normal experience in 
times of adversity. It is largely for this reason that clinical depression is so hard to define 
and so often misunderstood. The term depression may refer to an ephemeral mood, a 
sustained affective change, a symptom, a syndrome or a psychiatric illness. Depression as 
a result of adverse circumstances or bereavement is considered "normal", but when it 
becomes inappropriate in severity, persistence or precipitating circumstances it is 
considered "abnormal" and requiring treatment. It is important to remember that it is largely 
not the individual, but society, which dictates the limits for "normality". This is exemplified 
rather neatly by a quote from the seventeenth century playwright Nathaniel Lee "They 
called me mad" he protested "and I called them mad and damn them they outvoted me" 
(Potter 1991). Although depression can be secondary to a number of factors (physical 
illness,other psychiatric illness or drug therapy) it is most commonly the primary condition 
characterised by a wide range of symptoms. Depression is heterogeneous with regard to 
biology, treatment response and prognosis. Therefore depression probably consists of a 
number of pathophysiologically distinct conditions which we arbitrarily classify as one. 
This is illustrated by the variety of descriptions of depression given by depressed people. 
Naime and Smith (1984) quote a number of patients, examples of which are given below.
"For me, to be depressed means a cold empty feeling that I haven't been nice enough to be 
happy" Janice
"Depression feels like I can't handle anything anymore. It feels like things are not in my 
control" Theresa
"I feel as though I'm at a fancy dress party wearing a sack. Nobody can guess who is 
inside it and I cannot explain who I am " Penny
"Depression overcomes your whole being. You seem to be enveloped by feeling low. It
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erodes your confidence and your motivation. You want to withdraw into a world of your 
own and opt out of the ordinary world". Patricia
Depression is broadly subdivided in terms of causality and symptomatology as shown in 
the quotes below taken from the Penguin dictionary of psychology (Reber 1985):
Endogenous depression "Depression resulting from "internal" factors. The term is 
used clinically when there is no apparent precipitant (Many clinicians now prefer not to use 
this term believing that there will always be a precipitating event.)
Exogenous / Reactive depression Depression resulting from events occurring in 
one's life.
Neurotic depression "Ordinary" severe depression (used to cover any depression that is 
not psychotic)
Psychotic depression Severe depression in which the individual loses contact with 
reality and suffers from an array of impairments of normal functioning.
Unipolar depression The qualifier unipolar is used for cases in which the depressive 
episodes recur without the appearance of the manic phase that is observed in the classic 
form of Bipolar disorder.
With the exception of unipolar versus bipolar the above definitions are losing popularity 
(Opjordsmoen 1991). Unipolar and bipolar depression are more clearly different in their 
symptomatology and although they have been argued to be clinically and genetically 
homogeneous, different treatments are often used for the two disorders (e.g. Lithium has 
tended to be used for bipolar disorder - although it is also used in unipolar disorder).
A Sociological view of depression
Although depression is an illness common to all classes of society, it occurs with highest 
frequency amongst poorer working class females. Brown and Harris in 1978 studied the 
incidence of neuroses ( using the Present State Examination FSE) in the Camberwell area ( 
a mainly working class area of inner London) and found that about one quarter of working
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class women with children were suffering from some form of neurosis - mainly severe 
depression. The incidence amongst a similar group of middle class women was only 6 
percent. A large proportion of these depressed individuals had suffered severe threatening 
events in their lives within the last year, such as loss of husband or income. The use of 
drugs, and in particular tranquilisers was very high.
Brown (1977) argues that depression is a social phenomenon. In comparison to the women 
studied in inner London depression is almost absent from women with children living in 
the Outer Hebrides irrespective of social class. Brown argues that biological or genetic 
factors are unlikely to have a primary role in the aetiology of the disease, but does not argue 
that they are not implicated. He believes that depression is precipitated by certain kinds of 
severe life events and difficulties and found that this correlated well with women suffering 
from depression whether or not they had been previously diagnosed or were picked up by 
the investigation. However the provoking agents themselves are not sufficient to bring 
about the disease, although they do determine when the disorder occurs. This was 
illustrated in the studies mentioned earlier, in that a severe life event and or difficulty is 
more likely to precipitate depression in a working class mother in inner London than a 
middle class mother in inner London, who is more likely to develop depression than a 
woman of either class living in the Outer Hebrides.
In addition there are a set of vulnerability factors which make a precipitating event more 
likely to result in a bout of depression. These are the lack of a close relationship with a 
husband or boyfriend, three or more children under fifteen at home, unemployment and 
loss of the mother before the age of eleven. Loss of other relatives during childhood or 
parental separation can also influence the type and severity of the depressive episode. 
Brown (1977) termed these 'symptom formation factors', loss by death is strongly 
associated with psychotic-like depressive symptoms whereas other losses such as parents 
separating is more likely to lead to neurotic-like depressive symptoms. Two crucial facts 
emerge from this model: firstly, provoking life events involve major losses, or sometimes 
major difficulties or threat of loss; secondly, if no vulnerability factors are present then 
provoking agents rarely bring about depression. Oatley (1984) described depression as
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occurring when a person has suffered a serious crisis but has no immediate way of putting 
it right.
Low self esteem appears to be the common feature behind all four vulnerability factors, and 
this is perhaps the most important point behind the sociological model. It is not the loss 
itself that is important but the capacity of the individual to believe in the future; in response 
to a provoking event they are most likely to feel a sense of hopelessness if they have low 
self-esteem. If this develops into a general hopelessness then this can form the central 
feature of the depressive episode. Self-esteem is also important in that it allows the person 
to go through a proper grieving process and therefore complications leading to depression 
are less likely to arise. Brown strongly emphasises the cognitive aspect of depression (see 
Chapter 3) arguing that perceptions of abandonment lead to psychotic symptoms, whereas 
perceptions of rejection and failure lead to neurotic symptoms. Brown and Harris’s 
findings in Camberwell and the Outer Hebrides have been confirmed by closely replicated 
studies in Oxford, Sheffield and Calgary. Some recent research by Garnefski and 
co-workers (1990) has expanded the idea of low self esteem being very important in the 
development of depression. They found in a group of women aged 22 to 64 years that 
difficulties in recent and present relationships with parents, partners and others and low self 
esteem were all likely to predict that the depressive episode would be severe. They also 
found that experience of physical or sexual abuse before the age of 19 was strongly 
associated with the severity of depression. Undertreatment of depression in adolescents is 
now being recognised together with the implications for the future of the individual if the 
episode is not treated (Keller et al 1991).
Diagnosis of depression
A major pitfall in the treatment of depression is the problem of accurate diagnosis and this 
also compounds the difficulties encountered in research in this area. For a diagnosis to be 
useful, it must make a statement about the patient's condition such that treatment selection, 
prognostication and communication are facilitated. The strongest argument in favour of 
rigid diagnosis is that as treatments become more selective, more restrictive diagnostic
13
groups are needed, (although this argument is obviously rather a circular one). Researchers 
in particular tend to prefer very narrowly defined categories in an attempt to reduce 
heterogeneity within their studies, consequently ; new sub-types of depression continue to 
be "discovered" e.g. recurrent brief depression (Angst et al 1990). However, rigid 
categories can only be truly useful if they are correct, and the problems that occur in 
accurate diagnosis of depression are enormous (Rush 1990). Many psychiatrists now use 
the DSM-III-R ( American Psychiatric Association 1987) or the Research Diagnostic 
Criteria - RDC (Spitzer et al 1978) but even with these, sources of variance are high. 
Subject variance can arise from a specific patient having different diagnoses at different 
times. Occasion variance can arise if a patient with the same underlying condition presents 
with different symptoms on different occasions. Information variance can occur when 
diagnosticians obtain information from two different sources or ask different questions of 
the same source. Observer variance, is perhaps the most important, and occurs when two 
clinicians observe the same information or data differently. Criterion variance occurs when 
clinicians gather the same data but render different diagnoses because they use different 
criteria. For example, some patients with schizoaffective disorder according to RDC will be 
diagnosed as having psychotic depression with mood incongruent features by DSM-III-R.
If one looks at the use of self-administered rating scales, then problems of observer 
variance are immediately removed. The reliability of these questionnaires to give an 
indication of the severity of the disorder is good, for example the BDI (the Beck 
Depression Index - designed to measure depression) when compared with a clinical 
diagnosis has been shown to have correlation coefficients of 0.6 to 0.74 (Feightner and 
Worralll990). The BDI is also a good marker of change in a patient and therefore allows 
monitoring of the patient to take place without the intervention of a physician.
The essential features of an episode of depression are either depressed mood (often seen as 
irritability in adolescents and children) or most commonly, and most significantly 
anhedonia. The symptoms will represent a change from the previous functioning of the 
individual and they will be relatively persistent.
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The appearance of depressed patients is often changed in a very characteristic fashion. 
Dress and grooming may be neglected. The facial features are often characterised by a 
turning downwards of the comers of the mouth and by vertical furrowing of the centre of 
the brow. The rate of blinking may be reduced, shoulders bent and gaze averted 
downwards with minimal gestural movements. However it is very important to stress that 
many patients show no outward signs and will deny feelings of depression. They may 
instead present with a variety of different symptoms and will need extensive and very 
sensitive interviewing to determine the underlying condition. Psychomotor retardation is 
frequent- although some patients may be agitated. The overall mood of the patients is one 
of misery which does not improve under circumstances which would normally be expected 
to elevate mood. The mood is often different from normal sadness - many patients speak of 
a black cloud pervading all mental activities. Patients will often conceal this mood from 
other people, due to the fact that depression is still socially unacceptable, and this makes it 
very hard for a doctor to detect.
Anxiety is very commonly associated with depression particularly in the less severe cases. 
Agitation and irritability often accompany depressive episodes sometimes in conjunction 
with loss of energy, this combination of symptoms can be very confusing for the observer. 
In a recent study, Zung et al (1990) found the comorbidity of anxiety and depression to be 
as high as 67%.
Pessimistic thoughts ("depressive cognitions") are important symptoms which can be 
divided into three groups. The first group is concerned with the present. The person sees 
the unhappy side of every event, feels he or she is a failure and lacks confidence. The 
second group of thoughts is concerned with the future. The depressed patient expects the 
worst from everything, he or she may feel that life is no longer worth living and may even 
contemplate suicide. The third group of thoughts are concerned with the past. They often 
take the form of unreasonable guilt and self-blame about minor matters. Preoccupations of 
this kind strongly suggest depressive disorder.
A group of symptoms often termed "biological” are extremely important. They include
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sleep disturbance, diurnal variation in mood, loss of appetite, loss of weight (or sometimes 
excessive weight gain), constipation, loss of libido and among women, amenorrhoea. 
These symptoms become more common with increasing severity of the illness.
The extent of the problem
The vast majority of patients suffering from a depressive episode will be treated by their 
general practitioner, and certainly the patients seen by the Open Centre which were 
involved in the following piece of research, would fall into this category. Relatively very 
few patients are actually referred to a psychiatrist and still fewer are hospitalised. In view of 
this I shall concentrate on the incidence of depression as seen by the General Practitioner.
Community surveys of the prevalence of depression have generated estimates of 3.5-27% 
(Prestidge and Lake 1987; Weissman and Myers 1978 a and b). Clearly such estimates are 
affected by the choice of criteria defining depression, the population studied, the 
assessment methods and the time scale. As early as 1947 (Watts 1947) , attention was 
drawn to the problem of depression in general practice, 'endogenous depression’ being 
much more common than was previously appreciated. The problem in assessing the 
incidence of depression often lies in the derinition of caseness (i.e. at what point a set of 
complaints becomes serious enough to be considered epidemiologically, sociologically or 
clinically significant) and this has made interpretation of studies difficult. Determining the 
appropriate cut-off points for case identification to allow detection of milder disorders is 
thus an incredibly complicated task. A well known study by Shepherd et al (1966) found 
that within a range of London practices 7% of men and 13% of women "usually felt 
unhappy", 2% and 6% respectively "felt so unhappy that they wished they were dead", 
1.8% and 2.5% always "felt miserable and blue", and 2.7% males and 4.4% females "felt 
life was entirely hopeless". Their pooled practice figures for all forms of psychiatric illness 
in their sample revealed a total prevalence rate of 140 per 1,000 persons at risk with female 
cases predominating in a ratio of nearly two to one. Over the last decade our understanding 
of the epidemiological features of depression has considerably improved. And it now 
appears that between 15-30% of adults experience clinically significant depression at some
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point in their lives. Many studies use the definition of a cut off score on a psychological 
questionnaire e.g. Nielsen and Williams (1980) using the BDI found 19.8% of patients 
scored above 10 on the BDI, Zung et al (1983) used the Zung Self-rated Depression Scale 
(SDS) and found 13.2% scored above 55 and Hankin and Locke (1983) found 21% of 
patients scored above 16 on the CES-D. As this evidence shows, the experience of 
depression is itself a common one in the primary care situation. However it must be 
stressed that further examination of such patients shows that only a small proportion of 
them fulfil diagnostic criteria for depressive disorder as defined in DSM-III-R ( Diagnostic 
and Statistical Manual of Mental Disorders). The Epidemiological Catchment Area study 
(Regier et al 1984), involving over 18 (XX) people, identified a 6-month prevalence rate of 
2.2-3.5% for major depression. This really highlights the point made in the opening part of 
this chapter, that it is society who dictates what is and is not normal, after all if so many 
people are affected then is it "abnormal"?.
The reliability of epidemiological studies in general practice has been greatly enhanced by 
more rigorous definitions of caseness due mainly to the provision of structured interview 
and diagnostic instruments such as the Present State Examination (FSE) (Wing et al 1974) 
and the Research Diagnostic Criteria (RDC) (Spitzer et al 1978). Nevertheless these tools 
are far from perfect and fail to account for the GP's opinion on the patient's personality, 
physical illnesses and other important axes which will exert a strong influence on the 
physicians normal case-making decision.
More reliable studies of depressive disorder which avoid the problem of case definition by 
GP's include those of Wright et al (1980) and Nielsen and Williams (1980). Wright 
reported a high rate for RDC depressive disorder of 17% of consulting patients. Nielsen 
and Williams found that 10% of consulting patients fulfilled the diagnosis of 'Depressive 
Neurosis' (DSM-III). Another study by Casey et a/(1984) revealed a figure for overall 
psychiatric morbidity of 7% - roughly half that found by Shepherd et al in 1966. Many 
clinicians have expressed the opinion that these figures are too low and represent the fact 
that many patients go unrecognised.
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Many GPs have their own ways of defining caseness and labelling disorder (Clare 1982). 
In particular, many GP's resort to the notion of a disorder's 'understandabiliiy' in defining 
caseness, e.g. life events, social problems, relationship difficulties. The role these social 
factors play in the context of depression is complex and very poorly understood (Jenkin 
and Shepherd 1983) particularly in the GP setting. It is in this area that the psychotherapies 
concentrate, by identifying causes of the depression, allowing the patient to understand 
them, and showing the patient how to overcome them. It is perhaps for this reason that 
psychotherapy is most commonly regarded as a means of relapse prevention in recurrent 
depression than as an acute treatment (Miller et al 1989).
Epidemiological studies, by their very nature, require a high recruitment if questionnaires 
such as the General Health Questionnaire are to be used. The reason for this is that primary 
care patients are usually the most reluctant to participate in questionnaires and interviews, 
and those least willing to participate are very likely to be suffering from some sort of 
emotional distress e.g. bereavement or psychiatric disorder (typically alcoholism, 
personality disorder and major depression). Their non-inclusion therefore exerts a powerful 
influence upon prevalence rates.
The definitive epidemiological study in primary care remains to be done due to the many 
methodological problems outlined above. However we can be sure that depression is a 
common, debilitating, often misunderstood disease, and as I shall demonstrate later one 
requiring more methods of treatment particularly for patients who suffer relapses.
Concern has been expressed that the incidence of depression is increasing and that the 
world is entering an age of melancholy (Jablensky 1987)
Sociodemographic factors
Exposure to general practice tends to give the impression that the majority of depressives 
are young, working class women, but this may be due to to the fact that young women are 
over-represented in this setting, Tischler at al (1975 a and b) reported that single,
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unemployed people, living on their own were the greatest user of general practice services 
when compared with other groups from the general population from which they were 
drawn. Marks et al (1979) demonstrated that doctors are more likely to detect psychiatric 
disorder in women than in men. Henderson (1981) showed that depressed people tended to 
devalue or underestimate the true nature of their supportive relationships. Few studies have 
controlled for other variables, although interestingly it appears that marriage increases the 
likelihood of a depressive episode in women, and decreases it in men (Hallstrom 1973: 
Radloff 1975). Three factors - gender, age and socioeconomic status, appear to be very 
important in the incidence of onset of depression.
Gender:- Almost all studies of depression conducted in general practice report a gender 
distribution in which women outnumber men. General population studies report a gender 
ratio for various depressive disorders of approximately 2:1 (Robins et al 1984, Myers et al 
1984) although in the general practice setting this is higher e.g. Sireling et al (1985), 
General population studies have shown that men are less likely than women to seek 
professional help when depressed (Weissman and Klerman 1977, Roberts and Vernon,
1982). Why women show a higher incidence of depression than men is not clear although 
it may, in part, be due to poorer treatment outcome, particularly in older women (Sargeant 
et al 1990). It may also be wrong to particularly identify women as being at risk from 
depression, there may also be a tendency towards sexism in diagnosis or it may be simply 
that men show it in different ways e.g. through violence or substance abuse, thus earning a 
label of personality disorder.
Age:- Depressive illness has traditionally been considered a disorder of middle-age and 
onwards, for instance Dunn and Skuse (1981) found that women became progressively 
more likely to consult for depression as they grew older and that they were less likely than 
men to recover once depressed. However Mazer in 1967 noted that the peak age group for 
women complaining of disorders which were predominantly psychoneurotic in nature was 
25-34 years (men peaked about a decade later). Other primary care studies have supported 
the view that younger females seem to be especially at risk from depression (Porter 1970; 
Bemdt et al 1983; Sireling et al 1985) Several studies in the general population indicate that
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young adults have more symptoms of depression and symptoms of a greater intensity than 
older age groups (e.g. Craig and Van Natta 1979; Weissman et al 1981; Robins et al 
1984). This has led to a need for greater examination of the processes of mental 
development in young adults and adolescents (Burke et al 1990).
In an elderly population depression is most likely to occur with advancing age, although 
other factors such as loss or serious illness of a partner, being alone, few hobbies and poor 
social participation are very important (Pahkala et al 1991)
Socioeconomic status:- Numerous studies have shown that the single most important 
predictor of score on a self report questionnaire was socioeconomic status. The higher the 
status or educational level, the less likely the person was to describe themselves as 
depressed (e.g. Nielsen and Williams 1980: Wright et al 1980; Robins et al 1984). 
Symptoms of depression are commonest in the lower social classes, but bipolar depression 
appears to be commonest in the upper social classes (McCormick 1989).
" • i .  i
Recent research by Sargeant et al (1990) has shown that the factors that are most likely to 
predict a poor treatment outcome are, high rates of relapse, chronicity and poor 
psychosocial environment. They did not find any evidence that sociodemographic factors 
could influence the outcome of a depressive episode once it had started. Other research, 
however has indicated that the number of previous episodes is not predictive of outcome 
(Gurguis et al 1990)
Treatm ent of depression in general practice
Given that depression is such a common problem, it is not surprising that most depressive 
illness is dealt with by the family practitioner, despite the fact that the GP is often ill 
equipped to deal with it. As early as 1966, Watts suggested that a motivated GP should be 
able to treat 90% of his depressed patients at home, emphasising that this was not only less 
costly than specialist care, but far better for the patients as it enabled them to maintain 
important ties with the family and community. Depressed patients often experience
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difficulties in their relationships with others, and it is an important part of any healing 
process that they learn to deal with this aspect of their life.
The mainstays of therapy have been tricyclics, Monoamine Oxidase inhibitors (MAOI's), 
"new generation" antidepressants and psychotherapy. Tricyclic antidepressants have long 
been considered to be effective and to decrease at least to some extent the risk of early 
relapse (Rogers and Clay 1975: Mindham et al 1973) Similar support exists for monoamine 
oxidase inhibitors (Robinson et al 1973), but thé potential side effects have limited their 
use. Psychotherapy, although widely practised and generally accepted as being effective, is 
more difficult to study, and the results of these evaluations are often very hard to interpret 
compared to drug trials. Most reviews of randomised controlled trials and meta-analyses, 
however, do support the effectiveness of psychotherapy (Weissman 1979: Steinbrueck etal
1983). Combined treatment with antidepressants and psychotherapy may produce better 
outcomes than either treatment alone (Beck et al 1985: Teasdale et al 1984: Blackburn etal 
1981).
Recent concern in both the medical journals and the popular press of apparent over 
prescribing of psychotropic medication has lead to increased public awareness of the 
possible side-effects of these medications. Although tricyclics, MAOI's and the new 
second generation antidepressants have broadly equal efficacy, they vary in their side effect 
profile and potential toxicity (Rudorfer and Potter 1989; Schulz and Dick 1989; Paykel 
1988; Baldessarini 1989). GPs are often criticised from within their own profession by 
psychiatrists, who accuse them of using antidepressants and anxiolytics in an inappropriate 
manner (e.g. Weissman et al 1981) or at sub-therapeutic doses (Parish 1982). In defence of 
the GP it should be pointed out that prescribing of psychoactive drugs to patients who are 
otherwise still leading normal lives is a very fine balancing act.
Given that antidepressants are so commonly prescribed how effective are they, and do the 
benefits out-weigh the risks? Published placebo controlled studies of antidepressant drugs 
are rare and many show no greater efficacy for the active medication than placebo. For 
example Gomez and Gomez (1988) and Porter (1970) were unable to demonstrate
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significant efficacy of 75mg Amitriptyline or 75-150mg Imipramine respectively over 
placebo. However Hollyman et al in 1988 found that whilst 75mg of Amitriptyline was 
ineffective, 160mg was efficacious. More recent work by Thompson and Thompson in 
1989(a) showed that low dose dothiepin (75mg/day) had no significant advantage over 
placebo, indeed on measures of depression and somatic symptoms, the placebo patients 
that completed the trial were more greatly improved. An important point to note at this 
stage is the difficulty in ascertaining efficacy in trials of this kind. As previously mentioned 
the diagnosis and assessment of depression is extremely vague and can result in small 
differences being lost due to huge individual variation.
Many studies indicate greater efficacy at higher doses, however many psychoactive drugs 
have unpleasant and even lethal side effects. The majority of patients will recover from 
depression whether or not they are treated with antidepressants, therefore it is important 
that these drugs are used carefully and discriminately. A physician must consider carefully 
the side-effect profile and the overdose toxicity of a drug when deciding what to prescribe. 
For instance the older tricyclics such as amitriptyline should be used with caution in 
patients with ischaemic heart disease. They also have pronounced anti-cholinergic side 
effects such as dry mouth, sweating, postural hypotension and tachycardia.» The 
antihistaminic actions of some antidepressants result in sedation (e.g. amitriptyline, 
mianserin, dothiepin) which has been proven to reduce the patients ability to drive and 
increase the likelihood of the patient having an accident at home or work. This obviously 
causes problems for the GP patient and may result in non-compliance (e.g. Thompson and 
Thompson 1989b). New antidepressants are continually being developed and a whole host 
of 5-HT uptake inhibitors are now being marketed. These include paroxetine, fluvoxamine, 
sertraline, citalopram and fluoxetine, they are as effective as the traditional tricyclic 
medication but lack anti-cholinergic side-effects (Aberg Wistedt 1989; Dechant and Clissold 
1991; Langdon 1991;Harris et al 1991; Ottevanger 1991a; Smith and Dunbar 1991; 
Lamelle et al 1991) and may also be effective as longterm preventative treatment for 
recurrent depression (Jakovljevic and Mewett 1991) and have limited effects on 
psychomotor function (Kerr et al 1991). However they may have a whole new side-effect 
profile of their own, fluoxetine has been implicated in suicidal ideation, although in
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depression this is difficult to prove (Creaney et al. 1991; Ottevanger 1991b) and also in acts 
of violence ( fluoxetine prescription is being used as a defence by American lawyers in 
murder cases).
A major consideration in the treatment of depression is that of all the affective disorders, 
treatment failure is most likely to result in deliberate self-harm (e.g. Urwin and Gibbons 
1979) . A number of studies have indicated that many people who attempt or commit 
suicide have had contact with medical services, particularly GPs, shortly before their 
attempt or death. (e.g.Tumer, 1982; Skegg et al, 1983; and Diekstra 1984). The use of 
antidepressant medication as a primary therapeutic agent to alleviate suicidal ideation has 
been advocated by some authors (e.g. Goldney and Pilowsky 1980). However there is 
very little evidence that antidepressants can decrease suicidal behaviour in the clinical 
setting (Hirsch et al 1985; Montgomery and Montgomery 1982; Adam et al 1983), although 
Montgomery et al (1983) found a small benefit of flupenthixol over placebo and 
Ottevanger (1991a) has also claimed similar efficacy for Fluvoxamine. The danger of 
indiscriminate prescribing of psychotropic medication without a proper assessment of the 
suicide risks are enormous. The toxicity of antidepressants even in moderate overdose is 
high (Henry 1988; Beaumont 1989), where death occurs it is normally the result of 
depressed myocardial function (Dziukas and Vohra 1991). The difficulty of prescribing is 
that the potentially suicidal person is being given the means to commit suicide, Lundberg 
(1982) likened the prescription of such drugs "to giving a homicidal man a loaded 
revolver". A recent survey in the Netherlands showed that 36% of suicides and 64% of 
suicide attempters used their antidepressant drugs (either alone or with other medication or 
methods) as the means of committing or attempting suicide (Diekstra and Van Egmond 
1989). Some tricyclics are considered to be safer than others, but there is little evidence for 
this. In particular dothiepin is often quoted as relatively safe. In fact the number of fatal 
poisonings per million prescriptions with dothiepin is around 50, slightly more than with 
amitriptyline. Dothiepin, amitriptyline, dibenzapin and desipramine have the highest fatal 
toxicity indices (Cassidy and Henry, 1987). New generation antidepressants are much 
safer in overdose (approx 13 deaths per million) and have roughly equal efficacy, therefore 
one would expect that prescription selection would favour these drugs. In actual fact
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current surveys suggest that imipramine, amitriptyline and dothiepin are the most widely 
used antidepressants (Thompson and Thompson 1989b) presumably mainly due to their 
low cost. If suicidal deaths were considered an adverse drug reaction and actually reported 
to the Committee of Safety On Medicines (CSM) there is no doubt that drugs such as 
dothiepin would be withdrawn. Nomifensine was withdrawn by the manufacturer when 7 
deaths fiom immunoallergenic reactions per million prescriptions were reported (CSM 
1986).
A relatively new form of treatment which is gaining popularity for the treatment of seasonal 
affective disorder (SAD) is bright light therapy (Wirz-Justice 1986). Seasonal affective 
disorder is a recurring depressive illness induced by the change of seasons, generally into 
winter, but bright light therapy does not appear to be effective for non-seasonal depression 
(Mackert et al 1991). There is an extensive literature and these data are reviewed elsewhere 
(T m nm eta l 1989).
There has also been some success using 40 hour sleep deprivation (Roy-Byme 1984), 
however with the possible exception of use with concurrent antidepressant medication 
(Baxter et al 1986) patients usually arise from their first night of sleep in a relapsed state 
(Wehr et al 1988). What does seem possible is that in predisposed individuals some factor 
associated with sleep may be partly responsible for the induction of a depressive episode 
(Southmayd et al 1990). This theory is also supported by the fact that some antidepressants 
(e.g. imipramine) can dissociate components of circadian rhythms (Wirz-Justice and 
Campbell 1982), and deliberate dis
sociation of circadian rhythms using sleep deprivation appears to improve mood in about 
60% of subjects (Szuba et al 1991).
In summary, it appears that depression is a common, sometimes fatal disease which, in 
many patients will recur. The drug treatment options available are low in efficacy and can 
be highly toxic, psychotherapy represents a safe alternative to drug therapy but its efficacy 
is often questioned and the costs are high in terms of time (up to 2-3hours per week), 
person-power and facilities.
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CHAPTEBJ3 
PSYCHOTHERAPY-MAIN TECHNIQUES
The three main types of therapy that were used during this study were encounter, 
bioenergetics and Gestalt. However it is important to note that therapists at the Open Centre 
have a a wide range of experience in many techniques and each therapist tends to use an 
eclectic mix to suit the needs of the individual or the group. Cognitive psychotherapy and 
behavioural psychotherapy, although not offered by any of the therapists nevertheless 
form an important part of psychotherapy in Britain and much research has been done on the 
efficacy of these psychotherapies. The National Institute of Mental Health (NIMH) in the 
USA recently completed a huge collaborative research programme on the treatment of 
depression ( Elkin et al 1985,1989). The therapies investigated were interpersonal therapy, 
cognitive behaviour therapy, imipramine hydrochloride plus clinical management, and 
placebo plus clinical management. Patients from all treatment groups improved over the 16 
week treatment period. Although there was an ordering of treatment efficacy at the end with 
imipramine doing best and placebo worse, when the severity of the presenting illness was 
taken into account there was no difference between imipramine and the two 
psychotherapies. For the least severely depressed patients there was no difference between 
any of the four treatments (including placebo). The outcome of this research is likely to be 
an increasing focus on the treatment of depression with psychotherapy alone or in 
combination with antidepressants (Klerman 1989) especially when the safety aspects of 
antidepressant use are considered. The importance of the psychotherapies in relapse 
prevention seems particularly promising (Shaw 1989).
It is important to stress that the Open Centre is a growth centre and does not exist merely 
for people with a clinically significant level of psychiatric disorder. However for the 
purposes of this study it was requested that the therapists present only those patients 
showing clear signs of a depressive disorder.
It is not the aim of this research to review or comment on the relative efficacy or value of
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the different psychotherapeutic techniques, however in order to put the work into context I 
shall briefly outline the principles of each theory, but will not describe details of their 
practice as they are very variable depending on the individual and the therapist. In addition I 
shall devote a small section of this chapter to a description of primal therapy. Although 
primal therapy did not form any part of the treatment of these subjects it was used in the 
pilot study to this research.
1. Bioenergetics
Dr Alexander Lowen, the founder of bioenergetic therapy began his first workshop in 
London with the words 'Bioenergetics is a psychotherapy which seeks to harmonise the 
body and the mind'. Bioenergetics originated in 1958 but did not come to London until 
1975. Bioenergetics, in common with many other psychotherapies sees human problems 
as having their origins very early in life. It is the conflicts that occur in the present 
connecting with past events that manifest in a variety of psychological and physiological 
disturbances. Bioenergetics sees the physical manifestations of the illness as just as 
important as the psychological and so attempts to treat both. Bioenergetics does not believe 
in 'cure' rather it finds a way to let people live with their problems.
Psychological health is to be found in the harmony of mind and body. The energy which 
the body produces should be used to maintain a feeling of strength, authority and 
aliveness, it should not be allowed to maintain tensions and defences. Lack of 
psychological health is indicated by loss of energy, lack of spontaneity, awkward 
movement and limited self-expression . The site of the trauma in the body can provide the 
clues for the diagnosis and treatment of the disease.
" A person who doesn't breathe deeply reduces the life in his body. If he doesn't move 
freely he restricts the life of the body. If he doesn't feel fully he narrows the life of his 
body. And if his self expression is restricted he limits the life of his body." (Lowen 1975)
According to bioenergetic theory psychological disturbance is acquired early in life possibly
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even prebirth (Lake 1981). The theory is that the infant protects itself from psychological 
pain by tensing its muscles and that if no outlet for those feelings is provided the tension 
will increase. The result of this is the bioenergetic concept of character armour and leads to 
five basic stmctures of character analysis (Reich 1961). The five types of character, which 
are rarely found singly but are normally mixed are: Schizoid (caused by maternal hostility); 
oral(caused by abandonment in the first 9 months e.g. during war (Mahler 1975)); 
psychopathic (caused by an overpowering figure - usually the father); masochistic ( caused 
by the mother smothering the child) and rigid (caused by the experience of a tragedy at 3 or 
4 years of age - possibly an early manifestation of Oedipal material when the child's early 
sexuality is rebuffed by a fearful parent (Whitfield 1988)).
The four main factors involved when working with a client in bioenergetic therapy are:- 
Character analysis, grounding, breathing and energy. Whatever the presenting problem 
may be,"the critical issue is character structure and this is central to the therapeutic process. 
If a client presents with depression, that will only be examined in the context of their 
character structure i.e. the permanent features which are visible in the body, of which the 
presenting problem is merely a symptom. One of the goals of therapy will be to alter the 
structure to eliminate tensions and defences and if necessary, physical posture is altered.
The second factor is grounding and this is literally contact with the ground. Lowen (1975) 
claimed it was more beneficial to work upright in a standing position. In this way the client 
experiences contact with the ground and discovers the authority to stand for themselves in 
life.
The third factor is breathing. Reduced or shallow breathing reduces contact with physical 
and emotional pain e.g. the wince response to painful stimuli. Whilst this is effective for 
short term relief from pain it can become a learned conditioned response which cuts off our 
ability to feel stress within our bodies caused by physical and emotional needs. Increasing 
the breathing increases the contact with the feelings which can be distressing, however if 
the breathing is developed the feeling is released.
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Finally there is the principle of energy. Unlike the other three factors energy is visible in the 
body, in terms of the colour of the skin, temperature and muscle movement. Where a 
person is breathing, grounded and tension free the energy will produce a sense of being 
alive. Where the energy is locked up there will be a lack of vitality.
The ultimate goal of therapy will obviously depend on the type of personality and the 
presenting disorder. Like many of the psychotherapies the therapeutic style will vary 
widely with the therapist, however there are three broad techniques which are commonly 
used; grounding, breathing and discharge.
Grounding, very simply is the process of the client using their legs to make contact with the 
ground and thereby experience the authority of their own body. This sounds simple but the 
techniques to achieve grounding require time and patience.
Breathing can be aided using a bioenergetic stool which will produce immense stress on a 
tense chest and enables the client to release and breathe easily.
Discharge techniques are used for the release of feelings. Singing and shouting, kicking 
and striking can help to release aggression, hurt and anger. It is also important to be able to 
harness gentle tender emotions, this is best achieved lying down with the knees raised so 
that contact with the ground is maintained. There are a variety of techniques which can then 
be used such as reaching out the arms or vocal cries for help. This can lead to discovery of 
having been neglected and can result in anger and pain, the therapist must therefore have 
the training and experience to lead the client through this process of discovery. The art of 
the therapist is then to assess the appropriateness of exercises and the timing and depth of 
intervention (Cox 1978).
2. Behavioural therapy
In the early 1950’s Skinner first used the term behaviour therapy, but it was not until 1958 
that the therapy became popularised by Lazarus. According to traditional behaviourist
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principles all behaviours are learnt, and therefore abnormal behaviour is merely the result of 
faulty learning. The central theme of behaviourism is objectivity, that is it concentrates on 
the behaviour which can be seen and the environment. Traditionally it did not explore 
subjective influences or any of the internal problems that may underlie the condition. 
However Lazarus in 1971 stressed the importance of the individual's perception of the 
environment rather than just considering the direct influence of external events (i.e. a slight 
move in a cognitive direction).
The concept of normal vs abnormal as defined by behaviour therapy is determined entirely 
by the society in which we live. If one steps outside what is considered normal by society 
by the way in which we behave, then behavioural therapists will act to change that 
behaviour. Psychological well-being is viewed in terms of the individual's ability to control 
their environment and good adjustment, interpersonal, social, sexual, work and leisure 
activities.
Fear of anxiety or panic, avoidance of discomfort and learned helplessness are all situations 
where the individual loses control of their environment. An individual's behaviour is an 
index of his or her perceptions of self competence or self efficacy (Bandura 1977). In 
learned helplessness the individual sees their responses as futile (Seligman 1975) and so 
will eventually fail to initiate coping responses.
Behaviour therapy is most commonly used in treatment of anxiety and eating disorders. 
Depression alone does not normally result in behavioural disorders. In support of 
behaviour therapy work by Lelliot and co-workers (1989) has shown that avoidance can 
sometimes precede panic. Anxiety disorders are treated in very general terms by first of all 
behavioural analysis and then exposure to the fearful stimulus. This can be a very gradual 
or very rapid process (termed Flooding) but should always be therapist-aided until the 
patient is capable of facing their phobias alone.
Depression is not normally treated by behaviour therapy alone, but may be treated by 
so-called behaviour/cognitive therapy. Lewinsohn (1974) argued that depressives did not
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engage or engaged less often in positive reinforcing behaviours, therefore the treatment aim 
would be to improve social skills. Seligman (1975) suggested that the depressed individual 
has suffered from a life-long failure to control reinforcers in the environment In treatment 
various techniques such as self-monitoring, self-reinforcing and assertiveness training are 
utilised.
3. Cognitive therapy
Cognitive therapy is broadly divided into three different theoretical schools of thought. The 
first is that of Ellis (1962) who drew attention to the role of irrational beliefs in neurotic 
disorders and developed rational emotive therapy (RET) to change these beliefs 
systematically. RET is widely used in the USA but has little support in Britain. 
Meichenbaum (1985) has developed a form of cognitive therapy which concentrates on 
coping strategies. He uses self-instructions as a means of coping with stressful situations - 
so called 'Stress Inoculation Training'. Although Meichenbaum's principles are widely 
used in cognitive therapy they tend not to be used in isolation. The most extensively used 
and researched form of cognitive therapy in Britain is that developed by Beck (Beck et al 
1979; Beck and Emery 1985). Beck believes that depression is a form of thought disorder 
(Beck and Wynnwood 1963; 1964) where the patient distorts incoming information in a 
negative way. From work originally carried out in depression, cognitive therapy is now 
used to treat generalised anxiety, panic disorder (Clark 1986), hypochondriasis (Salkovskis 
and Warwick 1986) and eating disorders (Fairbum 1985).
Cognitive therapy makes a number of assumptions about the nature of the human 
individual.
1) The person is an active agent who interacts with the world around them.
2) This interaction takes place through interpretations, inferences and evaluations that the 
person makes about the world around them.
3) The results of these cognitive processes are thought to be accessible to the consciousness 
in the form of thoughts or images, and so the person has the potential to change them.
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In the cognitive model of depression, the illness results as a failure in the accuracy of the 
process of interpretation and evaluation such that the processing is usually biased in a 
negatively distorted way. This thinking tends to be global, judgmental and absolute. For 
example a depressed person who sees someone they know in the street who ignores them 
because they are in some way in distracted, may conclude that that person did not 
acknowledge them because they do not like them and may take this one step further to 
decide that no one likes them. Psychological health is seen is seen as a state where the 
individual can make relatively accurate interpretations of events, but this does not 
necessarily mean that they will always act rationally.
If primitive thinking is in operation , as in the disease state then a number of what Beck 
termed "logical errors” are likely to occur, as summarised below:-
1) Arbitrary inference - drawing a specific conclusion without any evidence to support 
that conclusion and possibly even evidence to the contrary
2) Overgeneralisation - drawing a general rule or conclusion on the basis of one or 
more isolated incidents and applying the concept across the board.
3) Selective abstraction - focussing on detail taken out of context, ignoring other more 
salient features of the situation and conceptualising the whole experience on the basis of 
this fragment.
4) Magnification and minimisation - gross errors in evaluating the significance or 
magnitude of an event leading to distortion.
5) Personalisation - a tendency to relate external events to his or herself with no basis 
for making such a connection.
6) Absolutistic, dichotomous thinking - a tendency to place all experiences in one of 
two opposite categories e.g. immaculate or filthy, saint or sinner. The patient will select an 
extremely negative categorisation for himself.
(from Beck et al 1979)
There is good evidence that depressed patients do in fact distort infonriation in a very 
negative way (Brewin 1988 Review) whilst anxious patients tend to dwell on information
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that is in some way threatening (Mathews and MacLeod 1985; Macleod et al 1986)
People with psychological disturbances not only experience problems in the processing of 
information but they are also prone to frequent disruptive thoughts known as 'negative 
automatic thoughts'. These are spontaneous and unrealistic thoughts, although they may 
seem plausible at the time, for instance a depressed person may feel 'I can't do anything 
right'. Whilst everyone experiences these thoughts on occasion, they are much more 
common in people with psychological disturbance. In depression there is a so called 
negative triad formed by the patients view of their self, the personal world and the future. 
They may see themselves as inadequate, worthless or helpless. The world seems to make 
insuperable demands on them and interactions are misinterpreted as representing defeat or 
deprivation. They anticipate further failure in the future and this anticipation interferes with 
their motivation to try. It is important to stress that Beck does not believe that negative 
cognitions actually cause the disorder, rather that the primary pathology is in the cognitive 
apparatus. Beck and Emery (1985) describe predisposing factors such as; genetic 
predisposition, physical disease, developmental traumas, inadequate personal experience to 
provide coping mechanisms, and counter-productive cognitive patterns, which are then 
acted on by precipitating factors. Precipitating factors include; physical disease, severe 
external stress, chronic insidious external stress and specific external stress (which acts on 
psychological vulnerability).
Early life events, chronic stress or trauma can lead the individual to the adoption of 
idiosyncratic beliefs, known as dysfunctional cognitive schemata. For example a depressed 
person may hold the view that to be happy they must be totally successful, or loved, or 
never make a mistake. These assumptions may not cause a problem to the individual until a 
life event occurs which is of particular relevance to them. This is also termed the level of 
the cognitive unconscious (Kihlstrom 1987) where behaviour patterns and assumptions that 
were originally conscious cognitive patterns become habits and unconscious. The 
accessibility of nonconscious emotional memory is such that it may often require situational 
cues. (Brewin 1989)
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The three main goals of cognitive therapy are firstly to relieve symptoms and resolve 
problems, secondly to develop coping strategies, and thirdly to help modify the underlying 
cognitive structures in order to prevent relapse. Unlike many other psychotherapies 
cognitive therapy concentrates on the presenting problem.
The tools of cognitive therapy are highly standardised and brief. Each session consists of a 
review of the previous session, planning, specific tasks and assignment of homework 
(Beck et al 1979). The cognitive approach works from a position of logic, applying basic 
logical principles and experimentation to the automatic dogma by which the depressed 
patient perceives, organises and responds to the environment (Rush 1982). The persistent 
negative constructs accompanying the depression (e.g. I am a bad person, I am going to 
fail) are identified, the frequency and circumstances are noted and then the patient is asked 
to test the hypothesis within certain rules of reason and using evidence gathered from 
everyday events. To involve the patient at an early stage reading matter on coping with 
depression is given to them (e.g. Beck and Greenburg 1974) and they are asked to 
complete weekly activity schedules.
Following on from this cognitive strategies can be used to help the patient in 6 main areas:-
1) Detection recording and review of depressogeniic beliefs that are noted in the daily record 
card.
2) Recognition of the link between irrational cognitions and self defeating experiences
3) Recognition of recurrent themes, such as fear of failure, through helping the patient to 
categorise their emotions.
4) Correction of perceptions by increasingly difficult task assignments
5) Teaching the patient to find more rational and positive explanations of events
6) Development of more adaptive and gratifying thinking patterns.
The important point to note to note is that in cognitive therapy as with other 
psychotherapies (Karasu 1977) the therapist is a teacher or shaper. Cognitive therapy is a 
process of discovery, not persuasion (Young and Beck 1982)
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4. Encounter therapy
Encounter differs from most other psychotherapies in not having any one great founder; 
instead it has been described as having 'grass-roots origins' (Shaffer and Galinsky 1974). 
Overall, however, encounter groups are characterised by an emphasis on the importance of 
honest emotional here-and-now relating, and the emotional involvement of group leaders. 
In Britain encounter therapy lost some credibility in the late 1970's due mainly to a rather 
unrealistic approach, excessive amounts of group pressure and perhaps most importantly a 
number of untrained group leaders starting to practise. Encounter groups have now 
become much more realistic, more connected to real life with less use of group pressure 
and less extreme emotional expression. (The encounter group at the Open Centre used for 
this study was led by Mike Wibberley who is well recognised as an encounter therapist).
Schütz (1973) described encounter as seeing people as a unity of mind, body and spirit, 
and providing the space for them to explore and grow into these three areas. The central 
concept of encounter is identity which is divided into experience and expression. 
Experience is an inner aspect with both conscious and unconscious sides, it is from 
experience that we set the rules of what is, and is not acceptable for us as individuals to do. 
Expression of identity, like experience, has conscious and unconscious aspects and 
includes, speech, posture, movement etc.
Experience of identity and expression of identity are very closely inter-related. How we see 
ourselves will affect how we act towards others and therefore how they act towards us, 
which in turn affects how we see ourselves. For example if a person experiences that their 
opinion is often ignored they may cease to bother to give their opinion. If they then modify 
the way they express their ideas to give their voice more strength and assurance and seek 
eye contact, they may make their opinion heard. After this has occurred several times 
people expect to hear that person’s opinion and so act differently towards them.
Encounter maintains that each person has responsibility for themselves, that they must 
make their own choices in the group and say yes to what they want and no to what they do
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not want. The most important aspect of encounter therapy is the unity of mind, body and 
spirit, poorly led groups are in danger of concentrating on physical and emotional 
expression to the exclusion of mind and spirit. It is vital that emotions are not expressed 
without thought within the group, as this is both useless and potentially damaging. 
Encounter could also be described as exploration, as it allows individuals to explore all 
aspects of their identity and to give them responsible expression. For this reason encounter 
may be used by a person as a means of 'growth' and not just as a therapy. (Elliot 1976)
The qualities which are aimed for in encounter are: firstly, an adequate sense of self (i.e. a 
feeling of being in charge of our own lives); secondly, to have a sense of our own personal 
rights and boundaries; third; the ability to resolve conflicts, both internally and in 
relationships with others; fourth, a willingness to explore and take risks; fifth, the ability to 
communicate experience and feelings; sixth, the ability to play (Wibberley 1988).
Depression is a sign of disturbance due to repression of the self leading to impoverishment 
of the personality and experience. This not only leads to loss of energy and depression but 
also to acting out which, as it results from a repression of a part of the self, is usually 
accompanied by anger. This destructive acting can result in guilt, which leads to depression 
and so becomes cyclical.
Acquisition of psychological disturbance from the point of view of encounter does not 
result from traumatic events in life, rather it results from how we chose to respond to those 
events and what conclusions about ourselves we were able to draw. Distortions in identity 
not only result from traumatic events but also the force of day to day attitudes. The 
important element is expression of self, where any aspect of the self is denied the result is 
pain, anger and fear which together result in hate (Edwards 1976).
The goals of encounter therapy are very variable depending upon leadership style, group 
format, the length the group is intended to run for and the participants of the group. The 
general aims according to Wibberley (1988) are;- 
To increase awareness of self and one's personal style of relating
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To facilitate expression of the whole range of emotion
To engender a sense of response-ability, personal power and creativity
To increase skills in personal communications with others
The group should provide a place where clients can remove their social inhibitions and 
relate as honestly as possible. In order for this to be achieved a balance must be sought 
between honesty, caring, confrontation and support.
Although the individual style of the therapist leading the group will vary the main 
therapeutic techniques are as described below. (Wibberley 1988)
1) Direct feedback - This is a way in which individuals can discover how they come 
across to others. Within the group participants are asked to be direct and honest, but to give 
information rather than to project feelings.
2) Focus on contact - Direct contact is encouraged, both verbally (saying 'I-You' 
instead instead of 'one', 'they') and by eye contact.
3) Checking projections or assumptions - By asking the group
4) Repetition - Used when an emotional statement is made without apparent feeling. 
Repetition of the statement can produce the emotional response.
5) Opposites and exaggeration - If a person is experiencing very strong emotions that 
result in a physical response, increasing the physical response may help the person to 
understand better what they are experiencing.
6) Act as if - The person is asked to adopt a behaviour strategy very different to their own 
and act it out within the group. They may find that people then respond very differently to 
them and that they actually start to feel like the behaviour they have adopted. This is 
particularly useful to increase assertiveness.
7) Vocalisation and movement - Used when a person has problems expressing an 
emotion.
8) Confrontation - It is important to emphasise that these are not only about expressing 
anger, they can be positive or negative, intellectual or emotional, rational or irrational.
The role of the group leader is perhaps most complicated in encounter therapy. The nature
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of the therapy is such that the leader should be involved as a part of the group, but it is 
important that he or she is able to separate that position from the position of leader which
enables situations such as emotional confrontations to be controlled and therapeutic
»
decisions made.
5. Gestalt therapy
Gestalt was founded by Fritz Peris and his wife and co-worker Laura Peris, and first rose 
to public attention as a distinctive approach in the early 1950's. Gestalt is based on a 
holistic view of the individual in their relations with the world around them (Peris 1973; 
Peris et al 1974). It points out that humans do not see the world as individual shapes, but in 
coherent meaningful configurations or 'gestalts'. At the centre of the Gestalt philosophy is 
the view that personality is comprised of a number of functions - bodily, perceptual, verbal/ 
cognitive - that interrelate closely and exist in relation to the environment.
Parlett and Page (1990) quote Peris as saying that 'every individual, every plant, every 
animal has only one inborn goal - to actualise itself as it is'. In Gestalt therapy 
psychological health and disturbance are not seen as mental but rather as organismic, they 
are the result of the functioning of mind, body and spirit (Latner 1974). A healthy person 
will achieve a balance at the interface of themselves with the environment. Imbalances are 
perceived as needs, and in a healthy person the most important need for self-actualisation 
will be dominant. The gestalt comprises the need which is being attended to, the figure', 
from the rest of the conscious life termed 'the ground'. As the need increases excitement is 
generated which activates the person to satisfy the need, for instance a hungry person will 
make efforts to get food and eat it. After the need is satisfied the gestalt will dissolve and a 
new gestalt is formed - this is known as the cycle of awareness, and is described in a 
variety of forms (Zinker 1977; Hall 1976; Parlett and Page 1990). The cycle represents a 
healthy functioning process in which a gestalt forms, develops and finally destroys itself.
A block may occur at any stage in the cycle. For instance a block at the beginning may 
prevent the person identifying a need; a block later on may prevent the person letting go of
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what they required from the environment and therefore not allowing them to relax. 
Obviously incomplete gestalts leave the person, dissatisfied. Particular attention is paid to 
awareness and contact in Gestalt therapy.
Awareness is divided into three zones; self-awareness, world awareness and awareness of 
what's between. Self awareness is direct experience of feelings, emotions and physical 
sensations at the time they are felt. World awareness is experienced via the five senses. 
'What's between' refers to the persons representation of reality, and includes planning, 
thinking, daydreaming etc. Awareness is very much here and now', it is not the same as 
intellectual understanding. 'Contact' occurs when the individual is fully in touch with the 
environment. The Gestalt therapist is an awareness expert, who will actively encourage the 
person to attend to their own ongoing present experience, and will ask questions such 
as 'How did you feel when you said that?', 'What is happening?’. The questions will begin 
with What and How to focus attention on specific experiences, not Why which requires 
explanation. The therapist will work to identify where interruptions in the cycle occur by 
exploring the persons reality almost on a moment by moment basis. Interruptions in the 
gestalt may be spotted by a number of minor changes such as adjustment of eye contact or 
unfinished sentences. When interruptions are spotted the therapist can either intervene or 
allow the person to continue their story (Bolster 1987)
There are four patterns of disturbance at the contact boundary identified in Gestalt theory 
(Bolster and Bolster 1973). These are; introjection (taking in from the environment without 
evaluation), projection (displacing fi-om self into the environment), retroflection (self 
manipulation rather than engagement with the environment) and confluence (merging with 
the environment and avoiding separateness). It is the role of the therapist to try and identify 
these contact boundary disturbances. For instance if a person suppresses laughter in a 
group session it could be that he has an introjection that it is impolite to laugh, or that others 
may think him silly (projection). In addition, he is trying to swallow his laughter 
(retroflection) and conform to others around him (confluence).
Where interruptions occur there is a tendency to resist or stay with the familiar pattern of
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interruption. For instance someone who has been taught not to cry will find it difficult if 
they are suddenly told that this is wrong and that they are allowed to cry. For this reasons a 
gestalt therapist will not say that the resistance is wrong but should adopt a position of 
neutrality towards a person changing (Appelbaum 1983).
Experimentation forms a large part of gestalt therapy and although there are no set 
structures or techniques some experiments have become classics, e.g. the 'empty chair' in 
which a person may resolve unfinished business with someone, or another part of 
themselves, by talking to the empty chair. Gestalt can also involve working with dreams, 
fantasies or art. The techniques of gestalt are widely copied but their use outside the rest of 
the system is not recommended by practitioners of Gestalt (Yontef 1988).
6. Primal therapy
I shall only describe the principles of primal therapy quite briefly as the subjects involved in 
this research did not receive any of this type of therapy, and the techniques involved are not 
used by therapists at the Open Centre. Primal therapy, was however used in the pilot study 
to this research.
Primal therapy was first described by Arthur Janov in 1970. Twenty years on he has 
amended his theories slightly, but the broad principles remain the same (Janov 1990). 
Janov expresses emotional disturbances in terms of ''Primal pain". This pain cannot be felt 
physically but is continually processed by the sub-conscious and goes on forever. 
According to Janov the most catastrophic pains are early life threatening pains such as those 
caused by a difficult birth or those felt by an unloved child. Because these pains are so 
intolerable a system of repression or 'gating* is employed by the brain as a means of 
self-defence. Gating is a means of controlling the perception of pain, rather than the pain 
itself. Janov describes this as a physical process whereby electrical impulses from pain 
neurons are actually blocked and prevented from reaching the higher levels of the brain. 
The details of this process are described in pseudo-scientific terms by Janov but since the 
mechanisms of emotional pain are so poorly understood there are a huge number of
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assumptions made and the theory is a little incredible.
Janov uses the term 'imprint' to describe the repressed memories which find their way into 
the biological system and produce distorted functions. These imprints' can either be 
imposed by a single traumatic event, or through the chronic failure to fulfil certain basic 
needs over a longer period of time. The main point about imprints is that they are most 
readily formed in very early childhood and our ability to imprint declines rapidly with age.
Neurosis is the result of the person existing as two selfs, the real pained self and the unreal 
self which is the consequence of repression. Primal theories argue that the neurotic is 
symbolically acting out their past needs in the present. The unloved child will in later life 
seek uncaring and aloof partners so that they can continue in the struggle to make 
themselves loved.
Many imprints however are actually formed either in the womb or in the process of birth. If 
the mother is very stressed, does not want the baby, drinks or smokes these are all factors 
which effect the quality of the foetal environment and according to Janov imprint on the 
brain. The trauma of birth itself is seen by Janov as the greatest source of Primal pain and 
takes a number of different varieties. A baby that is heavily anaesthetised at birth develops 
into a slow unresponsive child, a baby that's badly bruised and hurt during birth for no 
apparent reason may grow up determined to fight injustice and become for example a 
lawyer.
If the birth is painful and traumatic this will leave the infant with a very negative imprint, 
this imprint is subject to the gating processes of the brain resulting in suppression of the 
real self, and neurosis. As a result of these assumptions we have a set of so called 
"Janovian Laws", as follows:
1) keeping secrets from yourself makes you sick,
2) suffering is healing as long as it is at a level that can be integrated,
3) salvation lies in pain,
4) he who acts it out lasts it out, he who acts it in caves in.
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Janov envisages illness as the silent scream, the cure to which is to give it a voice. In 
primal therapy is it not enough for patients to discuss their early life traumas, rather they 
must relive them in order to reexperience the emotions. This wiU involve many patients in 
reliving their birth and early childhood. Reliving these emotions allows the blocked energy 
to escape, tears may be shed and the gating mechanism can be broken down. This is 
obviously a traumatic and painful experience through which the patient has to go, and for 
this reason is not used by many therapists.
Evidence for the efficacy of psychotherapy
Economical and ethical considerations will always tend to be foremost in the arguments for 
and against psychotherapy. From the economic point of view psychotherapy is expensive 
in terms of both the patients time and the time of a qualified practitioner. The patient may 
have to give up an hour or two from work each week to receive psychotherapy, this means 
that in addition to the time factor involved they have to admit their psychiatric illness to an 
employer. Sheperd (1984) wrote that much of the problem for psychotherapy lies in the 
way it is perceived "an undefined technique applied to unspecified cases with unpredictable 
results. For this technique rigorous training is required". The definition that he quotes may 
to some extent be true - but in that case where does pharmacotherapy stand? The 
explanation that pharmacotherapy can offer for the effectiveness of a wide range of 
'efficacious antidepressants' although scientifically based is no more rational and is 
probably less complete than most psychotherapies. It cannot even be argued that 
pharmacotherapy defines its population with greater accuracy - if this was so then why is it 
possible to treat anxious patients with antidepressants? So what of outcome, the 
assumption must surely be that antidepressants, for example, have undergone rigorous 
scientific testing for their efficacy whereas psychotherapy has not. This is an interesting 
point, most trials of psychotherapy are carried out on a single centre with relatively small 
patient numbers. Drug trials are much larger scale, however a drug recently accepted onto 
an already overcrowded antidepressant market in the States was Sertraline where only two 
trials showed the drug to be more effective than placebo, eleven did not. Aveline (1984)
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argues that psychotherapy is still a relatively new discipline within the NHS (since 1975) 
and that the risks of continuing to use pharmacotherapy without psychotherapy will 
outweigh the costs.
An increasing body of evidence is emerging to support the view that the most effective 
treatment for depression maybe a combination of psychotherapy with drug therapy 
(Weissman 1979) in a hospitalised population although cognitive therapy appears to be 
most effective in the GP population (e.g. Blackburn et al 1981). Cognitive therapy alone 
has been found to be as successful in treating depression as pharmacotherapy in a number 
of separate studies ( Blackburn et al 1983,1986; Teasdale et al 1984; Murphy et al 1984; 
Beck et al 1985; Covi and Lipmann 1987) and others have found it to be more effective ( 
Rush et al 1977). Behavioural therapy either in combination with pharmacotherapy or on 
its own is superior to drugs and leads to lasting improvenient ( McLean and Hakstian 1979; 
Wilson 1982; Marks and O’Sullivan 1988 review; Miller et al 1989 ). However not only 
behavioural and cognitive therapy have comparable efficacy to pharmacotherapy, similar 
results have been found with interpersonal therapy (Weissman 1979) self-control therapy 
(Roth eta l 1982) and social skills training (Bellack eta l 1983) The overall view now 
appears to be that psychotherapy in general, used with drug therapy is considered an 
effective treatment option (Gastpar 1989) and may help in the prevention of relapse (Miller 
et al 1989) However there has been some criticism of the levels of drug treatment given in 
comparative studies, which it is argued has biased the results ih favour of the 
psychotherapies (Meterissian and Bradwejn 1989). Meta analysis (the analysis of the 
results of a number of studies taken together) of psychotherapy studies has not proved 
particularly useful, Prioleau et al (1983) found psychotherapy to be no more efficacious 
than placebo, whereas Steinbruck et al (1983) in an analysis of 56 studies found 
psychotherapy to be more effective than drug therapy.
Research has set out to compare the efficacy and methods of different types of 
psychotherapy (e.g. Elkin et al 1989), or traditional psychotherapy versus mutual help 
group treatment (Marmar et al 1988) but given the fact that it has not proved possible to 
detect differences in drug treatments differences in psychotherapies are also likely to be
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hard to detect. The result of this work and has therefore tended to conclude, perhaps not 
surprisingly, that what is called for is an integrative and selective approach (e.g.Karasu 
1990a, 1990b). This is also the view of the NIMH study described briefly at the beginning 
of this chapter.
What is very clear is that no matter how the depressive episode is treated, early 
intervention is vital (Kupfer et al 1989) and can reduce the length of a depressive episode 
by up to 4-5 months. Fennel and Teasedale (1987) found that the response during the first 
two weeks of treatment is highly predictive of outcome. The suggestion has been made that 
the important aspect of psychotherapeutic treatment may be the relationship between the 
patient and the therapist, rather than the type of treatment (Beckham 1989). Another 
important factor that has been recognised is the difference between in-patient and 
out-patient populations and their very different needs in psychotherapy (Kapur et al 1988).
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CHAPTER 4 
SEROTONIN AND DEPRESSION
In 1965 Joseph Schildkraut proposed a theory of depression based on depletion of 
catecholamines, and also suggested possible involvement of other amines, particularly 
serotonin (5-Hydroxytryptamine 5-HT). More than a quarter of a century later, despite 
extensive clinical and laboratory experimentation we are little further in our understanding 
of the biochemical basis of depression. The original catecholamine hypothesis described 
by Schildkraut (1965) postulated depletion of noradrenaline at functionally important 
synapses within the brain, and was expanded to include deficiency of 5-HT, giving rise to 
the monoamine theory of depression. This theory however falls short due to its inability to 
explain a number of phenomena associated with the treatment of depression such as: why 
tricyclic antidepressants have such a slow onset of action, why not all amine uptake 
inhibitors have antidepressant action (e.g. amphetamine), why different agents with similar 
pharmacological profiles on the amine system have such different clinical effects and why 
some antidepressant treatments decrease amine metabolism.
Despite this the popularity of 5-HT and its involvement in depression has remained high, 
and with the development of a whole new range of highly selective 5-HT re-uptake 
inhibitor antidepressants the supporting evidence is increasing. 5-HT is an indoleamine, 
widely distributed through plants, animals and man. In mammals it is found in blood 
platelets, mast cells and the enterochromaffin cells in the gut. Within the brain and spinal 
cord 5-HT acts as a neurotransmitter and is thought to be involved in a variety of 
physiological and behavioural functions. Levels of serotonin in the CNS only represent 
1-2% of the total found in the body (Bradley 1989). The indoleamine cannot cross the 
blood brain barrier and so all neuronal 5-HT has to be synthesised locally. 5-HT is 
produced from L-tryptophan and metabolised as shown in figure 4.1 below.
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Figure 4,1
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L-tryptophan
4  L-tryptophan hydroxylase 
5-hydroxytryptophan
4  5-hydroxytryptophan decarboxylase 
5-hydroxytryptaniine (Serotonin)
4 Monoamine oxidase 
5-hydroxyindoleacetaldehyde
Aldehyde reductase 4 4 Aldehyde dehydrogenase
5-hydroxytryptophol 5-hydroxyindoleacetic acid
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The rate-limiting step in this process is the hydroxylation of tryptophan by tryptophan 
hydroxylase. As under normal physiological circumstances the enzyme is not saturated, 
increasing brain tryptophan will increase synthesis of serotonin. This has led to 
L-tryptophan preparations being given orally to patients for treatment of depression with 
some success (e.g. Zmilacher et al 1988). However, overall the results have been 
equivocal, although, it has been established that tryptophan potentiates the antidepressant 
effects of monoamine oxidase inhibitors (Coppen and Swade 1988). In addition there have 
been several other studies which have demonstrated successful use of tryptophan ( or 
another agonist -fenfluramine) challenges to investigate neuroendocrine function (in the 
form of prolactin release) in normal and depressed patients (Soininen etal 1981; Heninger 
et al 1984; Siever et al 1986; Cowen et al 1988; Goodwin et al 1987; Dealdn et al 1990). 
A blunted prolactin and growth hormone response to L-tryptophan has been implicated as a 
possible marker of state dependent depression in patients Without recent weight loss 
(Upadhyaya et al 1991) and is reversible with antidepressant treatment (Shapira et al 1989).
Within the general scheme of synthesis and metabolism of serotonin there are several stages 
at which drugs can act to either decrease or increase serotonergic function as shown in 
Figure 4.2 below. (Drugs acting directly on 5-HT receptors are not included.)
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A number of different lines of evidence suggest that dysfunction of the serotonergic system 
may be involved in depression. The methods used for studying functional transmitter 
neurochemistry in the human brain can roughly be divided into three (review by Dodd et al 
1988). The first is to use human peripheral tissues to study CNS function, the second is to 
use post-mortem human brain tissue, and the third is to use animal models. All three 
methods have indicated a possible involvement of 5-HT in depressive disorders
Changes in measures of serotonin function in peripheral human tissues
5-hydroxyindoleacetic acid (5-HIAA) is the final product of 5-HT metabolism within the 
brain, and its concentration in cerebrospinal fluid is believed to reflect the metabolism of 
serotonin in the brain. Alterations in the levels of 5-HIAA have been found in a number of 
studies comparing depressives with control subjects. For example Asberg etal, (1984) 
measured 5-HIAA and two other neurotransmitter metabolites, homovanillic acid (HVA) 
and 3-methoxy-4-hydroxyphenylglycol (MHPG) in the cerebrospinal fluid (CSF) of 83 
patients suffering from depression and 66 healthy subjects. The data were adjusted for 
differences in age, sex, and height distribution between the groups. Significantly lower 
concentrations of 5-HIAA and homovanillic acid were found in depressed patients 
compared to healthy subjects, while levels of MHPG did not differ between the groups. 
Levels of 5-HIAA have also been shown to return to a more normal level after clinical 
recovery. Traskman-Benz eta l (1984) were able to demonstrate that concentrations of 
5-HIAA , but not HVA, were higher following recovery than during depression, but only 
in patients with low 5-HIAA during their depressive episode.
Similarly Gjerris et al (1987) measured CSF levels of 5-HT in so called endogenously 
depressed patients and controls and found the concentration in the CSF to be increased in 
depressed patients compared to healthy subjects. However Molchan et al (1991) were 
unable to demonstrate any differences in CSF monoamine metabolites between depressed 
patients and controls.
The data tends to support a hypothesis of decreased serotonin turnover in depressed
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patients, generally around 40% (Review by Kalus e ta l 1989). The decrease in .CSF 
5-HIAA could be the result of or could lead to, increased post synaptic 5-HT receptor
sensitivity. Kahn et al (1990a) tested this hypothesis using MCPP (a 5-HTi/5-HT2 
agonist) as a probe to detect the effect on behaviour and plasma prolactin levels. MCPP 
significantly elevated prolactin levels compared to placebo, but there was no difference 
between depressed subjects and controls. MCPP did not affect anxiety, depression, 
hostility, fatigue or vigour responses. They concluded that from these findings there was 
no hormonal or behavioural evidence for increased 5-HT receptor hypersensitivity. These 
conclusions may be premature, MCPP was given only in single dose, antidepressants 
acting on 5-HT systems take 2-3weeks to have their effect suggesting that serotonin may 
act as a mediating system enabling other changes such as down-regulation of 
B-adrenoreceptors to take place. The effects of MCPP on prolactin release can be reversed 
using 5-HT antagonists such as metergoline (Kahn et al 1990b).
CSF studies are extremely useful in that they enable direct assessment of 5-HT and its 
metabolites in the fluids that bathe the brain. However there is not any very strong evidence 
to suggest that these levels particularly closely resemble functional levels of free 
neurotransmitter within the brain. Furthermore sampling CSF is a highly skilled process 
and has considerable discomfort and risks for the patient, and for this reason is not a 
suitable technique for longitudinal studies.
Blood platelets and neuronal synaptic tissue are derived from the same embryonic origins in 
the foetus and for this reason the surface of the platelet contains a number of receptors also 
found on presynaptic nerve terminals. In 1951 Rand and Reid reported that blood platelets 
contained the vasoactive substance 5-HT, however at this time it was not known that 5-HT 
was a neurotransmitter. The connection with psychiatry was not made until 1960 when 
Marshall et al (1960) showed that patients receiving imipramine had decreased levels of 
platelet 5-HT. It was subsequently shown that imipramine binds to an uptake site on the 
platelet, hence stopping uptake of 5-HT and that this uptake site had the same properties as 
5-HT uptake sites within the brain (Briley et al 1979; Pletscher et al 1984; Stahl 1977). 
Furthermore this site appeared to be specific to tricyclic antidepressants and their active
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metabolites (Paul et al 1980). Peters and Grahame-Smith (1980) demonstrated that 5-HT 
actually binds to two specific sites on platelets, one of which is associated with platelet 
aggregation and the other is associated with 5-HT uptake.
Work on serotonergic function in the affective disorders using platelets has focused into 
two main areas, that of 5-HT uptake by intact platelets and the binding of 5-HT uptake 
inhibitors, such as imipramine, to platelet membranes. However it is worth emphasising 
that platelet receptor binding experiments have also been conducted on other potential
psychiatric markers e.g. a 2-adrenergic receptors and monoamine oxidase activity 
(Wirz-Justice 1988)
5-HT uptake studies
Low values of 5-HT uptake have been consistently found in depression (e.g. Coppen et al 
1978; Egrise et al 1986; Ehsanullah 1980; Hallstrom et al 1976; Humphries et al 1985; 
Lingjaerde 1984; Malmgren et al 1981; Meltzer et al 1981 &1983a; Modai et al 1984; 
Rausch et al 1984; Scott et al 1979; Suranyi-Cadotte et al 1985a; Tuomisto and Tukiainen 
1976; Tuomisto et al 1979) and appears to be corrected by treatment with antidepressants 
(e.g. Quintana 1989). 5-HT uptake does not appear to be affected by age or gender 
(Lingjaerde 1984; Tam et al 1985) but interestingly, it has been reported to be increased in 
manic patients (Meagher et al 1990) and treatment of these patients with lithium reduces the 
rate of 5-HT uptake (Meltzer et al 1983b). Additionally levels of 5-HT within platelets of 
depressed patients are lower than controls (e.g. Muck-Seler et al 1983)
However most attention has been directed towards platelet binding studies and in particular
the binding of the 5-HT re-uptake inhibitor imipramine. Although imipramine binds to a
site associated with uptake of 5-HT, some studies have reported relatively different
decreases in 5-HT uptake and imipramine binding. This suggests that although the
mechanism of 5-HT uptake and the imipramine binding site are associated, they are not
identical ( e.g. Raisman et al 1982). Langer and Raisman (1983) proposed that the
imipramine binding site may be a modulator unit for serotonin and that serotonin and other
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uptake blockers change the affinity of this site for imipramine (see Figure 4.3). It seems 
probable that ah endogenous ligand exists which binds to the imipramine recognition site to 
modulate the 5-HT transporter (Langer et al 1987) and that this imipramine recognition 
site may play a role in the pathogenesis of depression (Langer et al 1986).
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These findings were supported by Marcusson and Tiger (1988) who showed that the 
imipramine binding site in the brain was localised to serotonergic neurons and appeared to 
be identical to the substrate recognition site for 5-HT uptake.
Imipramine binding studies:-
Decreased [3H]-imipramine binding to platelets of depressed patients has been 
demonstrated by a number of investigators (e.g. Asarch et al 1980; Asberg and Wagner 
1986; Baron e ta l  1983; Briley et al 1980; DeMet e ta l  1991; Paul e ta l  1981; 
Suranyi-Cadotte et al 1983 &1985a; Wagner et al 1985; Slotkin et al 1989 ) .  However 
there have been a few studies which have either found no difference (e.g. Braddock et al 
1986; Gentsch eta l 1984; Tang and Morris 1985; Quintana 1990) or an actual increase 
(e.g. Mellerup et al 1982). Theodorou et al (1989) showed decreased binding in female but 
not male subjects.
In studies where [^Hj-imipramine binding has been found to be decreased in depressed 
patients it has been possible to demonstrate increases in the binding levels following 
treatment with; some antidepressants (e.g. Asberg and Wagner 1986; Healy et al 1983 and 
1991; Langer et al 1980 Suranyi-Cadotte et al 1982 &1985a), light therapy for seasonal 
affective disorder (Szadoczky et al 1989) or ECT (e.g Langer et al 1986). Sherwin and 
Suranyi-Cadotte (1990) were able to show increased imipramine binding to platelets 
combined with improved mood when oestrogen was given to surgically menopausal 
women suffering from depressive symptoms. This effect was reversed in a double blind 
crossover study when placebo was administered. Some research has shown that 
antidepressant treatment with chlomipramine given to normal volunteers may decrease 
imipramine binding to platelets (Poirier eta l 1984) and this led to the suggestion that 
differences seen in binding between controls and depressed subjects were due to the 
residual effects of antidepressants. This resulted in a number of investigations into 
imipramine binding in previously untreated depressed patients, and decreased imipramine 
binding was still found, showing that this decrease is not the result of antidepressant 
treatment (e.g. Benkelfat eta l 1985; Raisman eta l 1981 & 1982; Poirier eta l 1986). 
Wagner and coworkers (1990) investigated changes in imipramine binding to platelet
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membranes following treatment with fluvoxamine ( a highly selective 5-HT uptake 
inhibitor) and actually found a decrease in binding sites after 3 weeks of treatment. They 
suggested that this may be due to destruction of the binding sites, and found that as 
treatment continued imipramine binding started to increase again. Similar results were also 
found using clomipramine (Martensson et al 1991). It is possible that these findings in 
some way are related to the high relapse rate seen when antidepressant drugs are only used 
for short periods and may also explain the increase in severity with subsequent relapses.
Researchers in the field of depression have made considerable efforts to identify both trait 
(ie some characteristic of the individual which identifies them as a potential depressive) and 
state (ie some characteristic present when the individual is suffering from the disorder) 
markers for depression. Not surprisingly, there has been suggestion by some workers that 
platelet [^H]-imipramine. binding may represent a trait rather than a state marker. Baron et 
al (1986) showed decreased imipramine binding to the platelets of bipolar depressives but 
not unipolar depressives, which led them to suggest that that imipramine binding may 
represent a trait marker for depression. However other work contradicts this finding, 
Muscettola et al (1986) were unable to show any difference in imipramine binding of 
bipolar patients and controls. Berrettini et al (1982) found that euthymie bipolar patients 
did not differ from controls in their platelet imipramine binding and concluded that 
imipramine binding was not a trait marker for affective illness. Imipramine binding has also 
been proposed as a possible marker of sub-types of depression e.g psychomotor agitation, 
bipolar depression and sporadic depression (Carstens et al 1986a, Lewis and McChesney 
1985a) although others have failed to distinguish between subtypes e.g. delusional and non 
delusional depression (Lykouras et al 1988). Jeanningros and co-workers in 1989 
investigated further the possibility that platelet [^H]-imipramine binding may be an 
important trait marker for depression. They concluded that it may represent a trait marker 
for bipolar disorder and a state marker in dysthymic disorder, as only patients with 
dysthymic disorders showed a correlation between symptom severity and imipramine 
binding. What would appear to be most probable is that intipramine binding is decreased 
during a depressive episode and that the more severe the episode the greater the decrease 
and therefore the longer the time taken for full recovery. This may therefore be considered
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a trait marker for depression in that depression is a cyclic recurrent illness, but it is unlikely 
that decreased levels of imipramine binding could be used to predict possible depressive 
disorders in a healthy population with no previous affective disorder.
Other research has suggested that [^H]-imipramine binding might be useful as a possible 
predictor of response to treatment. For example Hrdina et al (1985) looked at binding 
levels in a group of 20 patients before and after treatment with antidepressants for two 
weeks and found that patients with the lowest binding levels before treatment were the most 
likely to be non-responders.
Psychogenic pain also appears to affect imipramine binding in association with depression, 
resulting in lower imipramine binding in depressed patients suffering from pain than in 
those solely suffering from depression (Mellerup et al 1990). Eberhard and co-workers 
(1989) monitored imipramine binding in a group of patients with psychogenic pain but no 
diagnosis of depression and found that they had decreased imipramine binding which 
increased with antidepressant treatment.
[^H]-imipramine binding has been investigated in a number of other disorders such as 
panic disorder (Pecknold and Suranyi-Cadotte 1986)) Alzheimer's dementia 
(Suranyi-Cadotte eta l 1985b; Galzin eta l 1989), mania (Lewis and McChesney 1985), 
disruptive behaviour disorders (Stoff eta l 1991) obsessive compulsive disorder (Won 
Kim et al 1991) and schizophrenia (Joseph et al 1977) and since no difference was found 
between psychiatric patients with these disorders and controls the validity of imipramine 
binding as a marker of depression seems useful. However Marazziti et al in 1989 were 
unable to demonstrate any differences in imipramine binding between patients with major 
depressive disorder and patients with bulimia, panic attacks, schizophrenia or suicide 
attempters. Other workers have found decreased imipramine binding in patients with 
agoraphobia (Lewis gf a/ 1985).
Although imipramine binding is probably not affected by many other psychiatric disorders, 
this does not imply that serotonin is not involved. Increased levels of 5-HT in platelets has
55
been observed in schizophrenics (Muck-Seler et al 1988) and some studies have shown 
increased platelet 5-HT uptake (Lingjaerde 1983; Modai et al 1979) although others have 
not (Arora and Meltzer 1982). There is good evidence for the involvement of 5-HT in 
schizophrenia but interestingly schizophrenics that commit suicide do not appear to have 
decreased CSF 5-HIAA levels (Lemus et al 1990). Serotonin is also implicated in 
Alzheimer's disease where autoradiographic analysis of post mortem brains has shown a
reduction of 5-HT2 and 5-HTiA receptors in the cortex (Cross et al 1988). Eating
disorders are almost certainly under some form of serotonergic control (Review Jimerson et 
al 1990) and the role of serotonin in maintaining normal weight is currently under 
investigation.
Most studies have found no difference in [^H]-imipramine binding between the sexes (e.g. 
Asarch e ta l  1980). However Langer e ra / (1980) found that there was a decrease in 
maximal binding with increasing age of the patient and Slotkin et al (1989) have reported 
similar findings of decreased 5-HT uptake with age.
Evidence from  hum an brain  tissue for the involvement of 5-HT in 
depression
There are obvious problems associated with working with human brain tissue, but the 
usefulness of such studies should not be under-emphasised, as ultimately it is 
understanding of the human brain in depression that will lead to the answers. One of the 
greatest problems is obtaining tissue to work on. There is known to be a high prevalence of 
depression amongst people who commit suicide and so for this reason suicides are often 
studied in depression. Stanley et al (1982) were some of the first workers to investigate 
imipramine binding to serotonin uptake sites in the Brodmann area of the frontal cortex of 
suicides. They found decreased levels (44% lower) of imipramine binding in suicides 
compared to controls. Similar results have since been found in a number of other studies 
(e.g. Crow et al 1984). These results were not however supported by Meyerson et al 
(1982) who actually found increased imipramine binding in suicides or by Arora and 
Meltzer (1989) who found no difference. Some workers have reported an asymmetrical
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distribution of imipramine binding within the brain of suicides although this now does not 
appear to be the case (Arora and Meltzer 1991).
Pandey eta l (1990) using have found that 5-HT2 receptors on platelets are
increased in drug free depressed patients and that this is most marked in those that had 
recently attempted suicide. This finding has also been observed in the pre-frontal cortex of
suicides (e.g. Mann et al 1986; Meltzer et al 1987). Such up-regulation of 5-HT2 receptors
is known to result from serotonin deficiency (e.g. Roth et al 1987). A review by Mann et 
al (1989) postulates a role for serotonin in suicide where a decrease in the level of serotonin 
causes an up-regulation of 5-HT2 receptors and a decrease in uptake sites. How this then
affects depressive mood and or suicidal behaviour is not clear but a theory put forward by 
Roy and Linnoila (1988) suggests that serotonin may actually control impulsiveness. They 
argue that abnormality in serotonin systems has been associated with suicide, particularly 
violent suicide (Mann et al 1986), aggression towards others (Linnoila et al 1983) and 
aggression towards inanimate objects e.g arsonists (Virkkunen et al 1987). They argue that 
whilst these behaviours are multi-determined they all reflect poor impulse control and that 
this may reflect low serotonin turnover. Coccaro (1989) also argues that the role of 
serotonin may be to control impulsiveness and particularly impulsive aggression. Sparks 
and Little (1990) investigated changes in serotonin binding in the pineal of suicides and 
found that high affinity binding was reduced in some but not all suicides, these results were 
very preliminary but suggest a possible control role for the pineal via either melatonin, 
serotonin, noradrenaline or a combination of these. It is worth noting that recent work by 
Arato et al (1989) found that although 5-HIAA levels in the CSF of suicides tended to be 
lower than controls, if the CSF was examined within ten hours of death increased levels of 
5-HIAA were found. Traskman-Benz eta l (1991) have suggested that higher levels of 
whole blood serotonin may be associated with impulsive violent suicide.
Although relatively few studies have been carried out on the brains of depressed patients
dying from causes other than suicide the findings tend to indicate a role for serotonin. Perry
et al (1983) compared tritiated imipramine binding to various brain regions in normal,
depressed and demented (Alzheimer's type) patient brains post-mortem. They found
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decreased imipramine binding in the hippocampus and occipital cortex of depressed patients 
only. More recently Demeter et al (1989) investigated tritiated imipramine binding in the 
frontal cortex of homicide victims either with or without previous psychiatric illness. The 
number of imipramine binding sites in the frontal cortex of psychiatric subjects was 
significantly higher in the left hemisphere than in the right, the opposite was true for the 
normal controls. They conclude that the significant increase in imipramine binding sites in 
the left hemisphere may indicate a biochemical lesion of serotonin metabolism and may 
itself predict psychiatric illness. This experiment however involved a whole range of 
psychiatric illnesses (alcoholism, depression, schizophrenia, schizo-affective disorder and 
drug abuse) and only 15 subjects. Given the very different symptomatology and treatment 
of these diseases, a single underlying cause is improbable.
Imipramine binds to two sites in human brain tissue, one low affinity and one high affinity 
site, it now appears that only the high affinity sites are related to 5-HT uptake sites (e.g. 
Plenge et al 1990)
Evidence from animal models for the involvement of 5-HT
The use of animal models in investigation of the affective disorders is a highly controversial 
area. It seems almost certain that animals do not suffer from depression as such, and that 
the models that we choose to use such as learned helplessness, are in fact models of despair 
(ie utter loss of hope and extreme stress, in these cases produced as a result of physical 
factors). What we do not know is whether the mechanisms behind despair are the same as 
those in depression. Other models induce "depression" using drugs such as reseipine, and 
are validated in as much as the fact that current antidepressants work in them ( Vetulani et al 
1986). What we do not know is whether or not they are good enough models to have any 
predictive value for future research.
Work using these models has indicated potential new antidepressants e.g. reversal of 
learned helplessness in rats by 5 -H T ag o n is ts  (Giral et al 1988). It could be argued that 
the usefulness of animals in the study of depression comes from being able to monitor
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changes in binding sites in the brain with administration of antidepressants. This may 
eventually lead to a fuller understanding of how antidepressants work and then, maybe, the 
mechanism behind depressive disorder. Mizuta and Segawa (1989) investigated changes in 
different 5-HT receptor sub-types using quantitative receptor autoradiographic procedures 
in rat brains after chronic administration of imipramine or lithium for 21 days. They found
decreases in 5-HTi, 5-HTia» 5-HTjc and 5-HT2 sites in the frontal cortex, hippocampus 
and choroid plexus for both lithium and imipramine treatment (although in different 
amounts) and proposed that this technique could offer a means of characterising and 
understanding the local effects of drugs on 5-HT receptor sub-types. More recent work by 
Perez et al (1991) has shown that both noradrenaline and 5-HT re-uptake blockers with 
antidepressant activity increase cAMP binding indicating that this may be part of the 
adaptive change brought about by antidepressant treatment. Electrophysiological 
assessments of 5-HT neurotransmission in rat brain following treatment with 
antidepressants has shown that all the antidepressants tested produced an enhancement of 
5-HT activity, although each one may have achieved this by a different mechanism (Blier et 
al 1988).
Imipramine binding in human platelet cells has been reported by some workers as being 
subject to circadian variation, the effect of photoperiod on imipramine binding in the rat 
brain has also indicated circadian variation (Rovescalli et al 1989). Jemej et al (1989) 
however, found no evidence for significant circadian or seasonal oscillations.
Animal studies are useful in order to investigate the localisation of binding of 
antidepressants within the brain. Rainbow et al in 1982 found a heterogeneous distribution 
of imipramine binding sites in the rat brain. They found little or no specific binding over the 
white matter, or in the reticular formation and ventral thalamus. They found a moderate 
amount of binding in several brain areas including the caudate putamen, all layers of the 
cerebral cortex, and all subregions and laminae of the hippocampus. A high level of 
specific binding was found in the dorsal and medial raphe nuclei, the interpeduncular 
nucleus, the superficial layer of the superior colliculus, the locus coeruleus, the 
dorsomedial nucleus of the hypothalamus and the central grey. They concluded that the
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distribution of imipramine binding sites was in close agreement with the distribution of 
5-HT terminals in the brain.
The use of animals has also been important to demonstrate the validity of imipramine 
binding as an marker of changes occurring in the brain. Briley and co-workers in 1982 
were able to demonstrate parallel decreases in imipramine binding to platelets and 
hypothalamus in cats treated chronically with imipramine for 20 days. Evidence from work 
with pregnant rats is that treatment with antidepressants during pregnancy actually 
decreases imipramine binding sites in the newborn rats (Montero era/ 1990).
Further evidence comes from the fact that known antidepressants influence 5-HT 
metabolism and that 5-HT precursors can improve the condition (e.g. Raba et al 1984). 
Over the last decade increasingly more specific 5-HT uptake inhibitors have been 
introduced onto the antidepressant market, these include fluoxetine, fluvoxamine, 
sertraline and citalopram (See Aberg-Wistedt 1989 for review). The fact that they work in a 
number but not all depressives, suggests M important role for serotonin in depression but 
also implies that it is not the full picture (Swinson 1989).
Although most of what I have discussed above emphasises the importance of serotonin in 
depression, it would be wrong to give the impression that the picture is that simple. A 
major problem with the serotonergic theory of depression is that the serotonin system is 
linked, both functionally and anatomically, to other neurotransmitter systems, so that 
alterations will produce changes in both dopaminergic and noradrenergic systems (e.g. 
Amt et al 1984; Agren et al 1986; Sulser 1987; Bijak and Smialowski 1988; Potter et al 
1988).
Another problem is the huge number of disorders where serotonin related abnormalities 
have been found; serotonin dysfunction is implicated in schizophrenia (e.g. Le-Quan-Bul 
et al 1984), alcoholism (e.g. Borg et al 1985), obsessive compulsive disorder (e.g. Zohar 
and Insel 1987; Hollander et al 1989; Bastani et al 1991), panic disorder (e.g. Nemeth et 
al 1989; Targum and Marshall 1989) and eating disorders (e.g. Kaye et al 1988; Marazitti et
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al 1988; Jimmerson et al 1989). Decreased serotonergic activity can also be seen in 
Parkinson's disease and dementias (e.g. Argentiero and Tavolato 1980; Palmer et al 1984; 
Volicer et al 1985; D'Amato et al 1987; Mayeux et al 1988). Decreased 5-HIAA in the CSF 
is also found in a number of conditions such as infantile spasm (Silverstein and Johnson
1984) and the psychiatric symptoms that accompany hypeiparathyroidism (e.g. Almay et al 
1987; Jobom et al 1988). High levels of 5-HIAA have been associated, with among others, 
hypertension (Sharma et al 1985) and sub-arachnoid haemorrhage (Suzuki at al 1987). 
Autism has been linked with a blunted prolactin response to fenfluramine, decreases in
platelet 5-HT2 receptors, decreases in platelet serotonin uptake and increased levels of 
serotonin in the blood (MacBride et al 1989; Rolf et al 1989; Launay et al 1988). It is 
rather difficult to explain how one neurotransmitter system can be responsible for so many 
diverse conditions if we only allow ourselves to refer to simple overactivity or 
underactivity.
Additionally there has been the failure of a number of studies to demonstrate a relationship 
between change in markers and clinical change, and also the fact that therapeutic treatments, 
although effective, may produce different alterations in the serotonergic system. For 
example antidepressant treatment may decrease 5-HIAA in the CSF (e.g. Bjerkenstedt et al
1985) or may decrease the uptake of serotonin into platelets (e.g. Schlake et al 1989). The 
specific serotonin re-uptake inhibitors are therapeutic in conditions where they must 
apparently exert opposite effects e.g. obsessive compulsive disorder (Goodman et al 
1989a, 1989b) and impulsive aggressive personality disorder (Coccaro et al 1989; 
Cornelius et al 1989). In the former 5-HIAA levels in the CSF are elevated (Chamey et al 
1988; Hollander et al 1989), in the latter 5-HIAA is decreased (Brown et al 1982,1985).
The validity of strategies in serotonin research still needs clarifying. We cainnot be certain 
that levels of 5-HIAA seen in the lumbar CSF actually represent brain levels. Indeed there 
is some evidence that it may not (Gjerris 1988).
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The noradrenergic theory of depression
It was originally intended that as part of this research the effect of psychotherapy on
a 2~adrenergic receptors would also be investigated. There is considerable interest in the
functioning of adrenergic systems in people suffering from psychiatric disorders. 
Schildkraut (1965) proposed two possible methods by which adrenergic function may 
relate to depressive illness. The first possibility was that depression was directly associated 
with decreased adrenergic function and that effective treatment would be to increase 
adrenergic function and thereby alleviate the symptoms. The alternative was that depression 
may be associated with a variety of biochemical changes which result in decreased 
adrenergic function in the central nervous system in an attempt to adapt to the changes. 
Under these circumstances treatment would need to promote the decrease in adrenergic 
function rather than oppose it. The former possibility now seems to be the most likely, as
down regulation of p-adrenoceptors is seen in depressive disorder (Extein et al 1979) and 
effective antidepressants or electroconvulsive therapy cause an up-regulation of
P-adrenergic function and increases in plasma noradrenaline levels (Rudorfer e r a /1991; 
Coopérera/1985)
Although current information concerning the role of a 2-adrenergic receptors in depression
is far from conclusive it does appear that a 2~adrenoceptor activity is increased in
depressive compared to euthymie subjects (Wood and Coppen 1981; Coppen and Wood 
1980). This has also been observed in patients with pre-menstrual dysphoric changes 
(Halbreich et al 1989) and in the frontal cortex of depressed suicide victims (Meana and
Garcia-Sevilla 1987). The a 2-adrenoceptor under normal circumstances inhibits
noradrenaline release into the synapse thereby preventing excess release and allowing levels 
of noradrenaline to fall between stimuli. As shown in Figure 4.4 increased
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a 2-adrenoceptor capacity centrally would reduce adrenergic activity at the synapse as
mediated by the post-synaptic p-adrenoceptor. This could be both as a result of increased 
inhibition of noradrenaline release via presynaptic autoreceptors causing down regulation of
P-receptors or resulting from inhibition of adenylate cyclase activity at the post synaptic 
a 2-adrenoceptor.
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There are only limited data available on a 2-adrenoceptor binding characteristics in human 
brain tissue comparing depressed and non-depressed subjects, so it is difficult at this time
to assess which radioligand best reflects the central a 2-adrenoceptor changes, if any,
associated with depression. However clonidine, a mixed a 2-agonist-antagonist is known
to stimulate growth hormone release, via the noradrenergic system and this response can 
be shown to be blunted in endogenously depressed patients (Chamey et al 1982; Horton et 
al 1986), even following clinical recovery (Mitchell et al 1988), This is suggestive of
persistent tt2-hypersensitivity.
In animal models long-term administration of tricyclic antidepressants reduced the 
a2-adrenoceptor binding capacity as measured by [^HJclonidine, in specific areas of the rat 
brain - the amygdala, hippocampus and locus coeruleus ( Smith eta l 1981; Smith and 
Garcia-Sevilla 1982). However no changes were observed in the binding capacities of 
[3 H]-yohimbine or [3h]-DHE (Campbell and McKernan 1982). Other forms of 
antidepressant treatment, such as electro-convulsive therapy, have also been shown to 
reduce [^HJclonidine binding (Pile and Vetulani 1982; Stanford and Nutt 1982).
A number of different radioligands have been used to label platelet (X2-adrenergic receptors
(e.g. Motulsky etaL  1980,1982; Shattil etal. 1981; Cheung etal. 1982; Carstens etal. 
1986b ). Consequent discrepancies in the binding capacities identified by each radioligand
constitute a major problem in the interpretation of platelet (%2-adrenoceptor binding studies
in depression and may at least in part be due to an apparent heterogeneity of a 2-adrenergic
receptors observed in rat brain (Boyajian et al 1987; Boyajian and Leslie 1987). In addition 
there has been some difficulty in obtaining consistent results even using certain of the same
ligands. For instance, using the selective a 2-adrenoceptor antagonist [^Hj-yohimbine or its
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isomer [^HJ-rauwolscine, several independant studies have observed no difference 
between depressed and euthymie subjects in their platelet binding characteristics (Daiguji et 
al 1981; Pimoulecra/. 1983; Stahl era/. 1983; Cameron etal. 1984;Campbell e r a /1985; 
Braddock et al. 1986). There are however conflicting results on the effects of 
antidepressants on [^H] yohimbine or [^H] rauwolscine binding to platelets in depressed 
subjects. For instance, Pimoule et al. (1983) reported no change in [^H] rauwolscine 
binding in patients receiving chlorimipramine or amitriptyline for periods of up to 35 days, 
whereas Braddock et al. (1986) found treatment of depressed patients with amitriptyline for 
28 to 42 days significantly reduced [^H] yohimbine binding, but they were unable to 
demonstrate any correlation between this reduction and improvement in clinical condition. 
Cooper et al. (1985) using [^H]-rauwolscine showed a reduction in platelet binding in 
depressed patients after electroconvulsive therapy but they too were unable to relate this to 
clinical improvement. Overall the choice of yohimbine-alkaloids for binding to platelet 
adrenoceptors has failed to produce uniform results in differences between binding in 
depressed and control subjects (Reviews by Kafka and Paul 1986; Katona et al 1987).
Using the non-selective a-adrenoceptor antagonist dihydroergocryptine (DHE), Wood and 
Coppen (1981; 1983) reported fewer platelet binding sites in a group of depressed patients 
when compared to controls, with no change in binding afGnity. In direct contrast to this, 
Healy et a i (1983), using the same radioligand, reported significantly higher binding 
capacity in depressed patients as compared to controls, and subsequently, in those patients 
showing clinical improvement the binding capacity fell to a level similar to the controls. 
However supporting evidence for Healy et a/'s (1983) results have since emerged and it 
now appears that DHE may be a useful marker (e.g. Roy and Kafka 1989)
The only radioligand at the time when this research was set up, in which repeated studies 
had shown significant differences between depressed and control subjects was
[^Hjclonidine, and for this reason it was the marker of choice for labelling a 2-adrenergic 
receptors in this study. Shattil et al. (1981) demonstrated that [^H] clonidine could be used
6 6
to identify high-affinity tt2-adrenergic receptors on human platelets. Furthermore it had
been demonstrated that clonidine binds to a different subset of receptors than yohimbine 
(Piletz and Halaris 1985) and therefore there was a possibility that it may not be as 
susceptible to the variation in results as discussed above. Binding of [^H] clonidine to the 
platelets of depressed subjects is significantly higher than that of normal controls (e.g. 
Pandey et al 1989), and furthermore, this binding level is seen to fall in association with 
clinical improvement following administration of tricyclic antidepressants, lithium or 
electroconvulsive therapy (Smith and Garcia-Sevilla 1982; Smith etal. 1983; Cameron et 
al. 1984). It would therefore appear that [^H]-clonidine binding may represent a state 
dependent marker for depression, and possibly schizophrenia (Pandey et al 1989). It is
perhaps worthy of mention at this stage that studies on a 2-adrenergic receptors in
depression have concentrated on the so called endogenous subtype of major depressive 
disorders. To my knowledge no research has been conducted on people with less severe
cases of reactive depression such as were to be studied in this project.
Since the setting up of this project the situation regarding markers of alpha2-
adrenoreceptors on platelets has been further clarifîed, with the result that, [^HJ-DHE, 
[^Hj-clonidine, [^Hj-para-aminoclonidine, and [^H]-adrenaline have all been identified as 
showing increased platelet binding in depression (Garcia -Sevilla et al 1986,1987; Garcia 
-Sevilla 1989; Doyle et al 1985; Kafka et al 1985; Roy and Kafka 1989; Piletz and Halaris 
1988; Piletz et al 1990, 1991; Pandey e ta l  1989; Takeda e ta l  1989). It has been 
suggested that the reason that these compounds detect differences between depressed and 
non-depressed subjects may be because these agents label high affinity agonist induced 
states, whereas yohimbine and rauwolscine at the concentrations used tend to label low 
affinity binding states. As a result of these findings Garcia-Sevilla et al (1986 and
Garcia-Sevilla 1989) proposed that only high affinity a 2-adrenergic receptors are elevated
in depression. However it should be emphasised that even using these assays differences 
are not always apparent between depressed and control groups (e.g. Carstens et al 1986b;
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Theodorou et al 1986; Georgotas et al 1987). Therefore, the status of platelet 
a 2-adrenoceptors in depression, remains unclear.
Roy and Kafka (1989) and Siever et al (1983) have shown that depressed patients have
reduced prostaglandin E 2-stimulated cyclic adenosine 3*,5' monophosphate (cAMP)
production, and a significantly decreased percentage inhibition of cAMP production by 
noradrenaline, furthermore noradrenaline levels could be correlated with [^H]-DHE
binding where there was adequate PGE% stimulation of cAMP (Siever et al 1984). Roy and
Kafka proposed that there may be a dissociation between a 2-adrenceptor binding and 
responsivity in depression.
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CHAPTER 5
PILOT STUDY
As discussed in Chapter 4 platelets have been used widely as models for neurones in 
binding, storage and uptake studies. The similarities and differences of the serotonin and 
noradrenergic systems in platelets and neurones are discussed elsewhere (e.g. Stahl 1985; 
Pletscher et al 1984) as is the relative usefulness of platelet studies (e.g. Dodd et al 1988). 
The most widely used marker has been imipramine binding to platelet membranes which 
has generally been found to be decreased in depressed patients (e.g. Slotkin et al 1989) 
and this was the marker of choice in a pilot study set up in this laboratory. In the following 
sections I shall briefly outline the results found in this study as they were the basis upon 
which the present project was set up and are relevant to the discussion of these data.
M ethod
As far as I am aware the first work to be carried out investigating changes in biochemical 
markers in patients undergoing psychotherapy was, carried out by this laboratory in 1984 
(Rose and Murphy 1987). The therapy that the individuals were undergoing was a 
particularly intensive form of therapy known as primal therapy whose theory explains 
psychic distress in term of traumatic events occurring very e^ly  in life, possibly even at 
birth (e.g. Janov 1990). The treatment of the disorder can involve a re-birthing process 
and can be, in itself be a very traumatic process (see Chapter 3). A group of 16 volunteers 
entering a period of primal therapy at Dr Janov's centre in Paris, had blood samples taken 
3 days before therapy began, on the day therapy started, on day 21 and 6 month and 12 
month (only 8 samples) follow ups. The population had an even sex distribution and was 
aged between 24 and 45. None were taking any prescribed psychoactive medication during 
the study.
A control group of similar age and sex distribution was taken firom the Open University 
and blood samples taken on a similar time scale. An n of 17 fell to 13 by the 6 month time
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point and no 12 month samples were taken.
Therapists were also asked to rate primal subjects on a 13-item assessment scale devised by 
Janov, on the basis of clinical notes written prior to the start of therapy and at the 6 month 
follow up. Items were assessed on a 1-4 scale and ranged from anxiety and depression 
through to concentration difficulties and sleep disorders. These were converted to global 
scores for each subject for each assessment point (minimum score indicating least distress 
= 13, maximum score = 52)
The assay of choice for this study was imipramine binding to platelet membranes. Blood 
samples were drawn and assays performed using the methods described in Chapter 6.
Results
As can be seen in figure 5.1, the results were very promising. They indicated that self 
referring individuals entering a period of primal therapy had maximal imipramine binding 
levels that were approximately half that of a normal control group. Also, six months after 
starting a course of primal therapy their imipramine binding levels had increased to a level 
indistinguishable from control levels. Eleven subjects showed an improvement according to 
the psychiatric assessment scale, and there was a very weak positive correlation between 
this improved assessment score and increased imipramine binding (see figure 5.2). 
Interestingly some evidence of circannual variation was seen in imipramine binding in both 
controls and Primal subjects as had previously been reported elsewhere (e.g. Galzin et al
1986). However the pattern of seasonality was very different in primal and control 
subjects, and may represent changes as a result of the primal therapy in addition to seasonal 
effects (see Figure 5.3)
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Figure 5.1
The graph below shows the change in primal therapy client [^H]-imipramine binding to 
platelet membranes compared to controls over the 12 month period of the study
Change In primal therapy clients Imipramine binding compared to controls
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Control values:
-3 days n=17; 0 weeks n=15; 3 weeks n=16; 26 weeks n=13 
Primal therapy client values:
-3 days n=16; 0 weeks n=14; 3 weeks n=13; 26 weeks n=14; 52 weeks n=8
Results are expressed as means +/_ standard error of means. Statistical analyses were 
performed using a one tailed students t-test. The control data being taken to represent the 
normal population.
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Figure 5.2
t.
The graph below shows the correlation between the changes in imipramine binding and the 
change in the psychiatric rating scales in the Primal therapy clients.
Correlation of imipramine binding with psychic state
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The results shown are firom the Primal group only. 
A very weak positive correlation is apparent
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Figure 5.3
The graph below shows the effect of season on the primal and control group imipramine 
binding.
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S
Effect of season on control and primal groups Imipramine binding
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Control values: J-F n=15; M-A n=10; M-J n=6; J-A n=8; S-O n=7; N-D n=4. 
Primal values: J-F n=8; M-A n=6; M-J n = ll;  J-A n=10; S-O n=5; N-D n=14.
Results are expressed as means +/- standard error of mean.
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Whilst these observations were not in any way an endorsement of the theoretical claims of 
the particular type of psychotherapy involved, they indicated that such therapies may result 
in lasting biochemical changes. These data led to the current research, to investigate 
whether it would be possible to detect changes in biochemical binding parameters in parallel 
with psychological change.
Although the Primal Study provided us with some extremely interesting data it was not 
particularly well controlled, in as much as individual primal subjects were not matched with 
individual controls. Also the timing of samples, although on the same scale was different in 
Paris to the control samples in England. In addition the handling that samples received 
(transport back from Paris etc.) was potentially quite different.
Another methodological problem was that the questionnaires were not standard or well 
validated and were completed by therapists in France, and by the individual involved in 
England. For these reasons the present study was set up with highly validated self-rating 
questionnaires (See Chapter 6) and age and sex matched controls. It is important to 
emphasise that it was not a primary aim of the project to evaluate outcomes of 
psychotherapy as against, say, placebo or drug treatments, and I was not attempting to 
incorporate into the present design controls against the possibility that any observed 
changes in either biochemical or psychiatric rating scores may have been the result of 
spontaneous remission rather than the therapeutic process per se. Whilst testing the latter is 
an important goal of outcome studies, it must be clearly understood that the research 
reported in this thesis had a quite different purpose. These controls were intended to act as 
a population 'normal'.
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CHAPTER 6 
EXPERIMENTAL DESIGN 
The collaborating Centre
Agreement was reached with a group of therapists working from The Open Centre (Old 
Street, London ECl). The Open Centre is a part of the Community Health Foundation and 
has been established since 1977. The Centre does not see itself so much as a clinic, but more 
as a growth centre, which offers a range of individual and group psychotherapies within the 
broad spectium of the humanistic psychology movement (Despite the analogous name, it 
should be made clear that the Centre has no relation with the Open University). The range of 
therapies at the Centre includes; Encounter therapy, Bioenergetic therapy and Gestalt 
therapy. These are well-established psychotherapeutic techniques with an extensive 
methodological literature (e.g. Peris 1974; Lowen 1971; Wibberley 1988; Whitfield 1988; 
Parlett and Page 1990 ). Clients are carefully selected by therapists to participate in group or 
individual therapy and where necessary may be referred to other therapists within the group. 
People who are not considered appropriate for the type of therapies on offer are not taken 
on. All therapists at the Open Centre are Êighly experienced and well recognised within their 
field. Most clients at the Open Centre are involved in therapy at least once a week for a 
minimum of one hour (although generally longer). Therapists and Counsellors from the 
Open Centre informed new clients of the research, both verbally and in the form of a 
standard letter (Appendix 1), and provided the facilities required for administering the 
questionnaires and drawing the blood. Attempts were made to include NHS hospitals within 
this study, but were unsuccessful, as most centres would have patients on drug therapy in 
addition to the psychotherapy.
The Client sample
From January 1988, through to August 1989 new clients entering the Centre (and also 
clients who had been in therapy for some time but still had scope for improvement) were
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invited to participate in the research. Their therapist explained the aims and procedure of the 
investigation to the clients as early as possible in their course of therapy. If the client was 
interested, he or she was given an explanatory leaflet and enabled to make contact with 
myself. Thereafter, the therapist was not directly involved in the research programme. 
Clients accepted into the research were not currently, or in the three months prior to the start 
of the project, regularly using psychotropic drugs, and whilst no rigorous diagnostic 
categories were applied, the aim was to recruit mainly those presenting clear signs of 
depression with or without anxiety. It was assumed that clients accepted for the study were 
entering a period of regular (at least weekly) one-to-one therapy or counselling or weekly 
group therapy in small group situations. Clients who withdrew from therapy before 3 
months were discounted from the study. A total of 19 clients were included in the study, of 
these 12 were participating in encounter therapy, 4 in Gestalt and 3 in Bioenergetics (4 other 
clients were enrolled into the study but dropped out before 3 months treatment had been 
completed). The age range of the clients was 23-48 (mean 36) and 68% were female.
The control sample
Each client admitted into the sample was matched with a control of the same sex and similar 
age ( age range 23-49 (mean 36) 68% female). Controls came entirely from staff at the 
Open University.
There is an extensive body of literature indicating that measures of serotonin function are 
susceptible to both circadian and circannual variation (as seen in the pilot study). Diurnal 
patterns of uptake of serotonin into platelets have been shown in both depressed patients and 
controls (Rausch et al 1982; Arora et al 1984a; Modai et al 1986), but they are much more 
variable in patients (Humphries et al 1985). This effect is also seen in the rat suprachiasmatic 
nuclei (Wirz-Justice et al 1983). As well as the serotonin uptake studies imipramine 
binding assays have indicated lower levels of binding during the night (Nankai et al 1986). 
Further evidence comes from the fact that circadian rhythms in general can be altered by 
psychiatric illness (e.g. Wehr and Wirz-Justice 1982) and that effective antidepressant 
treatment actually slows or dissociates circadian rhythms (Wirz-Justice and Campbell 1982).
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Furthermore the diurnal rhythm of platelet 5-HT has actually been found to have circannual 
variation (Wirz-Justice and Puhringer 1978)
Circannual variation has also been extensively reported in both depressives and controls, 
although the period with the highest values varies from the autumn and winter (Arora et al 
1984; Whitaker et al 1984) through to winter and spring (Healy et al 1990), and late 
summer and autumn (Egrise et al 1983; Egrise et al 1986; Arora and Meltzer 1988). Overall, 
highest values seem to be found around September.This effect has also been reported on 
subclasses of imipramine binding sites (DeMet et al 1990a), Other work however has failed 
to find any evidence of seasonal variation. (Galzin et al 1986). A study using paroxetine 
binding to measure circannual changes in serotonergic function found highest values in 
December(Klompenhouwer etal 1990).
The important point that is stressed by t^th circadian and circannual studies is that controls 
and subjects should be assessed at the same time of day as far as possible (certainly samples 
should be made at the same time of day for each individual) and at the same time of year. 
The effects of age and gender on both binding assays and self rated assessments are not 
particularly clear with various different findings reported (e.g. Klompenhouwer et al 1990; 
Maes et al 1988; Langer et al 1980; Theodorou et al 1989; Andersson and Marcusson 
1990). The purpose of the control group was to provide a background population 'normal' 
value so that age, sex, circadian and circannual changes would not falsely influence the 
results.
The Nurses group - stressed control group
In order to provide a population of possible depressed controls co-operation was obtained 
from Milton Keynes General Hospital to allow recruitment of up to 30 nurses onto the 
study and provide the necessary facilities for blood withdrawal and administration of 
psychiatric rating scales.
Assessments were made on a group of 27 nurses from Milton Keynes General Hospital over 
a period of 1 year starting in November 1988. Every effort was made to ensure that all
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nurses were sampled at each visit, however due to shift-work, holidays and sickness this 
was not always possible. The age range was 21-55 (mean 30) and was 89% female.
Given the uncertainty about which types of nursing are the most stressful and therefore most 
likely to result in depression, I chose not to specify and agreed to take nurses from 
anywhere in Milton Keynes General Hospital. In actual fact they came from surgical, 
medical and accident and emergency departments. There are a number of questionnaires 
designed specifically to investigate stress in the health profession (e.g. the Health 
Professions Stress Inventory (HPSI) Wolfgang 1988b). However the questionnaires used 
in this study have been successfully used in nursing studies (e.g. Motowidlo et al 1986; 
Livingstone and Livingstone 1984) and it was not our intention to try and investigate 
sources of stress in this population. This group was intended to act as a control group of 
individuals who were more likely to to be depressed than the 'normal' population but who 
were unlikely to receive any treatment.
The Choice of Questionnaires
The three questionnaires were all designed to give a numerical score of psychiatric rating. 
They were chosen after consultation with Dr Power at the Institute of Psychiatry in London 
as they are widely accepted questionnaires requiring no psychiatric training to administer. 
Each time the questionnaires were given the subject was asked to mark the descriptions 
which best described how they had felt over the last week. Often subjects would request 
help with completing the questionnaires, in these circumstances they were reminded that 
they should reply with how they have felt most of the time. Subjects were strongly 
encouraged to answer all questions, but where they were unable to the complete the whole 
questionnaire their results were excluded. The questionnaires chosen were three self-report 
questionnaires, the General Health Questionnaire 28 (GHQ-28) (Goldberg and Hillier 
1979), the Beck Depression Inventory (BDI) (Beck et al. 1961) and the Multiple Affect 
Adjective Check List (MAACL) (Zuckerman and Lubin 1965)
The GHQ-28 consists of 28 multiple choice questions; it is intended to assess the general
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State of well-being of the subject and breaks down into 4 "sub-scales"; somatic, anxiety, 
social dysfunction and depression (See Appendix 2), An overall score is given by marking 
all answers in the two right hand columns as one point, a score of 5 points or more (out of a 
possible 28) is considered to be a "psychiatric case". One problem with this questionnaire in 
very mild patients is that if the subject has a minor illness such as influenza the somatic score 
will be high and push up the overall score. For the purpose of analysis on this study figures 
are presented both with and without the somatic scores included. The GHQ-28 is widely 
recognised as a diagnostic tool particularly in epidemiological studies involving General 
Practitioners (e.g. Boardman 1987)
The BDI is composed of 21 multiple choice questions (see Appendix 3), each answer gives 
a score of between 0 and 3 points (maximum 63 points). Kendall et al. (1987) recommended 
the following cut-off scores: 0-9 = non-depressed, 10-15 = dysphoric, 16-20 = dysphoric, 
possibly with secondary depression, 21-30 = moderate depression, 31+ = severe 
depression. The BDI is very widely used in psychiatry and is acknowledged to be most 
useful in patients that are not too severely affected and correlates well with scores made on a 
Clinical Global Impression by psychiatrists (Faravelli et al 1986).
The MAACL is a list of 132 words (see Appendix 4), the subject is asked to mark an "X" by 
those words which best describe their feelings over the last few days. It is essential that this 
questionnaire was completed rapidly otherwise the subject may reject words simply because 
they appear to conflict with what they have already crossed. Of the 132 words, 43 have no 
scores at all associated with them, of the others some are so called "plus" words and others 
are "minus" words. For instance when scoring for depression words such as: awful, blue, 
lonely, lost, sunk, etc (plus words) score +1 point each, when marked; whereas words such 
as: active, alive, fine, healthy, young, etc (minus words) score +1 point each when not 
marked. The scoring is on three separate scales; anxiety (21 words), depression (40 words) 
and hostility (28 words). As this study was mainly concerned with anxiety and depression, 
scores are presented with and without the inclusion of hostility. Of the three scales used in 
this study the MAACL is the least well validated and the least frequently used.
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It is worth commenting at this stage that for ease of use all of the above questionnaires are 
self-rated and so for this reason do not meet any rigid diagnostic or treatment effect criteria 
as defined by the World Health Organisation (Bech et al 1984). However in a recent review 
of questionnaires for use in the early detection of depression using questionnaires both the 
BDI and GHQ-28 met the designated quality criteria (Feightner and Worrall 1990).
In addition, on each of the sample dates the therapist was asked to fill in a short report 
containing visual analogue rating scales for anxiety and depression, and asked for any 
comments they may have had on the condition of the client (See Appendix 5) Unfortunately, 
in the event, the therapists were too busy to fill these in at the time, and it was felt that 
retrospective analysis was not desirable.
The Choice Of Assays
1. Measures of serotonergic function:-
As discussed in chapter 4, imipramine binding to blood platelet membranes has been used 
extensively as a measure of serotonergic function in the study of depressive disorder where 
it is found to be decreased in depressed subjects (e.g Langer and Raisman 1983; Poirier et al 
1986; Innis et al 1987). The affinity of imipramine for its binding site on the platelet 
membrane can be altered by administration of antidepressant drugs ( Rehavi et al 1980; 
Plenge and Mellerup 1985; Mellerup and Plenge 1986) and this effect has been seen to occur 
concomitantly in brain and platelet assays in animal studies (Briley et al 1982). It has also 
been suggested that imipramine binding may represent a possible predictor of response to 
antidepressant treatment (Hrdina et al 1985).
However a number of studies have failed to demonstrate any difference between imipramine 
binding in controls and depressed patients (e.g. Plenge et al 1988; Desmedt et al 1987) or an 
actual increase in binding in depressed patients (e.g. Mellerup et al 1982; Baron et al 1983). 
Some doubt has therefore been cast on the validity of imipramine as a marker for 
depression, and it was being investigated by the world Health Organisation (Morozov 1985) 
at the time when this study was being set up. The preliminary results from centres in Basle,
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Brussels and Copenhagen indicated that no pronounced differences were apparent between 
depressed patients and matched controls (Bech et al 1988) and when the final results were 
published they confirmed the preliminary findings (Mellerup and Langer 1990). However 
despite extensive efforts to standardise methods across the laboratories a wide range of 
Bmax values were found. The control values varied from 360 (Tokyo) to 2514 (Irvine) and 
the patients group from 388 (Tokyo) to 2006 (Irvine). Rihmer (1991) has suggested that 
these differences may be due, at least in part to latitudinal differences reflecting on day 
length, although it is interesting to note that those centres with shortest day length reported 
highest Bgiax- O" closer inspection of these results it is not my opinion that they provide 
sufficient evidence to eliminate imipramine as a marker of depressive disorder. Whilst it is 
true that common diagnostic procedures were used, there still exists enormous cultural and 
ethnic differences in patients who will present with depression in these different countries 
(e.g. Moscow compared to Tokyo, Irvine, Brussels etc). This impact need not however 
have been as marked if the number of patients studied in each centre had been greater, the 
majority of centres only contributing 10-20 patients (5 in Tokyo), and in some cases 
significantly less controls. Whilst these results inevitably must cast some doubt over the 
validity of imipramine binding as a marker of depression, I feel that they are not of high 
enough quality for further consideration of imipramine to be discounted.
Imipramine is known to bind to at least two different sites in brain and platelets, one low 
affinity and one high affinity site (Conway and Brunswick 1985) and it is also recognised 
that the high affinity sites may exist in multiple affinity states dependent on the amount of 
imipramine present (Phillips and Williams 1984; DeMet and Chicz-DeMet 1990), and that 
different subclasses of receptors may respond differently to antidepressant treatment (DeMet 
et al 1990b). The conditions under which binding takes place could presumably influence 
the relative proportions of high and low affinity binding and therefore influence the results. 
It seems probable that quite small changes in assay methodology may account for at least 
part of the variation seen in results (Mellerup and Plenge 1988). Factors such as protein 
concentration (Arora et al 1985; Theodorou et al 1989) and the proportion of intact platelets 
(Friedl et al 1983;Svereson et al 1990) in the reaction mixture are all known to affect binding 
levels.
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For these reasons an alternative to the imipramine binding assay was investigated. Measures 
of serotonergic metabolites in blood platelets correlate well with measures of the same 
metabolites in CSF (Sairias et al 1990), so an alternative measure of serotonergic function 
was sought. Paroxetine is known to be a selective and potent inhibitor of 5-HT uptake into 
serotonergic neurons which binds to a single high affinity site in the brain of rats (Habert et 
al 1985). Studies in human brains have shown that paroxetine also binds to a low affinity 
site (Backstrom et al 1989) but that its high affinity binding is of higher affinity than 
imipramine and allows a more precise determination of B ^ax (Plenge et al 1990). 
Paroxetine is, therefore the marker of choice for investigating 5-HT uptake sites in the 
human (Hrdina et al 1989; Backstrom et al 1989) and animal brain (Scheffel and Haitig 
1989). When the binding of paroxetine to platelet membranes is compared with imipramine 
it is found to have a much higher affinity (Mellerup et al 1983) but to show a very similar 
distribution within the brain (Cortes et al 1988). Schoemaker et al (1986) found that the 
binding of paroxetine to platelet membranes occurred with greatest affinity at 37°C and 
concluded that 5-HT uptake activity was better reflected by paroxetine binding at 37®C than 
by imipramine at 0®C.
Due to the popularity of paroxetine, particularly in brain studies of 5-HT uptake, it was 
decided to investigate paroxetine rather than imipramine binding to platelets. However 
midway through the study (when a reliable clonidine assay for a 2-adrenergic receptors had 
still not been achieved) an interim analysis was done on the paroxetine binding, the results 
of which led me to use the platelets originally assigned to the clonidine assay to do 
imipramine binding assays in parallel with the paroxetine. Since imipramine and paroxetine 
bind to different polymers within the 5-HT uptake site, it was possible that different results 
would be seen using the two markers (Mellerup et al 1985).
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2. Measures of a 2-adrenergic function
As discussed briefly in the previous chapter a 2-adrenergic receptor hyperactivity has been 
implicated in depressive disorder (e.g. Piletz et al 1990). However very variable results have 
been reported using radioligand binding studies to platelets. Yohimbine is a potent «2 
antagonist (Garcia-Sevilla etal 1981; Motulsky and Insel 1981; Motulsky etal 1980) and so 
if used in platelet binding studies an increased binding would be predicted in depressed 
patients. In actual fact no difference between depressed patients and controls is seen (e.g. 
Daiguji et al 1981; Stahl et al 1983). Rauwolscine is also a highly selective a 2-antagonist 
and also shows no difference in platelet binding studies between depressed patients and 
controls (e.g. Pimoule et al 1983).
Clonidine is an a2  mixed agonist-antagonist which, like rauwolscine and yohimbine is 
highly specific (Garcia-Sevilla et al 1981; Shattil et al 1981). It has been shown that the 
long-term administration of amitriptyline decreases the number of high affinity sites in neural 
membranes isolated from specific areas of the rat brain (Smith e ta l 1981). Studies 
investigating binding of clonidine to platelet membranes of depressed patients have found 
increased numbers of binding sites although no change in affinity (Pandey e ta l 19S9; 
Garcia-Sevilla 1981). Similar results are also seen with the closely related compound 
para-aminoclonidine (Piletz et al 1990). This is in keeping with the adrenergic theory of 
depression indicating greater numbers of activated a 2-adrenergic receptors and so the 
clonidine assay was originally chosen for the analyses. However, failure to produce a 
reliable assay with the quantities of platelets available led to utilision of the imipramine assay 
of 5-HT uptake sites rather than the clonidine assay.
Investigation procedure
On entering the sample, clients, controls and nurses were asked to complete the three 
self-report questionnaires, the GHQ-28, MAACL and the BDL At the same time a blood 
sample was drawn for preparation of platelets. The same protocol was repeated on five 
subsequent occasions: 1 month, 2 months, 3 months, 6 months and 12 months after the start 
of therapy (even if the client dropped out of therapy after three months or so, efforts were
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made to retain him or her in the sample). As far as possible, sampling from the controls was 
done at the same time as from the clients, and sampling for any one individual was carried 
out at the same time of day on all occasions. In general, questionnaires were administered 
and blood samples taken at the psychotherapy centre (for clients), but on occasion and 
where appropriate the site was changed for mutual convenience of client and researcher. 
Sampling from controls was conducted at the Open University Medical Centre. Sampling 
from the nurses was completely independent from the control sampling times and took place 
at Milton Keynes General Hospital, but as far as possible individual nurses were sampled at 
the same time of day. All questionnaires and blood samples were coded as they were taken 
so as to preserve confidentiality. These were then independently recoded to ensure that 
subsequent analyses were performed blind.
The Assay Procedures
For the platelets, venous blood (20ml) was drawn into tubes containing citric acid/sodium 
citrate/dextrose anti coagulant and transported to the Brain Research Group laboratories at 
the Open University. Appropriate precautions were taken in the drawing of blood in the light 
of general medical good practice and the present concern over the hazards of HIV and 
hepatitis infection.
Platelets were prepared according to the method of Stahl et al (1977) as follows:- the blood 
was centrifuged at 600g for 10 minutes at room temperature and the platelet-rich plasma 
removed; the remaining blood was spun again to ensure that as much as possible of the 
plasma was collected. The platelet-rich plasma was then divided into two tubes, one 
containing approximately a third of the sample and the other the remaining two thirds; both 
tubes were then spun at 18000g for 10 minutes at 4®C. The smaller sample was used for 
the paroxetine assay and the larger one was intended to be for the clonidine assay, but as no 
reliable assay was found this fraction was used for an imipramine binding assay.
Preparation of platelet membranes for paroxetine binding assay:
Platelet membranes were prepared using the method described by Phillips et al. (1984). The
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platelet pellet was resuspended in 2nd cold 50mM Tris HCl buffer containing 120mM 
NaCl and 5mM KCl (pH 7.5), centrifuged again, resuspended in Ind of the same buffer 
and stored frozen at -20^C until it was assayed. (It is well established that platelet 
preparations may be stored for several months in this way without loss of imipramine 
binding activity, e.g. Lewis and McChesney (1985a)) For the assay, platelet pellets were 
disrupted using a homogeniser (20 strokes) and spun at 39000g for 10 minutes, at 4®C. The 
pellet was resuspended in Ind of buffer and sonicated, the membrane fraction was then 
divided into the appropriate aliquots.
Preparation of platelet membranes for clonidine binding assay (used for the 
imipramine binding):
Platelet membranes were originally prepared for use in the clonidine binding assay using a 
slightly modified version of the method described by Shattil et al. (1981). The platelet pellet 
was resuspended in 2nd of ice cold buffer containing 50mM Tris HCl, lOOmM NaCl, 5mM 
EDTA (pH7.4), centrifuged at 1800g for 10 minutes at 4®C, then resuspended in 2nd of the 
same buffer and stored frozen at -20°C. (As the clonidine assay was not actually used, 
these samples were used for the imiprandne binding assay and after thawing were washed in 
paroxetine buffer twice to remove EDTA then homogenised and sonicated as above.) It was 
very important that the process of sonication and homogenisation was done accurately and in 
a repeatable manner as the proportion of intact platelets can have a marked effect on results 
(Friedl et al 1983).
For the samples used to try to develop the clonidine assay the suspension was thawed and 
spun again as before. The washed platelets were then resuspended in a hypotonic buffer 
containing 5mM Tris HCl, 5mM EDTA (pH 7.5) and homogenised as described above. 
This suspension was then centrifuged at 3900g for 10 minutes at 4°C and the pellet 
resuspended in the same buffer and centrifuged a second time. The resultant pellet was then 
resuspended in 1.5ml of a buffer containing 70mM Tris HCl, 0.5mM EDTA, 8mM MgCl%, 
0.8mM sodium ascorbate.
Protein concentration of all membrane suspensions was determined on a portion of the
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preparation using a modified version of the method of Lowry et al. (1951). lOpl of platelet 
membrane suspension was added to 3ml of alkaline carbonate and the volume made up to 
5ml with distilled water. Similar tubes were set up with either no protein (blank), or a 
known amount of bovine serum albumin (Protein standard). The tubes were left to stand at 
room temperature for 10 minutes, then incubated with 0.3ml of Folin's reagent for 30 
minutes at room temperature. The depth of colour produced was then read on a 
spectrophotometer at 5(X)nM.
For the paroxetine binding assay approximately 0.1-0.2 mg of platelet membrane was 
incubated for 3 hours at 37°C in Tris buffer as above contmning approximately 9nM of 
^H-paroxetine in the presence or absence of ImM serotonin. These conditions were chosen 
on the basis of previous experience and data presented in the following chapter, to give 
maximal binding, they are very similar to the method described by Schoemaker et al (1986). 
I did not explore possible changes in affinity of the receptor, because this has not been 
reported as showing changes in the context of psychic distress or drug treatment. Following 
incubation, the mixture was diluted with 3ml ice-cold buffer and filtered under vacuum 
through Whatman GF/F glass fibre discs. The discs were washed three times with 3ml of 
buffer, dried overnight at 4®C and bound radioactivity measured in a scintillation counter. 
All assays were in sextuplicate (three with, three without, serotonin). Specific binding 
activity was taken as the difference between radioactivity bound in the presence and absence 
of serotonin and expressed as fmol. paroxetine bound per mg protein. An identical 
procedure was followed for the imipramine binding assay except that samples were 
incubated on ice for Ihour 15 minutes and specific binding was determined using 1.2mM 
5-HT.
The methodology for the clonidine assay would have been similar to the paroxetine assay 
but it proved impossible within the timescale of this research to obtain good repeatable 
results. This is discussed in more detail later.
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Statistical analyses
As discussed earlier the purpose of the control group was to act as a population 'normal* and 
clients and controls although matched for age and sex were not paired in any other way. 
Nurses were compared to the same control group as the clients and no attempt was made to 
match them in any way. For this reason mean values for the control group were taken to 
represent the population and the clients and nurses values were compared to this using a one 
tailed t-test. Change over the 12 month period for for each parameter analysed was assessed 
using a paired t-test to compare the value obtained at baseline with the final (12 month 
value). Additionally analysis of variance (ANOVA) and repeated measures ANOVA were 
performed to assess the change in the parameters over time.
Some researchers (e.g. Maes et al 1988) have reported differences in male and female 
reporting on self report questionnaires. For this reason male and female data were analysed 
separately in addition to the general analysis to see if there were any obvious differences.
The General Health Questionnaire and the Multiple Affect Adjective Checklist both break 
down into separate components, some sub-analyses of these scales were also made.
HYPOTHESES
On the basis of the information discussed in the previous chapters concerning serotonergic 
and adrenergic function in depression my hypotheses were:-
a) that the average levels of imipramine and or paroxetine binding to platelets derived from 
the blood of depressed people entering psychotherapy would be significantly lower than that 
of the matched control group.
b) that during the course of a period of psychotherapy of up to a year, average levels of 
imipramine and, or paroxetine binding in the client sample would rise towards those of the 
control group.
c) that for any individual client, changes in imipramine/paroxetine binding levels during the 
course of treatment would show correlations with changes in psychic state as measured
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using standard psychiatric rating sc^es.
d) that those nurses whose questionnaires indicate signs of depression/anxiety would show 
altered platelet imipramine and paroxetine binding levels, and that any improvement in their 
psychiatric rating would correlate with their binding levels moving towards those of control 
values.
e) that the average levels of clonidine binding to platelets derived from the blood of 
depressed people entering psychotherapy would be significantly higher than that of the 
matched control group.
f) that during the course of a period of psychotherapy of up to a year average levels of 
clonidine binding in the client sample will fall towards those of the control group.
g) that for any individual client, changes in clonidine binding levels during the course of 
treatment will show correlations with changes in psychic state as measured using standard 
psychiatric rating scales.
h) that those nurses whose questionnaires indicate signs of depression/anxiety will show 
altered platelet clonidine binding levels, and that any improvement in their psychiatric rating 
will correlate with their binding levels moving towards those of control values.
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CHAPTER 7 
DEVELOPMENT OF THE ASSAYS 
Imipramine binding assay
This assay had previously been worked on in this laboratory. Due to the failure to get the 
clonidine assay to work (as discussed later) it was decided to use imipramine and see 
whether any differences would be apparent between imipramine and paroxetine binding. As 
this method had already been used in the laboratory confirmation of the methodology was 
relatively straightforward. Freezing is known to not markedly effect imipramine binding, 
and this was confirmed by assaying freshly prepared platelets compared with samples frozen 
for 4 months.
The effect of increasing amounts of protein from O.Olmg to 0.2mg was assessed, higher 
amounts of protein were not investigated as they were unlikely to be available. There was no 
noticeable effect of the amount of protein on specific binding per mg of protein. As protein 
concentration increased, binding increased in a linear manner (see fig 7.1).
The effect of imipramine concentration on specific binding was assessed using 
concentrations of 0 tol7nM of imipramine. The optimal concentration was found to be 
8.6nM achieving approximately 85% specific binding (See figure 7.2). The B ^ax for 
imipramine binding was estimated at 575 fmol/mg protein, which is at the lower end of the 
range found in previous studies (e.g WHO multicentre collaborative study (Mellerup and 
Langer 1990))
Additionally the concentration of 5-HT required for maximal inhibition of specific binding 
was ascertained using concentrations of 5-HT from OmM to 2mM. Maximal inhibition 
appeared to be achieved at around ImM., but it was felt that it was preferable to increase this 
slightly to 1.2mM to ensure that all specific binding would be detected (see fig 7.3).
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The effect of time on imipramine binding up to 90 minutes was assessed. The graph shows 
that no binding was apparent at either 20 minutes or 40 minutes, the reason for this is not 
clear but may be due to the fact that the reaction takes place on ice and may be very slow to 
get started. In previous imipramine binding assays the incubation time had been 1 hour on 
ice, in view of the data shown in figure 7.4 this was extended to 1 hour 15 minutes
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Figure 7,1
The graph below indicates that increasing the protein concentration in the reaction mixture up 
to 0.2mg does not markedly effect the specific binding of imipramine per mg of protein.
Effect of Protein concentration on imipramine binding
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The results reported on this graph come from several experiments (O.Olmg n=l 0.02mg 
n=l; O.OSmg n=4; O.lOmg n=5; O.lSmg n=6; 0.20mg n=6). All assays were 
performed in triplicate (Intra-triplicate variation 3-6%). The results are expressed as means 
+/- standard error of mean.
All assays were incubated for 1 hour and 15 minutes at O^C (on ice) with 8.6nM of 
imipramine. After incubation they were filtered through Whatman GF/F filters and washed 
three times with ice cold buffer.
Specific binding was determined by inhibition with 1.2mM 5-HT and is expressed in terms
of disintegrations per minute.
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Figure 7.2a
The graph below shows the effect of increasing the imipramine concentration on binding. It 
indicates an optimal imipramine concentration of around 9nM.
Effect of imipramine concentration on binding
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The results reported on these graphs come from more than one experiment (n=l for all 
points). All assays were performed in triplicate (Intra-triplicate variation 3-7%). The results 
are expressed as means +/- standard error of mean.
All assays were incubated for 1 hour and 15 minutes at (P c  (on ice). After incubation they 
were filtered through Whatman GF/F filters and washed three times with ice cold buffer.
Specific binding was determined by inhibition with 1.2mM 5-HT and is expressed in terms
of disintegrations per minute.
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Figure 7,2b
A Scatchard analysis was performed using the first 4 points of the saturation curve for 
specific binding
Imipramine Scatchard Plot
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[D] = free imipramine (nM)
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Figure 7.3
The graph below shows the effect of increasing 5-HT on specific binding of imipramine. 
These data indicated that approximately 1.2mM 5-HT is an optimum amount for 
determining specific binding.
Effect of 5-HT concentration on imipramine binding
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The results reported on this graph come from more than one experiment (n=l for all 
points). All assays were performed in triplicate (Intra triplicate variation was 3-5%)
All assays were incubated for 1 hour and 15 minutes at O^C (on ice) with 8.6nM of 
imipramine. After incubation they were filtered through Whatman GF/F filters and washed 
three times with ice cold buffer.
Specific binding is expressed in terms of disintegrations per minute per mg of protein.
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Figure 7.4
The graph below shows the effect of time on specific binding of imipramine and indicates 
that 1 hour and 15 minutes is sufficient time to obtain maximum binding.
Effect of time on Imipramine binding
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The results reported on this graph come from one experiment ( 20 mins n=3; 40 mins 
n=3; 50 mins n=2; 60 mins n=3; 90 mins n=3). All assays were performed in triplicate 
(Intra-triplicate variation was 4-6%). The results are expressed as means +/- standard error 
of mean.
All assays were incubated at O^C (on ice) with 8.6nM of imipramine. After incubation they 
were filtered through Whatman GF/F filters and washed three times with ice cold buffer.
Specific binding was determined by inhibition with 1.2mM 5-HT and is expressed in terms
of disintegrations per minute per mg of protein.
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Paroxetine binding assay
The method was to some extent established from work previously performed in this 
laboratory on imipramine binding. The assay was therefore based on this technique but was 
conducted at a higher temperature and needed some modification. Preliminary work 
indicated that an incubation time of three hours was most appropriate so this was used 
throughout.-The effect of freezing was determined by assaying freshly prepared platelet 
samples and ones stored frozen for 3 months. There was no apparent effect on specific 
binding.
Previous studies have shown that protein concentration can have a marked effect on the 
apparent binding per mg of protein (Arora et al 1985; Theodorou et al 1988). In order to 
ensure that this would not effect the results, specific binding was determined using varying 
concentrations of protein up to 0.2mg. (Concentrations of more than 0.2mg were not likely 
to be available for assay). The results of these assays indicated that there was not likely to be 
major effect on the specific binding in terms of paroxetine bound/mg of protein (see Fig 
7.5).
The optimal concentration of paroxetine was assessed by a series of assays using 
concentrations of 0 to 26nM of paroxetine, the highest percentage specific binding being 
realised at 9 nM( approx 70%). As a result a concentration of 9nM was chosen for the 
assays (see fig 7.6) The ^max obtained from these data was 520 fmol/mg protein which is 
similar to those reported in the literature (e.g.D'haenen et al 1988)
In order to determine the minimum effective concentration of 5-HT required to inhibit 
specific binding of paroxetine, a series of assays were performed using concentrations of 
5-HT from 0 to 1.2mM. The minimum effective concentration for maximum inhibition of 
specific binding appeared to be ImM (see Fig 7.7).
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Figure 7.5
The graph below indicates that increasing the protein concentration in the reaction mixture up 
to 0.2mg does not markedly effect the specific binding of paroxetine per mg of protein.
Effect of protein concentration on specific binding
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The results reported on this graph come from several experiments (O.OSmg n=3; O.lOmg 
n=3; O.lSmg n=5; 0.20mg n=6). All assays were performed in triplicate (intra-triplicate 
variation 3-5%). The results are expressed as means +/- standard error of mean.
All assays were incubated for three hours at 37®C with 8.6nM of paroxetine. After 
incubation they were filtered through Whatman GF/F filters and washed three times with ice 
cold buffer.
Specific binding was determined by inhibition with ImM 5-HT and is expressed in terms of
disintegrations per minute.
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Figure 7.6
The graph below shows the effect of increasing the paroxetine concentration on binding. It 
indicates an optimal paroxetine concentration of around 9nM.
Effect of paroxetine concentration on binding
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All assays were performed in triplicate (Intra-triplicate variation was 5-8%)
All assays utilised approximately 0.2 mg of protein and were incubated for three hours at 
37®C After incubation they were filtered through Whatman GF/F filters and washed three 
times with ice cold buffer.
Specific binding was determined by inhibition with ImM 5-HT and is expressed in terms of
disintegrations per minute per mg of protein.
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Figure 7.6b
The Scatchard analysis was performed using the first 4 points of the specific binding 
saturation curve.
Paroxetine Scatchard Plot
140 -I
120 -
100 -
80 -
60 -
2000 100 300 400 600500
r = fmol paroxetine bound/ mg protein 
[D] = free paroxetine (nM)
r-
99
Figure 7.7
The graph below shows the effect of increasing 5-HT concentration. The data indicate that 
approximately ImM 5-HT is the ideal concentration.
Effect of S^ HT concentration on paroxetine binding
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The results reported on this graph are from more than one experiment. All assays were 
performed in triplicate (Intra-triplicate variation 3-8%)
All assays utilised approximately 0.2mg of protein and were incubated for three hours at 
37®C with 8.6nM of paroxetine. After incubation they were filtered through Whatman 
GF/F filters and washed three times with ice cold buffer.
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Clonidine binding assay
The methodology for this assay caused considerable problems. Initial attempts could not 
demonstrate any specific binding in the size of samples used. Previous work has generally 
used much larger quantities of blood (e.g.Cameron et al. 1984) but work on small samples 
has been successfully conducted in the past (Shattil et al 1981). Some small improvements 
were made to the method as detailed below, but the main problem encountered was the 
failure to reproduce results.
Slight increases in specific binding (~5%) were found when the temperature was raised from 
25 to 37®C. Although this was only a smaU improvement it was decided to run future assays 
at 370c.
When filter binding was measured (by filtering the label without any protein present) it was 
found to be extremely significant - in some cases equal to the non-specific binding. Different 
filters were tested (Whatman GF/B,GF/C and GF/F) and Whatman GF/F were found to 
have the lowest filter binding. However it still accounted for at least 80% of the non-specific 
binding.
Previous workers (e.g. Cameron et al 1984) had used an incubation time of 30 minutes. 
Binding assays were conducted at times from 10 minutes to 90 minutes and these findings 
' agreed with a minimum time of 30 minutes for the assay (see fig 7.7).
The effect of using different concentrations of clonidine ranging from 5nM to 30nM was 
assessed and a concentration of about 20nM was found to be sufficient to achieve maximal 
binding (see Fig 7.8). However this result was only found in one experiment and proved 
impossible to repeat. Other attempts to find an optimal concentration did not produce any 
consistent pattern of results.
The principal problem encountered in trying to improve the assay was a failure to repeat 
results. Possible reasons for this, such as fluctuations in the temperature of the assay, slight
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variations in the buffer etc. were all discounted. The most probable cause of the variation 
seemed to be the length of time for which the platelet membrane sample was frozen. In 
order to investigate this samples were frozen for periods of one day to two weeks and the 
effect of phentolamine concentrations on binding determined after the different lengths of 
freezing. The results which are illustrated in figure 7.9 indicated that there might be some 
loss of specificity as the sample was frozen for longer. However, although day 1 showed 
the highest specific binding and day 14 the lowest day 7 and day 8 were very different. 
Furthermore if 14 days freezing was having the dramatic effect seen on the 14 day sample 
then this assay would not have been suitable for my purposes.
In order to investigate the effects of longer term freezing, samples were frozen for periods of 
one week through to ten weeks and specific binding determined using a constant 
concentration of phentolamine at 120mM. These results further confounded the picture by 
indicating that the longer the sample was frozen the greater the specific binding (see fig 
7.10).
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Figure 7.8
The graph below shows the effect of time on clonidine binmng, it indicates that around 30 
minutes would be sufficient to achieve maximal binding.
Effect of time on specific binding of clonidine
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The results reported on this graph came from two experiments (lOmins n=3; 20mins n=3; 
30mins n=5; 40mins n=3; SOmins n=3; 60mins n=2; 90mins n=3). The results are 
expressed as means +/- standard error of mean.
All assays utilised approximately 0;2mg of protein and were incubated at 37®C with 20nM 
of clonidine. After incubation they were filtered through Whatman GF/F filters and washed 
three times with ice cold buffer.
Specific binding was determined by inhibition with 120mM phentolamine and is expressed 
in terms of disintegrations per minute per mg of protein.
(All values were corrected for filter binding)
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Figure 7.9
The graph below shows the effect of increasing the clonidine concentration, on binding. It 
indicates an optimal clonidine concentration of around 20nM.
Effect of clonidine concentration on binding
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The results reported on this graph were from one experiment (n=3 for all points). The 
results are expressed as means +/- standard error of mean.
All assays utilised approximately 0.2mg of protein and were incubated for 30 minutes at 
37®C. After incubation they were Altered through Whatman GF/F Alters and washed .three 
times with ice cold buffer.
SpeciAc binding was determined by inhibition with 120mM phentolamine and is expressed 
in terms of disintegrations per minute per mg of protein.
(All values were corrected for Alter binding).
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Figure 7.10
The graph below shows the effect of increasing phentolamine concentration with different 
ages of platelet samples. It indicates that there may be an effect of age on the specific binding 
of clonidine.
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The results expressed on this graph come from four experiments (1 day old samples; 1 week 
old samples; 1 week and 1 day old samples; 2 week old samples). n=3 for all points. The 
results are expressed as means +/- standard error of mean.
All assays utilised approximately 0.2mg of protein and were incubated at 37®C with 20nM 
of clonidine. After incubation they were filtered through Whatman GF/F filters and washed 
three times with ice cold buffer.
Specific binding is expressed in terms of disintegrations per minute per mg of protein. (All 
values were corrected for filter binding)
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Figure 7.11
The graph below the effect of storing platelet samples on specific binding of clonidine. The 
graph seems to indicate that the longer the sample is stored the greater the specific binding.
Effect of storage on clonidine binding
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The results reported on this graph come from a single experiment (n=3 for all points). The 
results are expressed as means +/- standard error of mean.
All assays utilised approximately 0.2mg of protein and were incubated at 37^C with 20nM 
of clonidine: After incubation they were filtered through Whatman GF/F filters and washed 
three times with ice cold buffer.
Specific binding was determined by inhibition with 120mM phentolamine and is expressed 
in terms of disintegrations per minute per mg of protein.
(All values were corrected for filter binding)
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CHAPTER 8
RESULTS FROM THE PSYCHOTHERAPY AND CONTROL GROUPS
The results presented in this chapter are from the psychotherapy clients and controls. Data 
are compared in terms of imipramine and paroxetine binding values as well as questionnaire 
vscores. Additionally an evaluation of the seasonality of the data and possible gender 
differences are made.
There were no significant differences between the groups with respect to age or gender as 
shown in table 8.1. (This was, however planned by the age and gender matching of the 
subjects in the trial.). The choice of controls is discussed fully in Chapter 6, however all 
controls were staff from the Open University and were intended to act as a population 
normal*. I did not chose to use untreated depressed patients or placebo tablet patients as the 
aim of the study was not to prove efficacy of psychotherapy.
Table 8.1. Age and gender of subjects.
Clients Controls
(N=19) (N=19)
Age: Mean 36 36
Range 23-48 23-49
Sex: % female 68 68
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Changes seen in the questionnaire scores 
Beck Depression Inventory (EDI)
Client values at the start of the study and up to the end of the first three months were 
significantly higher than control values (P<0.05 at 0 and 1 month and P<0.01 at 2 and 3 
months). After 6 months of therapy, EDI scores for clients were only slightly higher than 
controls and continued to fall up to 12 months, where the difference in client and control 
values was very small (less than 1 point). See figure 8.1.
As with all of the questionnaires used in this study, the higher the score the greater the level 
of psychiatric disorder. According to Kendall et al's (1987) criteria, a score of 10 or more 
indicates dysphoria although not depression. Client scores started with an average of 9.6 
(+/-1.4) indicating a mild level of affective disorder equivalent, in general terms, to low 
mood.
Comparison of baseline data (0 month) with the 12 month data using student t-test did not 
reveal any signifîcant change for the control values, but there was a significant change in 
client values (p<0.05). ANOVA and repeated measures ANOVA failed to demonstrate a 
significant difference in client and control values over time.
Sex related differences in the reporting of self rated questionnaires have been observed by
some workers (e.g. Maes et al 1988), so for all data separate assessments have been made
on male and female results to see if there were any marked differences. When male results
were analysed separately the differences in the client and control values became more
extreme and were still apparent at the end of treatment (see fig 8.2). However this appears
to be due mainly to the fact that the control males scores were lower than control females
rather than the client males scoring higher than client females. When female EDI data were
analysed separately, the differences in the scores for client and control data did not reach
statistical significance (possibly due to small sample size), but a very similar pattern of
results was seen as with the entire data set (see fig 8.3). Therefore it was concluded that
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there was no marked gender difference on this scale for the client subjects but that amongst 
the control population females appeared to score higher than males, although this did not 
reach statistical significance.
General Health Questionnaire (GHQ-28)
The GHQ-28 values from clients were higher than controls during the first three months of 
the study (statistically significant at 1,2 and 3 months P<0.05). As therapy continued the 
values fell to around the same as the controls, as shown in Fig 8.4. As defined in chapter 6 
a person is considered as a ’psychiatric case’ if they score 5 or more on the GHQ-28 
(Goldberg and Hillier 1979). For the first 3 months of the study the client group averaged 
scores of 5.9 (+/-1.4) to 7.1 (+/-1.6), indicating that although no rigid diagnostic criteria 
had been applied I did actually have a group suffering from a small but significant level of 
psychiatric disorder. The control group averaged 2.5 (+/-1.2) to 3.4 (+/-1.5) over the entire 
period of the study, and the client levels eventually fell to 3.0 (+/-1.4) by the 12 month 
sample.
A comparison of the first and last assessments for client and control values (0 months vs 12 
months) using a Students t-test, did not reveal any significant changes over time, ANOVA 
and repeated measures ANOVA also failed to demonstrate any statistically significant 
difierences in client and control scores over time. Separate analysis of male data revealed a 
similar pattern of results as with the combined data (P<0.05 at 1 month), however as with 
the BDI scores male control values were lower than the female data ( see fig 8.5). When 
female data were analysed separately the same pattern of results was seen (see Fig 8.6) but 
the only time point where the differences were actually significant was at 2 months 
(P<0.05). Given however, that the separated male and female data sets followed broadly 
the same pattern of results as the combined male and female data it was concluded that there 
were no major gender differences, although as with the BDI control females did appear to 
score higher than control males.
The GHQ-28 dépendis for 25% of its score on somatic symptoms. When comparing a
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group of moderate or severe depressives with controls the influence of the somatic score is 
not likely to heavily bias the results if a few people suffer from a minor illness such as 
colds and flu. However owing to the fact that the clients had a relatively mild depressive 
illness, the influence of somatic symptoms could be quite great so they were removed to 
see if this would affect the results (see fig 8.7). Somatic symptoms represent 6 out of the 
28 questions, so a psychiatric case would now be one with 3.75 points. It was found that 
client values were in the range 4.2 (+/-1.1) to 4.7 (+/-1.4) for the first 3 months and then 
fell to the same level as control values. Removal of somatic symptoms did not markedly 
affect the significance of the results except that the baseline value (0 months) also reached 
significance (0,1,2 and 3 months P< 0.05).
Student t-tests comparing the GHQ without somatic symptoms at the first and last visit (0 
month vs 12 month) approached a significant difference for the client values (P=0.107).
Multiple Affect Adjective Checklist (MAACL)
As with both the BDI scores and the GHQ-28 scores,'significant differences were found 
between client and control values during the first 3 months of the study. These differences 
were highly significant at the start of the study (0,1,2 and 3 months P<0.01), but unlike the 
BDI and the GHQ the differences remained over the duration of the research period (6 and 
12 months P<0.05) (see fig 8.8). What makes this even more complicated to account for is 
the fact that client values did not fall towards those of control values; rather that control 
values rose towards the clients. ANOVA and repeated measures ANOVA did not reveal any 
statistically significant differences between client and control values over the course of the 
study.
When the male and female data were analysed separately significant differences were found
up to the end of the first three inonths (Male; 0 and 1 month P<0.01, 3 months P<0.05:
Female; 0 and 1 month P<0.05,2 and 3 months P<0.01) but not at six or twelve months.
However on both graphs the pattern of results was the same as the combined graph
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indicating that there were no significant gender differences in the way the questionnaire was 
answered (see figs 8.9 and 8.10).
The MAACL consists of three parts:- anxiety, depression and hostility. As this study was 
concerned with depression with or without anxiety, hostility was removed from the scale to 
see whether this could in any way account for the rise at the end of the control graph. The 
data shown in figure 8.11 show that removing hostility did not markedly change the rise in 
control MAACL scores (increase score of 21% with hostility included, 23% excluding 
hostility). There was still no fall overall in client values although the differences observed 
in the scores at 6 and 12 months were no longer statistically significant.
Student t-test comparisons of the first and last (0 months and 12 months) MAACL values, 
either with or without the hostility score were not statistically significantly different.
It is an interesting observation that the control value is fairly stable (with or without the 
hostility value) up until 6 months, and that at this stage the client value appears to be falling 
towards the control value. I am not aware of published long term studies using the MAACL 
and would question whether the increased score seen in both groups at the end of treatment 
may be due to the effect of repeated exposure to the questionnaire. In order to investigate 
this an assessment was made of the number of. boxes ticked by the subjects over the course 
of the study. It is interesting to note that whilst the number of boxes ticked by the controls 
remains relatively constant there is a marked decline in the number of boxes ticked by the 
clients. A students t-test comparing number of boxes ticked at 0 months vs 12 months 
indicates significantly less boxes were ticked at 12 months (P<0.05). The scoring of the 
MAACL is such that failure to tick certain 'affects' such as 'happy', scores a point 
(increasing the score) so it may be that at the end of the study when the clients may have 
been losing interest that they failed to tick as many boxes and therefore their scores 
remained artificially high (see fig 8.12).
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Figure 8.1
The graph below shows the change in client scores on the Beck Depression Inventory
compared to the control group (population 'normal') over the twelve month period of the
study.
Change in BDI score over 12 months
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Control values: 0 months n=I9; 1 month n=18; 2 months n=18;
3 months n=19; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=I8; 12 months n=16.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.2
The graph below shows the change in male client scores on the Beck Depression Inventory
compared to the male control group (population 'normal') over the twelve month period of
the study.
Change in male BDI score over 12 months
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Control values: 0 months n=6; 1 month n=6; 2 months n=6;
3 months n=6; 6 months n=6; 12 months n=5.
Client values: 0 inonths n=6; 1 month n=6; 2 months n=5;
3 months n=6; 6 months n=5; 12 months n=5.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,were
performed using a one tailed students t-test, the control data being taken to represent the
population normal' value.
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Figure 8.3
The graph below shows the change in female client scores on the Beck Depression 
Inventory compared to the female control group (population 'normal') over the twelve 
month period of the study.
Change in female BDI score over 12 months
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Control values: 0 months n=13; 1 month n=12; 2 months n=12; 
3 months n=13; 6 months n=13; 12 months n=11.
Client values: 0 months n=13; 1 month n=12; 2 months n=12;
3 months n=13; 6 months n=13; 12 months n= ll.
Results are expressed as means +/- standard error of mean.
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Figure 8.4
The graph below shows the change in client scores on the General Health questionnaire 
compared to the control group (population 'normal') over the twelve month period of the 
study.
Change in GHQ score over 12 months
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Control values: 0 months n=19; 1 month n=18; 2 months n=18;
3 months n=19; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=18; 12 months n=16.
«
Results are expressed as means +/- standard error of mean. Statistical analyses shown,were
performed using a one tailed students t-test, the control data being taken to represent the
population normal' value.
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Figure 8.5
The graph below shows the change in male client scores on the General Health
' I
Questionnaire compared to the male control group (population 'normal') over the twelve 
month period of the study.
Change in male GHQ-28 score over 12 months
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Control values: 0 months n=6; 1 month n=6; 2 months n=6;
3 months n=6; 6 months n=6; 12 months n=5.
Client values: 0 months n=6; 1 month n=6; 2 months n=5;
3 months n=6; 6 months n=5; 12 months n=5.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.6
The graph below shows the change in female client scores on the General Health 
Questionnaire compared to the female control group (population 'normal') over the twelve 
month period of the study.
Change in female GHQ-28 score over 12 months
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Control values: 0 months n=13; 1 month n=12; 2 months n=12;
3 months n=13; 6 months n=13; 12 months n = ll .
Client values: 0 months n=13; 1 month n=12; 2 months n=12;
3 months n=13; 6 months n=13; 12 months n = ll .
Results are expressed as means +/- standard error of mean. Statistical analyses shown,were
performed using a one tailed students t-test, the control data being taken to represent the
population 'normal' value.
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Figure 8.7
The graph below shows the change in client scores on the General Health Questionnaire
(excluding somatic symptoms) compared to the control group (population ’normal*) over
the twelve month period of the study.
Change in GHQ-28 score (not including somatic symptoms)
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Control values: 0 months n=19; 1 month n=18; 2 months n=18;
3 months n=19; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=18; 12 months n=16.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal* value.
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Figure 8.8
The graph below shows the change in client scores on the Multiple Affect Adjective
Checklist compared to the control group (population 'normal') over the twelve month
period of the study. '
Change in MAACL score over 12 months
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Control values: 0 months n=19; 1 month n=18; 2 months n=18;
3 months n=19; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=18; 12 months n=16.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.9
The graph below shows the change in male client scores on the Multiple Affect Adjective
Checklist compared to the male control group (population ’normal') over the twelve month
period of the study.
Change in male MAACL score over 12 months
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Control values: 0 months n=6; 1 month n=6; 2 months n=6;
3 months n=6; .6 months n=6; 12 months n=5.
Client values: 0 months n=6; 1 month n=6; 2 months n=5;
3 months n=6; 6 months n=5; 12 months n=5.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population normal' value.
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Figure 8.10
The graph below shows the change in female client scores on the Multiple Affect Adjective
Checklist compared to the female control group (population 'normal') over the twelve
month period of the study.
Change in female MAACL score over 12 months
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Control values: 0 months n=13; 1 month n=12; 2 months n=12;
3 months n=13; 6 months n=13; 12 months n= ll.
Client values: 0 months n=13; 1 month n=12; 2 months n=12;
3 months n=I3; 6 months n=13; 12 months n= ll.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.11
The graph below shows the change in client scores on the Multiple Affect Adjective 
Checklist (Depression and Anxiety scores only) compared to the control group (population 
'normal') over the twelve month period of the study.
Change in MAACL depression and anxiety score
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Control values: 0 months n=19; 1 month n=18; 2 months n=18;
3 months n=19; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=18; 12 months n=16.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
1 2 2
Figure 8.12
The graph below shows the change in the number of boxes ticked on the MAACL by
clients compared to the control group (population 'normal') over the twelve month period
of the study.
Change in the number of boxes ticked on the MAACL
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Control values: 0 months n=19; 1 month n=18; 2 months n=18; 
3 months n=I9; 6 months n=19; 12 months n=16.
Client values: 0 months n=19; 1 month n=18; 2 months n=17;
3 months n=19; 6 months n=18; 12 months n=16.
Results are expressed as means +/- standard error of mean.
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Discussion of questionnaire results
Overall, the results of the questionnaires indicate a significant improvement in the 
psychological well being of the clients during the course of the study. It is important to 
emphasise that both the General Health Questionnaire and the Beck Depression Inventory 
are well recognised psychological testing tools (e.g. Boardman 1987; Feightner and 
Worrall 1990), whereas the MAACL is less well validated. Obviously with the type of 
control group that was used no firm conclusions can be drawn about the effectiveness of 
the psychotherapies. However what is clear is that the clients' psychological state improved 
whilst undergoing a course of psychotherapy and that although there were significant 
differences between client and control groups at the start of the study they were 
considerably diminished or possibly even reversed by the end.
What is perhaps most exciting in terms of clinical relevance is that whilst, as a group, the
clients met the criteria for mild psychiatric disorder at the start of the study they did not at
the end. Depression is a recurrent, cyclic illness and it could be argued that the clients may
well have got better without any intervention at all. However taking into account the criteria
for psychiatric caseness discussed above it is interesting to note that according to the BDI
criteria no clients originally classed as 'cases' relapsed (although 2 classed as 'cases' at the
beginning of the study did not improve). According to the GHQ criteria only 2 patients
relapsed (and 3 originally classed as cases did not improve). Even taking the worst possible
score of two out of 19 clients this only gives a relapse rate of 10.5% over 12 months. A
recent report by Raffaitin et al (1991) reports a 22% relapse rate with Tianeptine over the
same period and Jakovljevic and Mewett (1991) found a 14% relapse rate with paroxetine
and 12% with imipramine compared to a 23% relapse rate with placebo. Given these data
the relapse rate on this study looks particularly good. Although it should be emphasised
that these patients were only mildly depressed and therefore less likely to relapse, many of
them had complained to me that this was not their first experience of a depressive episode (
no data were collected on the number of previous episodes). Neumann and Schuttler
(1991) in a longitudinal study of depressed outpatients have shown that one year after first
being treated for depression 70% of patients were still receiving tricyclic antidepressants
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and that even after 5 years 60% were still taking tricyclics. Despite this however the rate of 
readmittance was 40%, and 50% were still suffering from psychological disorders five 
years later. In comparison to these data the present findings would tend to view the 
psychotherapeutic approach quite favourably.
An interesting observation seen in the questionnaire results is that whilst there are no very 
marked differences in the scores recorded by male and female clients (except possibly the 
GHQ-28 score), there is some evidence of a difference in control males and females 
particularly on the BDI. However there were relatively small numbers of males and the 
differences seen between males and females failed to reach statistical significance.
Changes in the binding assay results over 12 months
[^H] Imipramine binding
The results from the imipramine binding assay showed that levels of imipramine binding 
were lower (2 months P<0.01 ) in clients from the Open centre than in controls in the early 
stages of treatment. Furthermore after three months of psychotherapy the levels of the 
client imipramine binding rose to the same, or in fact slightly higher values than the 
controls (see fig 8.13). A t-test performed on the client data at the start of the study versus 
completion of the study (0 months vs 12 months) was not, however significant. ANOVA 
and repeated measures ANOVA did not show any statistical difference between client and 
control imipramine binding during the course of the study.
Although it is generally accepted that imipramine binding is not affected by the gender of
the subject( e.g. Asarch et al 1980), there have been differences reported (e.g. Theodorou
et al 1989), so in order to check this the male and female data were analysed separately.
When this separate analysis was carried out, the male client imipramine binding, which was
lower than controls at the start of the study, was actually significantly higher (P<0.01) at 3
months than the controls and remained higher (see fig 8.14). However the significance of
the results remained the same for the female data as for the combined data set (see Fig
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8.15) and the overall pattern of results was the same for male, female and combined data, 
indicating that there are no major gender differences.
[^H] Paroxetine binding
The data obtained for the paroxetine binding assay were on first inspection rather 
surprising. No significant difference between client and control binding levels were found 
at any stage during the study (see Fig 8.16). This was not what I would have predicted 
bearing in mind that paroxetine supposedly binds to the same sites as imipramine but with 
greater specificity. However this study is not the only one failing to report a difference 
between depressives and controls using a paroxetine binding assay (e.g.D'haenen et al 
1988). It is possible that that the differences seen in depressives versus control subjects 
with imipramine binding may be related to the less specific nature of the imipramine 
binding or to the fact that the two compounds apparently bind to different parts of the 5HT 
uptake system. In a recent study of patients treated with psychoactive drugs, some drugs 
produced very similar changes in both paroxetine and imipramine binding, whereas others 
produced very different responses (Mellerup et al 1991)
Although paroxetine binding is not thought to be influenced by gender (Andersson and 
Marcusson 1990), there is some evidence of a lower binding levels in men 
(Klompenhouwer et al 1990). Therefore male and female data was analysed separately to 
see if any differences could be detected, however the pattern of the data was still basically 
the same (although males seemed to have slightly lower paroxetine binding particularly 
after 3 months) with no statistically significant differences apparent between clients and 
controls (see figs 8.17 and 8.18).
Student t-tests, ANOVA and repeated measures ANOVA, all failed to demonstrate any 
significant differences in client and control values during the study.
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Figure 8.13
The graph below shows the change in client ^H-imipramine binding to platelet membranes
compared to the control group (population 'normal') over the twelve month period of the
study.
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3 months n=19; 6 months n=19; 12 months n=18.
Client values: 0 months n=19; 1 month n=18; 2 months n=19;
3 months n=19; 6 months n=18; 12 months n=18.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.14
The graph below shows the change in male client ^H-imipramine binding to platelet
membranes compared to the male control group (population 'normal') over the twelve
month period of the study.
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Figure 8.15
The graph below shows the change in female client ^H-imipramine binding to platelet 
membranes compared to the female control group (population 'normal') over the twelve 
month period of the study.
Change in female impramlne binding over 12 months
700-1
D>
650-
600 -
o
550 -
500 -
450 - -B* Control IMI 
Client IMI 
** P<0.01
a. 400 -
350 -
300
1 0  1 2 3 4 5 6 7 8 9 1 0 1 1 1 2  13
Month
Control values: 0 months n=I3; 1 month n=I2; 2 months n=12;
3 months n=13; 6 months n=13; 12 months n=I2.
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Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.16
The graph below shows the change in client ^H-paroxetine binding to platelet membranes 
compared to the control group (population 'normal’) over the twelve month period of the 
study.
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Results are expressed as means +/- standard error of mean.
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Figure 8.17
The graph below shows the change in male client ^H-paroxetine binding to platelet
membranes compared to the male control group (population normal') over the twelve
month period of the study.
Change in male paroxetine binding over 12 months
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Control values: 0 months n= 4; 1 month n= 6; 2 months n= 6;
3 months n= 5; 6 months n= 6; 12 months n= 6.
Client values: 0 months n= 6; 1 month n= 5; 2 months n= 6;
3 months n= 6; 6 months n= 4; 12 months n= 5.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 8.18
The graph below shows the change in female client ^H-paroxetine binding to platelet
membranes compared to the control group (population ’normal’) over the twelve month
period of the study.
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Results are expressed as means +/- standard error of mean.
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Discussion of imipramine and paroxetine binding results
The imipramine binding results found in this study were the same type of results as were 
seen in the previous study performed in this laboratory on Primal therapy clients and is also 
seen as a result of a drug therapy (e.g. Healy et al 1991) (see Fig 8.13). Additionally 
Suranyi-Cadotte et al (1982) investigating changes in imipramine binding in 10 patients 
during remission, found three of these patients were not receiving any medication but 
showed marked increases in imipramine binding.
The differences seen between the imipramine and paroxetine binding results are quite 
difficult to explain. Autoradiography of binding sites for imipramine and paroxetine within 
the human brain indicate that the two compounds bind to the same areas of the brain 
(Cortes et al 1988; Plenge et al 1990). However it appears that they bind to different sites 
within the serotonin transport mechanism (Mellerup et al 1985) and different responses 
have been observed in imipramine and paroxetine binding in the brain after antidepressant 
treatment in animal studies (Plenge et a/ 1986). The different results seen between 
paroxetine and imipramine binding may represent a very real and important clue as to the 
biological systems involved in depressive disorders.
As discussed earlier, reports of decreased levels of imipramine binding to platelets of
depressed patients are numerous (e.g. Langer etal 1987; Benkelfat etal 1985; Jeaningros et
al 1989; Poirier et al 1986; De Met et al 1991). It has also been shown that these binding
levels can be increased by treatment with antidepressants (e.g. Asberg and Wagner 1986;
Healy et al 1991), light therapy (Szadoczky et al 1989), ECT (Langer et al 1980) and
oestrogen therapy (Sherwin and Suranyi-Cadotte 1990).It is also fairly well established that
serotonin turnover may be reduced by up to 40% in these patients (Kalus et al 1989).
However there has not been any evidence of decreased paroxetine binding in depressed
patients (D'haenen et al 1988), and work in suicides has found no difference in paroxetine
binding whilst demonstrating differences in imipramine binding (Lawrence et al 1990).
Some authors have argued that since paroxetine binding assays are conducted at the
physiological temperature of 31^C (whereas the imipramine binding assay is conducted on
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ice) that paroxetine binding may better reflect 5HT uptake sites (Schoemaker et al 1986). 
Furthermore, whilst imipramine binding has generally been found to be reduced in 
depressed patients (presumably representing a decrease in 5HT uptake sites) it has proved 
difficult to correlate these findings with 5HT uptake from the same patients (e.g. Raisman 
et al 1982: Suranyi-Cadotte et al 1982), although reduced 5HT uptake in depressed patients 
is widely reported (e.g. Egrise et al 1986).One possible explanation for the differences 
seen with imipramine and paroxetine binding that cannot be excluded, is that the platelets 
used for the imipramine assay were originally intended for a clonidine assay and so were 
treated differently, this could have resulted in differences in the quality of the membrane 
preparations and possibly the proportion of intact platelets which would influence the 
observed binding (DeMet et al 1990).
What remains clear is that 5HT is almost undoubtedly involved in affective disorders as 
evidenced by the number of 5HT uptake inhibitors gaining popularity in the treatment of 
depression, and 5HT antagonists being developed for the treatment of anxiety. Recently 
attempts to correlate plasma levels of imipramine with response have finally proved 
successful (Garvey et al 1991). Deakin (1991) (Also Deakin and Graeff 1991) proposed a 
theory of 5HT involvement in affective disorders where anxiety results from dysfunctional
activation of anticipatory defence mechanisms leading to excessive stimulation of 5HT2,
1C and 3 receptors in the amygdala and other forebrain structures by the dorsal raphe 5HT
projections. Whereas depression results from attenuation of chronic defensive responses 
mediated by median raphe projections causing a decrease in 5HT1A neurotransmission. 
Although acceptance of a 5HT involvement in depression predominates it can in no way 
account for the differences seen in imipramine and paroxetine binding. What this theory 
does emphasise however is the extensiveness of the serotonergic system. In addition to this 
it should be remembered that the serotonergic system does not function in isolation, indeed 
there is evidence that imipramine may actually function as an antidepressant, not by
inhibition of 5HT uptake but by down regulation of p-adrenergic receptors. The evidence
for the interrelation of adrenergic and serotonergic systems being quite strong (Eison etal
1991; Plaznik et al 1989 ). This would, it is argued account for the slow onset of action of
1 3 4
imipramine (Beck and Halloran 1989).
Malmgren et al (1981) demonstrated that platelets of depressed patients had defective 
transport mechanisms for 5HT. It also appears that the antidepressant binding sites are the 
same as the uptake sites (Marcusson et al 1989).It is possible that the part of the uptake site 
which imipramine binds to is defective and limits binding, whereas the part of the site 
which paroxetine binds to may be unaffected. If these 'damaged' uptake sites were also 
incapable of 5HT uptake this would account for the comparable efflcacy of imipramine and 
paroxetine in the treatment of depression. It is also possible that these two sites are 
differently affected in the brain from the platelets, so that we may not actually be observing 
the true picture by conducting platelet studies.
As discussed previously a number of researchers have suggested that imipramine binding 
represents a trait marker for depression (e.g. Baron et al 1986). The results from this study 
do not support this hypothesis as the clients imipramine score clearly improved during 
therapy, I would therefore agree with the theory that imipramine is a state dependent marker 
of depression (as indicated by other research e.g. Langer et al 1986), but whether or not it 
is actually truly representative of serotonergic function requires further investigation. 
Interestingly, decreased imipramine binding has now been demonstrated in patients 
suffering from premenstrual syndrome immediately prior to development of the symptoms 
and returns to normal after menstruation (Rojansky et al 1991)
Paroxetine on the other hand appears not to be a marker of affective disorders at least in this 
population
Correlations between binding assays and questionnaires
One aim of this research was to try and demonstrate a correlation between changes in
imipramine/paroxetine binding with changes in questionnaire values. Since both
imipramine binding and questionnaire values changed over the time and on roughly the
same timescale a correlation might have been expected. However there was no correlation
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between paroxetine/imipramine binding and the questionnaires (the same effect is seen if 
client and control values are looked at independently) See figs 8.19-8.24.
As well as attempting to correlate actual questionnaire values with imipramine and 
paroxetine binding, change since last assessment and change from baseline were also 
compared with no signiflcant correlation being found.
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Figure 8.19
%.
The graph below shows the level of correlation between BDI scores and imipramine
binding.
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The results shown are from client and control results. No correlation is apparent.
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Figure 8.20
The graph below shows the level of correlation between GHQ-28 scores and imipramine
binding.
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Figure 8.21
% .
The graph below shows the level of correlation between MAACL scores and imipramine
binding.
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The results shown are from client and control results. No correlation is apparent.
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Figure 8.22
% .
The graph below shows the level of correlation between BDI scores and paroxetine
binding.
Correlation between BDI score and paroxetine binding
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The results shown are from client and control results. No correlation is apparent.
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Figure 8.23
% .
The graph below shows the level of correlation between GHQ-28 scores and paroxetine
binding.
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The results shown are from client and control results. No correlation is apparent.
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Figure 8.24
The graph below shows the level of correlation between MAACL scores and paroxetine
binding.
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The results shown are from client and control results. No correlation is apparent.
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Discussion of correlation data
Why no correlations are apparent is not clear,but has been found by several other 
investigators (e.g. De Met et al 1990; 1991), and may possibly represent either a delay in 
imipramine binding response or early imipramine binding response before the change is 
observable in the client, such as might be seen if alteration in a second receptor (e.g.
p-adrenoceptor) actually bought about the clinical change. Another possibility is that in 
some clients imipramine binding may actually have decreased as their questionnaire scores 
decreased. This has been observed in some drug studies and is generally believed to be a 
direct effect of the drug action, but it may be that different people respond in different ways 
depending on the type of treatment and that this may represent an indicator for patients 
most likely to relapse.
To take this argument further, imipramine binding levels are generally accepted to be 
decreased in depressed patients. This is believed to represent diminished 5HT function at 
the synapse. To treat depression psychiatrists administer SHT uptake blockers which allow 
levels of 5HT at the synapse to increase thus increasing post synaptic stimulation. This 
means that there are two ways a patient could improve with or without the intervention of 
drug therapy. The first is a genuine increase in 5HT activity at the synapse. This would 
result in an increase of 5HT uptake sites required to take up the 5HT. This is what is seen 
in studies where imipramine binding increases with drug therapy. Alternatively there may 
be a type of temporary coping mechanism employed by some subjects where 5HT uptake 
sites actually decrease in number. This would temporarily restore the level of 5HT at the 
synapse, until the uptake sites can no longer decrease in number, and 5HT levels continue 
to decrease resulting in depression. It would be these subjects that are most likely to 
relapse.
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Seasonality of the data
1) Imipramine
A number of workers have reported seasonal changes in imipramine binding and serotonin 
uptake, with lower values reported in autumn and winter months (e.g. Hrdina et al 1985; 
Egrise et al 1986; Aroia et al 1984; Mahngren et al 1989). It was not a primary aim of this 
study to look at seasonality and so clients and controls were not assessed evenly over the 
course of a calendar year. Most data was collected from February through to September 
(data for January, July, October, November and December was from 5 or less clients or 
controls). It is interesting to note however that there does seem to be a tendency for 
imipramine binding values to rise over the course of a calendar year and are highest around 
October as seen in several other investigations (e.g.Arora and Meltzer 1988; Egrise et al 
1983; Whitaker et al 1984). (see fig 8.25). However as most clients started the study in 
the spring it is likely that their increased imipramine binding over the course of the year 
represents improved psychological state rather than a true effect of season. Other 
investigators, have also not found any evidence of seasonality e.g. Tang and Morris 
(1985), and Galzin et al (1986).
When the client and control data were combined there was still no strong evidence of 
seasonality (see fig 8.26).
2) Paroxetine
Although relatively little work has been done to investigate seasonal changes in paroxetine 
binding there is some evidence of seasonal fluctuations (Klompenhouwer et al 1990). 
From work on rabbits it appears that paroxetine binding is susceptible to circadian variation 
(Rocca et al 1989), which might suggest that it could also be influenced by daylength and 
therefore season. However from the present results, the paroxetine data appears to be 
fairly stable over the year (see figure 8.27). It was also not affected by combining the client 
and control data (see fig 8.28)
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Figure 8.25
The graph below shows the effect of seasonality on client and control imipramine binding. 
Effect of season on client and control imipramine binding
1000 - I
0
1
f
1
-G- Control IMI 
Client IMI
800 -
g
600 -
Q.
E 400 -
200
J A S O N DJ F M A M J
Month
Control values: Jan n = l; Feb n=l; Mar n=29; Apr n=18; May n=16; 
Jun n=7; Jul n=3; Aug n=9; Sep n=8; Oct n=4; Nov n=l; Dec n= l. 
Client values: Jan n = l; Feb n= l; Mar n=29; Apr n=19; May n=16; 
Jun n=8; Jul n=3; Aug n=9; Sep n=8; Oct n=4; Nov n=l; Dec n= l.
Results are expressed as means +/- standard error of mean,
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Figure 8.26
The graph below shows the effect of seasonality on combined client and control imipramine
binding.
Effect of season on total imipramine binding
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n values are a combination of the values on the previous figure.
Results are expressed as means +/- standard error of mean.
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Figure 8,27
The graph below shows the effect of seasonality on client and control paroxetine binding. 
Effect of season on client and control paroxetine binding
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Control values: Jan n = l; Feb n=l; Mar n=29; Apr n=18; May n=16; 
Jun n=7; Jul n=3; Aug n=9; Sep n=8; Oct n=4; Nov n= l; Dec n = l. 
Client values: Jan n = l; Feb n= l; Mar n=29; Apr n=19; May n=16; 
Jun n=8; Jul n=3; Aug n=9; Sep n=8; Oct n=4; Nov n= l; Dec n = l.
Results are expressed as means +/- standard error of mean.
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Figure 8.28
The graph below shows the effect of seasonality on combined client and control paroxetine
binding.
Effect of season on total paroxetine binding
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n values are a combination of the values on the previous figure. 
Results are expressed as means +/- standard error of mean.
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Discussion of seasonality data
These data do not provide any clear evidence for seasonal changes in imipramine or 
paroxetine binding. Although there appears to be a change in paroxetine binding towards 
the end of the year it should be emphasised that the last two points are from one client and 
one control each. The reason that no seasonality is apparent may very probably be due to 
the fact that I wasn't actually looking for it. It could be more interesting to look at 
imipramine binding in patients with seasonal affective disorder and see how their 
imipramine binding changes over 12 months.
Patients suffering from seasonal affective disorders have been shown to respond to light 
therapy (Terman et al 1991), some authors have argued that the white light exposure 
needs to be made early in the morning (Wirz-Justice 1986), whereas others have utilised 
evening white light therapy (Grota et al 1989). However this therapy is not effective in 
non-seasonal disorder (Wirz-Justice 1986; Mackert et al 1991). Other workers have 
demonstrated distinct physiological responses to bright light therapy indicative of an 
antidepressant effect (review by Dilsaver 1989). Changes in imipramine binding to platelets 
of these patients after bright light therapy has also been observed in parallel with clinical 
improvement (Szadoczy et al 1989) so it may be that studies which have shown evidence 
of seasonal changes actually reflect different light levels.
These findings of change in imipramine binding as a result of changing light levels is also 
supported by work which shows elevated imipramine binding in the hypothalamus of rats 
exposed to a reverse darkrlight regime of 10:14 (Rovescalli et al 1989).
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CONCLUSIONS \
The first prediction of this study was that on entry clients would have lower imipramine 
and or paroxetine binding levels than controls and that during the course of psychotherapy 
their binding levels would increase to equal that of the control values. This prediction was 
proved true for imipramine but not for paroxetine.
The second major prediction was that it should be possible to correlate imipramine and 
paroxetine binding with questionnaire scores, in the event this did not prove to be the case, 
and no correlations were obtained.
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CHAPTER 9
RESULTS FROM THE NURSES (UNTREATED CONTROL) GROUP.
The results presented in this chapter are from the group of nurses compared to the same 
control group as was used for the psychotherapy clients. Even though they were not 
specifically matched for age and gender, they were fairly similar except for the fact that 
there were less males in the nurses group.
Table 9.1. Age and gender of subjects.
Nurses Controls
(N=27) (N=19)
Age: Mean 30 36
Range 21-55 23-49
Sex: % female 89 68
Generally the nursing staff were too busy to complete the questionnaires at the time of my 
visit and so it was agreed that they would complete them that day and return them to me at 
the next visit. It is an interesting observation that all questionnaires returned were from 
female nurses (with the exception of one male set of questionnaires at 0 months).
Changes seen in the questionnaire scores
Beck Depression Inventory (BDI)
Control values on the BDI were statistically significantly higher than the nurses values 
throughout the twelve month period except for the 6 month time point where statistical
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significance was not reached (0,1 and 2 months P<0.01; 3 and 12 months P<0.01). This 
would apparently indicate that the control group was more depressed than the nurses (see 
fig 91). This was not what was predicted as there are a large number of publications 
showing that nurses are in a stressful occupation and are likely to show higher levels of 
psychiatric disorder than a control population, e.g Livingstone and Livingstone (1984), 
Wolfgang (1988) and McCue (1986).
Comparison of baseline and 12 month data revealed no change over time for the nurses 
data. When female data alone was analysed a similar pattern of results was seen but the 
differences reached statistical significance at all time points, which presumably reflects the 
higher value of female control BDI data.(0,1,2,3 and 12 months P<0.01; 6 months 
P<0.05), see figure 8.2. Male data were not analysed separately as there was insufficient 
male nurses data. ANOVA and repeated measures ANOVA did not reveal any statistically 
significant differences in the control and Nurses group over time.
General Health Questionnaire 28 (GHQ-28)
GHQ-28 values for the nurses were generally lower than controls (indicating greater 
psychological well-being) although only reaching statistical significance at 0 and 1 month 
(0 month P<0.05; 1 month P<0.01). Although statistical significance was only reached at 
the first two time points, the graph does not look as though the two sets of data are actually 
diverging (see figure 9.3). As with the BDI this is completely opposite to what would have 
been predicted from knowledge about levels of stress experienced by nurses.
There was no significant change in GHQ-28 scores over time, when analysed by t-test or 
ANOVA and repeated measures ANOVA . When female data alone was compared a 
significant difference was observed at 2 and 12 months as well as 0 and 1 month (0 and 1 
month P<0.01; 2 and 12 month P<0.05). Overall however the pattern of results was the 
same, and a gender difference was not apparent (see fig 9.4). As with the BDI male data 
were not analysed separately.
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As with the client and control data, the data from the GHQ-28 were also analysed in the 
absence of somatic symptoms (see previous chapter). Scores for the nurses were still 
markedly lower than the control values and reached statistical significance (P<0.01) at 1 
month and 12 months (see fig 9.5).
There was no significant change in the GHQ, excluding the somatic symptoms score over 
the time course of the study.
Multiple Affect Adjective Checklist (MÀACL)
Nurses scores on the MAACL were approximately the same as control values except for 
the 2 month assessment (P<0.01) when the nurses values drop suddenly and 12 month 
assessment when the control value increases sharply. As discussed in the previous chapter 
there is no clear explanation for the sudden rise in control values at 12 months. It is also not 
clear why there is a sudden fall in nurses values at 2 months, (see figure 8.6)
There was no significant change in nurses MAACL score over time. When the female 
results were analysed alone the same pattern of results was seen as above with a statistically 
significant difference being seen at 2 months (p<0.01) but at no other time point (see figure 
9.7). Male nurses MAACL data were not analysed separately due to insufficient data.
As with the client and control scores it was considered useful to look at the depression and 
anxiety sub-scales of the MAACL on their own. The data shown in figure 9.8 indicate that 
removing hostility did not markedly alter the relative value of the results, although the 
difference seen at 2 months was lessened (see Fig 9,8), There was no significant change in 
nurses anxiety and depression sub-scores of the MAACL over time.
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Figure 9.1
The graph below shows the change in nurses scores on the Beck Depression Inventory
compared to the control group (population 'normal') over the twelve month period of the
study.
Change in BDI score over 12 months
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Control values: See Figure 8.1
Nurses values: 0 months n=23; 1 month n=I3; 2 months n=I7;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,were
performed using a one tailed students t-test, the control data being taken to represent the
population 'normal' value.
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Figure 9.2
The graph below shows the change in female nurses scores on the Beck Depression
Inventory compared to the female control group (population 'normal') over the twelve
month period of the study.
Change in female BDI score over 12 months
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Control values: See Figure 8.3
Nurses values: 0 months n=23; 1 month n=13; 2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal* value.
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Figure 9.3
The graph below shows the change in nurses scores on the General Health Questionnaire
compared to the control group (population 'normal') over the twelve month period of the
study.
Change in GHQ-28 score over 12 months
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Control values: See Figure 8.4
Nurses values: 0 months n=23; 1 month n=12; 2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.4
The graph below shows the change in female nurses scores on the General Health
Questionnaire compared to the female control group (population 'normal') over the twelve
month period of the study.
Change in female GHQ-28 score over 12 months
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Control values: See Figure 8.6
Nurses values: 0 months n=22; 1 month n=12; 2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.5
The graph below shows the change in nurses scores on the General Health Questionnaire
(excluding somatic symptoms) compared to the control group (population 'normal') over
the twelve month period of the study.
Change in GHQ score (not Including somatic symptoms)
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Control values: See Figure 8.7
Nurses values: 0 months n=23; 1 month n=13; 2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/-. standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.6
The graph below shows the change in nurses scores on the Multiple Affect Adjective
Checklist compared to the control group (population ‘normal’) over the twelve month
period of the study.
Change in MAACL score over 12 months
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Control values: See Figure 8.8
Nurses values: 0 months n=23; 1 month n = ll;  2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.7
The graph below shows the change in female nurses scores on the Multiple Affect
Adjective Checklist compared to the female control group (population 'normal') over the
twelve month period of the study.
Change in female MAACL score over 12 months
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Control values: See Figure 8.10
Nurses values: 0 months n=23; 1 month n = ll;  2 months n=17;
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.8
The graph below shows the change in nurses scores on the Multiple Affect Adjective
Checklist (Depression and Anxiety scores only) compared to the control group (population
'normal') over the twelve month period of the study.
Change in MAACL depression and anxiety scores
{
(0•a
g
I
t
I
S
30 1
-B- MAACL D+A CONT 
MAACL D+A Nurse
20  -
1 0 1 2 3 4 5 6 7 8 9 10 1 1 12 13
Month
Control values: See Figure 8.11
Nurses values: 0 months n=23; 1 month n = ll;  2 months n=17; 
3 months n=15; 6 months n=10; 12 months n=7.
Results are expressed as means +/- standard error of mean.
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Discussion of questionnaire results
As with the client and control data a very similar pattern of results has emerged for the BDI 
and GHQ-28 data, but the MAACL fails to demonstrate any particularly meaningful 
results. Both the BDI and GHQ scores for the nurses fall below that of the control values 
indicating that nurses are less stressed than 'normal'. There are three possible reasons for 
this, the first of which is that nurses really are less stressed than controls. Given the body 
of literature indicating to the contrary this first explanation is very unlikely. Secondly, 
because the nurses were studied at work, even though they were assured that their 
questionnaires would not be passed to their managers, they may have felt some concern 
that they should come out of the study in a positive light so may have deliberately 
answered the questionnaires more positively. Thirdly it is possible that the coping 
mechanisms of nurses are such that they don't allow themselves to believe that they have 
problems and so on self-report questionnaires of this nature would artificially elevate their 
scores. The whole issue of successful coping strategies employed by nurses is confounded 
by methodological differences used in various studies (Bargagliotti and Trygstad 1987) and 
so is difficult to draw conclusions from.This could perhaps have been solved by the use of 
questionnaires designed specifically for health professionals or nursing (e.g. the Nursing 
stress scale Gray-Toft and Anderson (1981))
Changes in the binding assay results over 12 months
[^H] Imipramine binding
The imipramine binding levels seen in the nursing group throughout the study are
significantly lower than control levels (0,1,2,3 and 6 months P<0.01; 12 months P<0.05).
These results are highly significant (see figure 9.9) and given the prediction that lowered
imipramine binding levels are indicative of depression I would therefore have expected to
see increased scores on the psychiatric rating scales indicative of a relatively higher level of
psychic distress. However this was completely the opposite to what was observed and
may represent a reluctance on the part of nurses to admit to being stressed or possibly very
1 6 2
strong coping mechanisms.
Assessment of change over time by comparing the first and last values using a student 
t-test, ANOVA and repeated measures ANOVA indicated that there was no significant 
change in imipramine binding over the duration of the study. As the Nurses group had a 
higher percentage of females than the control group, it was possible that the different 
results reflected a gender difference, so the data was also analysed using only the female 
nurses and female controls (see figure 9.10) A very similar pattern of results emerged with 
significantly lower imipramine binding values found in the nurses group throughout the 
study (0,1,2,3 and 6 months P<0.01; 12 months P<0.05). Male data were not analysed 
separately due to insufficient data.
[^H] Paroxetine binding
Paroxetine binding was lower for the nursing group than the control group throughout the 
study (0 month P<0.05; 1,2,3 and 6 months P<0.01), see figure 9.11 (although no 
difference was seen between the 2 groups on ANOVA and repeated measures ANOVA 
assessment). This result is interesting given the fact that no difference was seen between 
clients and controls and that other research has failed to demonstrate decreased paroxetine 
binding in depressed patients (e.g.D'haenen et al 1988). A number of studies have 
indicated that paroxetine is a more accurate measure of 5-HT function than imipramine (e.g. 
Plenge et al 1990). Given the much more marked reduction in both imipramine and 
paroxetine binding seen in the nurses group it is likely that I have actually selected a group 
with markedly reduced serotonergic function. This may be an age or gender factor but this 
is highly unlikely given the near equal age distribution and the fact that female imipramine 
and paroxetine binding values were not significantly different in the client or control 
groups.
There was no significant change over time for the nurses paroxetine binding results. When
only female data was compared the results were very similar, the nurses results being lower
than the controls (1 month P<0.05; 2,3 and 6 months P<0.01). (see figure 9.12). As with
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the imipramine binding male data were not analysed separately.
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Figure 9.9
The graph below shows the change in nurses ^H-imipraimne binding to platelet membranes
compared to the control group (population 'normal') over the twelve month period of the
study.
Change in impramine binding over 12 months
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Control values: See Figure 8.13
Nurses values: 0 months n=27; 1 month n=14; 2 months n=21;
3 months n=20; 6 months n=16; 12 months n=9.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.10
The graph below shows the change in female nurses ^H-imipramine binding to platelet
membranes compared to the female control group (population 'normal') over the twelve
month period of the study.
Change in female imipramine binding over 12 months
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Control values: See Figure 8.15
Nurses values: 0 months n=24; 1 month n=13; 2 months n=19;
3 months n=19; 6 months n=15; 12 months n=9.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal* value.
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Figure 9.11
The graph below shows the change in nurses ^H-paroxetine binding to platelet membranes
compared to the control group (population 'normal') over the twelve month period of the
study.
Change in paroxetine binding over 12 months
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Control values: See Figure 8.16
Nurses values: 0 months n=27; 1 month n=14; 2 months n=21;
3 months n=20; 6 months n=16; 12 months n=9.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Figure 9.12
The graph below shows the change in female nurses ^H-paroxetine binding to platelet
membranes compared to the female control group (population 'normal') over the twelve
month period of the study.
Change in female paroxetine binding over 12 months
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Control values: See Figure 8.18
Nurses values: 0 months n=24; 1 month n=13; 2 months n=19;
3 months n=19; 6 months n=15; 12 months n=9.
Results are expressed as means +/- standard error of mean. Statistical analyses shown,
were performed using a one tailed students t-test, the control data being taken to represent
the population 'normal' value.
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Discussion of impramine and paroxetine binding results
These data are difficult to interpret. The first issue that needs establishing is whether or not 
the nurses were actually stressed/depressed or not. If it is concluded from the imipramine 
binding results that they were then this study provides evidence of reduced paroxetine 
binding in depressed subjects. If however if it is believed that the questionnaire data is 
correct then this study has identified decreased imipramine and paroxetine binding in 
non-depressed subjects, which to my knowledge has not been observed before. In the 
previous chapter I briefly alluded to a theory I would like to propose which would account 
for these results.
In this thesis I have cited numerous examples of research indicative of decreased 
serotonergic functioning in depression. I have also shown that precise correlations of 
psychological state to imipramine binding have proved difficult. Whether depression results 
from serotonergic dysfunction directly or as a consequence of some other factor 
(physiological or psychological), it would appear that when synaptic 5-HT activity falls 
below a certain level, depression follows in the patient. Work on women with 
premenstrual syndrome has indicated that these changes occur ahead of the symptoms of 
depression (Rojansky et al 1991). Therefore it is possible that the nurses coping 
mechanism maintains them iii^a state which is more likely to develop into depression than 
the general population (hence the higher incidence of depressive disorder observed in this 
group). Some antidepressants act by further reducing the number of 5-HT uptake sites and 
this may account for the high relapse rate. This would mean that stressed individuals might 
show decreased imipramine binding without comparable psychological changes.
If this could be proved, it might explain why decreases in paroxetine binding were not 
seen with the client subjects when they were with the nurses as the clients were already 
depressed and possibly already beginning to improve at the start of the study.
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Correlations between binding assays and questionnaires
As already discussed in the previous chapter, it was an aim of this study to demonstrate a 
correlation between questionnaire scores and platelet binding parameters. However as 
shown in figures 9.13-9.18, no clear correlation was found between either imipramine or 
paroxetine binding and any of the questionnaires, although there is possibly a very weak 
positive correlation between the BDI score and imipramine binding and also GHQ-28 
score. However this indicates that as psychological distress increases so does the 
imipramine binding which is the opposite to what was predicted.
As well as attempting to correlate actual questionnaire values with binding parameters, 
change since last assessment and change from baseline were also compared and again no 
significant correlation was found.
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Figure 9.13
%
The graph below shows the level of correlation between nurses BDI scores and imipramine
binding.
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The results shown are from all the nurses data. A very weak positive correlation is 
apparent.
171
Figure 9.14
The graph below shows the level of correlation between nurses GHQ-28 scores and
imipramine binding.
Correlation between nurses GHQ-28 score and imipramine binding
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The results shown are from all the nurses data. A very weak positive correlation is 
apparent.
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Figure 9.15
The graph below shows the level of coirelation between nurses MAACL scores and
imipramine binding.
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The results shown are from all the nurses data. No correlation is apparent.
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Figure 9.16
%.
The graph below shows the level of correlation between nurses BDI scores and paroxetine
binding.
Correlation between nurses BDI score and paroxetine binding
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The results shown are from all the nurses data. No correlation is apparent.
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Figure 9.17
% .
The graph below shows the level of correlation between nurses GHQ-28 scores and
paroxetine binding.
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The results shown are from all the nurses data. No correlation is apparent.
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Figure 9.18
%
The graph below shows the level of correlation between nurses MAACL scores and
paroxetine binding.
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The results shown are from all the nurses data, no correlation is apparent.
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Discussion of correlation data
There were no clear correlations between binding data and questionnaire data, despite quite 
marked reductions in both binding parameters compared to the control group. There are a 
number of different sources of stress and depression amongst nurses which broadly relate 
to work overload, difficulties in nursing severely ill patients, concerns over treatment of 
patients and the interdependence on other people (Cavagnaro 1983; Dewe 1987; Lee 1987). 
However personality and demographic issues also have a very pronounced effect 
(Ivancevich et al 1982; Numeroff and Abrams 1984). Certain areas of nursing obviously 
have specific stressors associated with their particular area e.g. Operation Theatre nurses 
(Marcus and Popovic 1985), intensive care nurses (Chiriboga and Bailey 1986; Keane etal 
1985), terminal care nurses (Gray-Toft and Anderson 1986). Evidence of these stressors 
may not be easily detected by the GHQ or the BDI as most studies of stress in nursing tend 
to use specifically developed scales (e.g. Wolfgang 1988). However I had deliberately 
chosen to use nurses from all wards so as to avoid observing effects that would be limited 
to one type of nursing only.
If this study was repeated I would recommend the use of the Health Professions Stress 
Inventory as this would better reflect the stress that is actually perceived by the nurses 
(Wolfgang 1988).
Seasonality of the data
As samples from all nurses were taken at approximately the same time (up to 4 sample days 
per sample point) the data were already in a seasonal form. However no samples were 
taken from August to November so the time when lowest values might be expected (around 
September-November) was not actually available. Highest values for imipramine binding 
were seen around June/July, to my knowledge this has not been reported elsewhere and 
only represents a relatively small increase, (see fig 9.19)
High values for paroxetine binding were seen in December-January of the second year but
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not December of the first year. This suggests that the changes seen are due to some factor 
other than seasonality, (see fig 9.20).
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Figure 9.19
The graph below shows the effect of seasonality on the nurses imipramine binding 
The effect of season on nurses Imipramine binding
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Results are expressed as means +/- standard error of mean.
179
Figure 9.20
The graph below shows the effect of seasonality on the nurses paroxetine binding
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Results are expressed as means +/- standard error of mean.
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Discussion of seasonality data
There was no marked effect of season on impramine or paroxetine binding in these 
subjects. There was a slight oscillation in the imipramine binding over the year however it 
was not marked enough to really constitute seasonal changes. The two paroxetine values 
observed in December were so completely different that a seasonal influence on paroxetine 
binding would appear very unlikely from these results. However, as with the client and 
control data, it was not a primary aim of this project to look for seasonal changes and so the 
project was not designed to pick this up. In addition nurses work shifts, including nights, 
and this is likely to impact on any seasonal influences.
CONCLUSIONS
The first assumption that nurses would be more stressed than controls was not particularly 
well supported by these results. The questionnaire values indicated little or no psychiatric 
disorder in these subjects, however the imipramine and paroxetine binding results were 
strongly suggestive of depressive disorder.
Perhaps not surprisingly there was no clear correlation between psychiatric rating scales 
and the binding assays.
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CHAPTER 10
GENERAL DISCUSSION AND PROPOSALS FOR FUTURE WORK
In this thesis attention has focussed on the split between psychotherapy and 
pharmacotherapy. Whilst this split still exists it is encouraging to note that a growing area 
of overlap for the treatment of depression, particularly in the area of cognitive 
psychotherapy is developing. There is however a more alarming split evolving concerning 
the cause of depression. The protagonists in this argument are firstly those that believe that 
depression (and other psychiatric illnesses) are caused by the genetics of the individual, and 
secondly those that believe it is entirely environmental. This argument is as fundamental as 
that between psychotherapy and pharmacotherapy but it is potentially much more 
dangerous, and is not limited to disorders in mental function, but extends to areas such as 
intelligence as well (McGue 1989). It is generally accepted that a family history of 
depression will predispose the individual to depressive episodes themselves (Weissman 
1987), but the debate centres around whether mental illness is inherited, environmental o r , 
as some authors have argued a combination of both (Reveley et al 1985). This dichotomy 
shows no signs of resolving in the short term. In a recent article Baron (1991), who 
favours a genetic cause, argued against equal funding being given to the search for an 
environmental marker.
The search for a gene for depression has tended to concentrate on family linkage studies 
using genetic markers (McGuffin 1988 - review). Classical studies using markers such as 
red cell types and histocompatability antigens have failed to demonstrate any evidence of 
linkage (Goldin et al 1983). However with the arrival of recombinant DNA techniques a 
whole new spectrum opened up for those in search of a genetic link. In a now famous 
investigation of the Old Order Amish in the USA, Egeland et al (1987) claimed to have 
found strong evidence for linkage between bipolar depression and the H-ras locus on 
chromosome 11. However other workers have since excluded any evidence of such a 
linkage in Icelandic, Irish and North American pedigrees (Hodgkinson e ta l 1987; 
Detera-Wadleigh etal 1987; Gill gf aZ 1988; Mitchell etal 1991) and it has also proved
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impossible to identify any chromosome 11 linkage in unipolar disorder (Neiswanger et al 
1990; Wesner et al 1990) and the claim has been withdrawn as a statistical artifact (Kelsoe
1989). Those most determined to find evidence of genetic linkage have countered these 
findings with the argument that maybe bipolar disorder exists in more than one form 
(McGuffin 1988).
Needless to say the X-chromosome has not been left out of this argument, and several 
studies claim to have evidence of linkage of bipolar disorder to the X-chromosome (Baron 
et al 1987; Mendlewicz et al 1987; Mendlewicz 1991).However the data has been reviewed 
recently and the evidence is far from clear and may represent higher psychiatric morbidity 
or greater relapse rate rather than a direct link to the disease (Baron et al 1990). 
Interestingly if unipolar disorder is looked at in isolation, evidence of linkage is harder to 
find (Andreason et al 1986; Neiswanger et al 1990; Wesner et al 1990 ), in fact McGuffin 
and Katz (1989) are forced to make the conclusion that neurotic depression is "somewhat 
less genetically influenced than endogenous depression".
Work has also been conducted on families with high incidence of the more severe mental 
disorders such as schizophrenia and in this field too there has been limited success (Byerley 
1989; Detera-Wadleigh et al 1989). Seven pedigrees of families with multiple schizophrenia 
showed linkage of the illness to a gene on chromosome 5 (Sherrington et al 1988), 
however replication studies found no such linkage, and this claim too, has been withdrawn 
(Detera-Wadleigh et al 1989; Kennedy et al 1988). Some authors have argued that there 
may be a genetic tendency to develop the disease, but that it requires environmental factors 
for the disease state to become apparent (Goldin et al 1987: Freeman 1989). Other authors 
have argued strongly from a sociological point of view against the dangers of identifying a 
genetic link for schizophrenia and other disorders (Marshall 1986).
Belmaker (1991) argues five major points against the argument of one gene for each 
psychiatric illness. Firstly the affective disorders do not fit Mendelian patterns for 
inheritance. Secondly, identical twins of severe schizophrenic or manic depressive patients 
may be completely normal. Thirdly, risk figures for offspring of schizophrenic or manic
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depressive illness are only 10-20%, ie similar risk to polygenic illnesses such as 
hypertension. Fourthly, at least 50% of manic depressive or schizophrenic patients have no 
family history. And finally the boundaries of related disorders are so difficult to define that 
whatever factors cause the disease must represent a continuum. Thus if genes are involved 
it is likely to be several genes per psychosis, which is likely to make them very hard to 
identify. However Crow (1990a) has argued that in psychotic disorders this continuum 
could relate to changes at a single gene locus, possibly located on the sex chromosomes 
(Crow 1990b). The search for genetic causes of psychiatric illness continues to push 
forward and gene loci for major receptors involved in psychiatric disorders are currently 
being identified (Wahlstrom 1990).
It is reasonably well established that the families of depressed people are most likely to 
show elements of depressive disorder (Klein 1990). This familial association, however is 
probably more easily explained from an environmental point of view than by genetics. 
Alnaes and Torgerson (1990) investigated the amount of parental care given by depressed 
parents to their offspring. Not surprisingly they found that these parents, particularly those 
with mixed anxiety-depression had very low levels of parental care, the influence that this 
is likely to have on child-parent bonding is obviously significant. The effect of early life 
events on the individuals likelihood of developing depression is high (Gamefski et al
1990), and it is well established that certain forms of adversity such as threatening or 
unpleasant life events may result in the onset of depression (Brown and Harris 1978; 
Bebbington 1985; Brown et al 1987). These events need not be outwardly traumatic, but 
may be long lasting and the chronic influence may result in depression, e.g. employment 
status, motherhood (Brown and Bifulco 1990)
Another argument in favour of the environmental standpoint is the influence of external 
factors in the outcome of the disease e.g. poor family relationships and lack of a confidant, 
are likely to indicate a poor prognosis (Moos 1990). Coryell et al (1990) have 
demonstrated that single patients who were socially impaired as adolescents are less likely 
to make a full recovery. If environmental factors have such a major effect on outcome then 
it is also likely that they have a major influence on onset.
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Whilst it is not my intention to argue that there is no genetic involvement in the affective 
disorders, there may in fact be some genetic predisposition which makes some individuals 
more prone than others. I would like to argue that environmental factors clearly do exist, 
and it is these factors which can be most readily studied and acted upon, particularly by 
psychotherapy. I am not clear of how we will react if and when we find a gene for 
depression, but the sociological implications are enormous (Marshall 1988). Much of the 
arguments against psychotherapy have centred around the so called 'non-specific' aspects 
of treatment, which I would not dispute exist, but also exist in drug therapy. However I 
would argue that any disease that can be treated by non-specific methods is unlikely to have 
its origin on a single gene. The relevance of this to the current study really lies in 
interpretation of results. In the group of nurses we studied we clearly demonstrated 
according to biological markers that they had lower affect than the controls, and yet 
according to psychological questionnaires they had higher affect than the controls. The 
danger of rigid categorisation in biochemical or genetic terms would lead to the conclusion 
that they were depressed without realising it!. This is obviously incorrect and 
inappropriate.
I have discussed in earlier chapters the growth in evidence to support psychotherapy as a 
treatment for depression, and our results seem to support this view. However part of the 
reason for so determined a search for a biochemical cure (and also to some extent genetic 
linkage), lies in the ease with which that cure can be administered. The placebo effect in 
treatment of depressive illness is large and well established (Beckham 1989), and some 
authors have argued that psychotherapy is no more effective than placebo (e.g. The Lancet 
1984). What is clear is that the placebo effect in psychiatric disorders is much greater than 
in other areas of medicine. Sheperd (1984) argues that ultimately all psychotherapies come 
down to are responses to demands for reassurance, hope and support. If this is even partly 
true it would account for the large placebo effect seen in drug studies, but also argues very 
strongly for more care to be given to patients both in the treatment and prevention of 
depression.
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The costs of providing psychotherapeutic care to patients in addition to drug therapy need 
not be prohibitive. Group work (such as that used in this study) is very effective as are 
mutual self help groups (Marmar et al 1988) and combination of drug and psychotherapy 
is generally believed to be efficacious (Blackburn etal 1981; Beck etal 1985; Weissman 
1979; Gastpar 1989). The biggest problem presented by depressive illness is the fact that it 
is recurrent. Modest benefits have been cited for the long-term use of antidepressants and 
lithium (Cooper 1989; Persad 1989; Mindham et al 1973), but the role of psychotherapy in 
prevention of further recurrences is likely to be important, and has already been proven, at 
least to some extent (Shaw 1989; Miller et al 1989; Klerman 1989). The results of the 
psychotherapy part of this research indicated that recurrence rates were low (10.5% 
compared with reported results of 22% with tianeptine (Raffaitin eta l 1991) paroxetine 
14% (Jakovljevik and Mewett 1991)) and I have suggested that this is indicative of a real 
recovery rather than a temporary treatment of the symptoms. Frank and Kupfer (1985) 
have proposed that psychotherapy, either with or without pharmacotherapy presents a very 
important treatment option for the prevention of relapse. Additionally Aveline (1984) 
argues very convincingly that the danger of psychiatry without psychotherapy is that the 
biological label absolves both patient and doctor from the confusion and pain of exploration 
and comprehension. The danger of this being that only the symptoms will be treated and 
the underlying cause remain dormant. One factor that I have not discussed, but should be 
mentioned is the issue of spontaneous remission. Before the arrival of psychotropic 
medication or psychotherapy, mental hospitals did not overflow. This is because 
depression is a cyclic illness that will, given time, in the majority of cases, resolve itself 
and particularly in these mild patients is likely to be a significant factor in recovery.
In an extensive review, Joyce (1989) has investigated the role of non-specific treatment 
effects on outcome in pharmacotherapy and links them to expectation of outcome both from 
the doctor and the patient, and the type of patient you are dealing with. Therefore even in 
pharmacotherapy there is an acknowledged influence of psychological factors. As 
discussed above there is evidence for longterm efficacy of anti-depressants, and this form 
of treatment is less demanding in terms of resource, so why not just administer 
anti-depressants. The answer lies in two main areas, firstly, that it is likely that
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anti-depressants are only treating the symptoms rather than the cause, and secondly the 
potential toxicity of anti-depressant medication. This to some extent is being resolved by 
the reduced toxicity of modem antidepressants e.g. paroxetine (Dechant and Clissold 1991) 
but still represents a real problem (Cassidy and Henry 1987; Dziukas and Vohra 1991). 
However all antidepressant drugs still have side effects even though they are now less 
severe (Dechant and Clissold 1991). Rouillon (1991) has argued that under some 
circumstances antidepressants can worsen the course of affective illness while inducing 
mania or hypomania. Pharmacotherapy is undoubtedly important for the acute treatment of 
psychological disorders (e.g. Bakish et al 1989; Bradwejn 1989) but perhaps the future 
lies in the coexistence of psychotherapy and psychopharmacology for the treatment of the 
presenting illness and prevention of recunence.
What seems fairly clear from this work and previous work discussed earlier is that 
serotonergic function is in some way altered during unipolar depressive disorder. What still 
needs to be established is the biochemical link to the depressive symptoms that are evident 
in these patients. It is well established that antidepressant medication results in down
regulation of p-adrenergic receptors, and this down regulation corresponds with the onset 
of antidepressant efficacy (Baneijee etal 1977). More studies clearly need to be performed 
to evaluate the interaction between the noradrenergic and the serotonergic systems in 
depression.
Neurochemical theories of depression postulate functional deficits of one or more 
neurotransmitters at critical synapses in the brain. However attempts to prove decreases in 
monoamine metabolites in these patients have met with varied success e.g. Asberg et al 
(1984) demonstrated decreased 5-HIAA in CSF whereas Koslow et al (1983) found no 
differences between depressed subjects and controls. Hsiao and coworkers (1987) 
demonstrated that changes in CSF monoamine metabolites could be shown, but only in 
those patients who responded clinically to the antidepressants.Sulser (1982) has argued 
against a monoamine theory of depression on the basis that it cannot explain the delayed 
therapeutic action of tricyclics, the efficacy of 'atypical antidepressants, lack of 
antidepressant action of effective amine inhibitors such as cocaine, variation in clinical
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response of agents with similar effects on the amine systems, failure of 5-HTP, tryptophan 
or L-dbpa as antidepressants and finally why some antidepressant treatments decrease 
amine metabolism. Despite this however the serotonergic theory of depression is probably 
still the most favoured (Grahame-Smith 1989). A recent electrophysiological study in the 
rat has demonstrated that tricyclic antidepressants and ECT act by enhancing synaptic
transmission by increasing the sensitivity of post synaptic 5-HTia receptors. On the other 
hand 5-HT uptake blockers produce their effect by reducing the function of terminal 5-HT 
autoreceptors thereby increasing the amount of 5-HT released per action potential (Chaput 
etal 1991).
. The P-adrenergic theory of depression (ie that depression results from supersensitivity of
p-adrenoceptors) has a number of strengths. Firstly, virtually all antidepressant treatments
result in down regulation of p-receptors, and secondly that the timescale for this down 
regulation and antidepressant efficacy are the same. This may also account for the failure in 
our study to correlate imipramine binding with change in questionnaire Scores, we may
have been more successful if we looked at p-receptors. The weakness in this theory 
however lies in the fact that most of the data comes from animals (e.g. Baneijee et al 
1977; Chamey et al 1981), human data are few and rely on peripheral studies (e.g. Mann 
et al 1985) and studies on human post-mortem brains of suicides show increased binding
(Zarko and Beigen 1983). Also the mechanism by -which P-adrenergic receptor 
desensitisation occurs is poorly understood, although some workers have suggested it may 
result from a secondary response to enhanced noradrenalin at the synapse induced by
antidepressants (Sulser 1979). Another complicating factor is that p-adrenergic down 
regulation may be a secondary change as a result of desensitisation of alpha 2 receptors, or 
that the adrenergic receptor cyclase complex itself may be a target for antidepressant 
action..
The finding that the chronic administration of desipramine reduced the
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alpha-2-adrenoceptor inhibition of noradrenalin release in the rat brain (Spyrakic and 
Fibiger 1980), increased interest in the possible roles of these receptors in depression. 
Results of platelet binding studies have produced very variable results^ however Kafka and 
Paul (1986) have argued that these findings should be viewed with caution due to the 
uncertainty of the relationship of the ligand binding to the functional aspects of the 
adrenoceptor and also that increasing the number of binding sites does not necessarily 
indicate receptor desensitisation. More recently studies have utilised the the administration 
of neurotransmitter agonists and antagonists as challenges to study the presynaptic receptor 
system function in depression (Price et al 1986; Henninger et al 1988). These studies 
suggest that patients with major depressive disorder do not have marked abnormalities of 
alpha-2-adrenergic function.
Overall, however I would tend to support a dysregulation hypothesis (Nair and Sharma 
1989) where the homeostatic regulatory mechanism of one or more neurotransmitters 
becomes impaired. Within this hypothesis it is possible to account for the successful use of 
a wide range of antidepressants, as well as the varied results seen from binding and similar 
studies. I think it may be the balance of the neurotransmitters that is important rather than 
the actual amounts available. A recent report on the anti-depressant efficacy of 
carbamazapine implicates both noradrenaline and dopamine in its efficacy (Sluzewska
1991), whilst a PET scan study of dopamine and serotonin function in depressed subjects 
indicated abnormalities for both these compounds in depressives (Agren et al 1991) and a 
significant correlation between peripheral parameters of the two systems has been reported 
(Castrogiovanni et al 1989). It also appears that treatment with antidepressants enhances 
dopamine function (Maj et al 1988; Muscat et al 1990). Although the data for the 
involvement of dopamine are still quite weak the influence of noradrenaline seems quite 
clear possibly implicating a serotonergic-catecholaminergic regulatory mechanism (Plaznik 
et al 1989). The results we found in this study indicate changes in serotonergic function, 
but these changes do not correlate with psychometric tests. Perhaps if we had looked at
P-adrenoceptors we might have found a correlation. The future for work in this area must 
lie in the multiple assessment of neurotransmitter function (as was originally attempted in 
this study), rather than studies conducted in isolation. By studying covariables we may
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identify underlying control mechanisms which would not otherwise become apparent. In 
the meantime more research is required to investigate the underlying causes of depression 
from an environmental point of view to enable better cures and better preventative 
measures.
Future work
The first proposal I would make is that any future work involves the assessment of more
than one receptor type. Given the timescale of response of p-adrenoceptor function being 
approximately the same as the time taken for antidepressant efficacy to be apparent it might 
be more appropriate for these receptors to be monitored in further studies using 
lymphocytes (Mann et al 1985). Alternatively, there does seem to be reasonably clear 
evidence of decreased serotonergic function in depressed suicides from measurement of
5-HT2 receptors (Pandey et al 1990), and a method is now available using 3H-Ketanserin
to study these receptors in platelets, which has demonstrated a correlation of binding with 
clinical change (Bigeon era/ 1990).
Any future proposals for work to continue in this area must attempt as far as possible to 
reduce confounding variables. Experience gained from working on this project and results 
obtained from the Primal work, point to areas which could greatly be improved.
For example;
a) To obtain statistical significance a much greater sample size is required, this will 
necessitate involvement of more centres.
b) Greater selectivity of subjects and controls to ensure subjects are significantly more 
depressed than controls at the start of the study.
c) More detailed psychological data required (e.g. more extensive questionnaires or 
researcher administered questionnaires). Also information about recent life-events e.g. 
giving up smoking, moving house,etc
d) Subjects should, ideally, have a more similar history of therapy. All subjects taken onto
the study should be at the start of a period of therapy (or at a fixed time into therapy) and as
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far as possible should all be involved in the same amount of therapy, and similar quality 
therapy.
e) Increased number of samples per subject during the period of therapy. This would make 
it easier to exclude any widely different values obtained and allow a more clear overall 
picture to emerge.
A possible direction in which further work in this area could develop would be to seek 
cooperation from one or more groups of General Practitioners and psychotherapists in the 
following manner.
Firstly the G.P. would be asked to identify patients within their practise who were 
currently suffering from depression and receiving drug therapy. If considered appropriate 
by their G.P. these people would then be approached (by the G.P.) to determine whether 
they would be prepared to consider psychotherapy instead of drug therapy. If the patient 
was interested then consent would be obtained and the psychotherapists involved in the 
work would interview the subject to satisfy themselves of the persons suitability for 
psychotherapy.
At this point, if appropriate, the person would be accepted on to the study and after a 
minimum (preferably longer) two week washout period start receiving psychotherapy. 
Sampling of blood and questionnaires would also begin at this point. All subjects would 
receive once weekly group therapy for a period of six months, after this time if they 
wished to continue therapy they would have to make their own arrangements. During the 
period of therapy all subjects would be sampled every two weeks, then at three monthly 
intervals after the end of the therapy period for six months.
In summary this enables a group of people who are known to be depressed, to start a 
period of therapy, with the same therapist, at the same time. The study would allow 
monitoring of drug-free subjects in therapy for six months, with a six month follow-up 
period.
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If funds permitted, controls could be taken from a volunteer panel to give a more 
representative control sample than employees at the Open University.
In order to persuade sufficient numbers of people onto the study the cost of their therapy 
would have to come at least in part from the project budget (unless cognitive therapy was 
already available at the G.P.'s centre) and this would obviously be expensive. However if 
all the therapy was carried out in groups, and as much as possible, locally, in order to keep 
travelling expenses down, then the cost need not be prohibitive.
It should not prove impossible to interest centres involved in cognitive therapy to participate 
in a study of this nature.
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APPENDIX I
STANDARD CONTACT LETTER
LETTER TO PSYCHOTHERAPY CLIENTS
We are a  research group at the Open University in Milton Keynes, 
interested in discovering how a  person's biology might change during 
a  period of psychotherapy. Many theories claim that there is a 
relationship between a persons body chemistry and their mental 
s ta te  - and indeed the reason why some psychiatrists prescribe 
drugs to their patients is because the drugs are supposed to change 
the body chemistry in a way that changes and improves mental state. 
But up till now no one has tried to find out whether similar changes 
take place in people going through psychotherapy. If we could show 
that real changes did occur it would be very exciting scientifically, 
and it would go part of the way to showing how it is that 
psychotherapy can help people without using medically prescribed 
drugs.
The therapists at the Open Centre have very kindly agreed to help us 
take this research forward by telling their clients about it, and we 
are now ctively seeking volunteers to participate in the research. If 
you feel that the project sounds interesting and you would like to 
become involved, then p lease fill in the form at the end of this 
letter. Involvement in the project would require you to complete 3 
short questionnaires and have a small sample of blood taken on each 
of six occasions over the course of a  year. Blood withdrawal will be 
carried out by a properly qualified person using sterile equipment.
We aim to publish the general findings from the study in the 
scientific literature, but information about any individual will of 
course  be treated in the strictest confidence. Every volunteer 
entering the study will be coded by number only and their names will 
not be known or identifiable in any way. However if you would like a  
copy of your own results and/or the overall findings, these  can be 
made available to you at the end of the study.
If you would like more information about any aspect of the research 
please do not hesitate to contact me.
Sarah Willis Biology Dept.
I am interested in participating in the study
Name. Age.
Please return to: Sarah Willis 
Department of Biology 
The Open University 
Milton Keynes 
MK7 6AA
LETTER TO NURSES
We are a research group at the Open University in Milton Keynes, 
interested in discovering how a person's biology might change during 
a period of psychotherapy. Many theories claim that there is a 
relationship between a  persons body chemistry and their mental 
state - and indeed the reason why some psychiatrists prescribe 
drugs to their patients is because the drugs are supposed to change 
the body chemistry in a  way that changes and improves mental state. 
But up till now no one has tried to follow, the changes taking place in 
people whose work makes them more likely to experience anxiety or 
depression, and who don't receive anv form of treatment. If we could 
show that real changes  did occur it would be very exciting 
scientifically, and it would go part of the  way tow ards 
demonstrating the problems associated with stressful professions.
The therapists at the Open Centre have very kindly agreed to help us 
take this research forward by telling their clients about it, and we 
are now ctively seeking volunteers to participate in the research. If 
you feel that the project sounds interesting and you would like to 
become involved, then please fill in the form at the end of this 
letter. Involvement in the project would require you to complete 3 
short questionnaires and have a  small sample of blood taken on each 
of six occasions over the course, of a year. Blood withdrawal will be 
carried out by a  properly qualified person using sterile equipment.
We aim to publish the general findings from the study in the 
scientific literature, but information about any individual will of 
course  be treated  in the strictest confidence. Every volunteer 
entering the study will be coded by number only and their names will 
not be known or identifiable in any way. However if you would like a 
copy of your own results and/or the overall findings, these  can be 
made available to you at the end of the study.
If you would like more information about any aspect of the research 
please do not hesitate to contact me.
Sarah Willis Biology Dept.
am interested in participating in the study
Name. Age.
Tel No. Ward.
P lease return to:- Sarah Willis 
Department of Biology 
The Open University 
Milton Keynes 
MK7 6AA
LETTER TO CONTROLS
We are a  research group at the Open University in Milton Keynes, 
interested in discovering how a  person's biology might change during 
a  period of psychotherapy. Many theories claim that there is a 
relationship between a  persons body chemistry and their mental 
s ta te  - and indeed the reason why som e psychiatrists prescribe 
drugs to their patients is because the drugs are supposed to change 
the body chemistry in a  way that changes and improves mental state. 
But up till now no one has tried to find out whether similar changes 
take place in people going through psychotherapy. If we could show 
that real changes did occur it would be very exciting scientifically, 
and it would go part of the way to showing how it is that 
psychotherapy can help people without using medically prescribed 
drugs.
We now require people not currently participating in psychotherapy 
to act a s  'controls'. If you feel that the project sounds interesting 
and you would like to become involved, then please fill in the form 
at the end of this letter. Involvement in the project would require 
you to complete 3 short questionnaires and have a  small sample of 
blood taken on each of six occasions over the course of a year. Blood 
withdrawal will be carried out by a  properly qualified person using 
sterile equipment.
We aim to publish the general findings from the study in the 
scientific literature, but information about any individual will of 
course  be treated in the strictest confidence. Every volunteer 
entering the study will be coded by number only and their names will 
not be known or identifiable in any way. However if you would like a 
copy of your own results and/or the overall findings, these can be 
made available to you at the end of the study.
If you would like more information about any aspect of the research 
please do not hesitate to contact me.
Sarah Willis Biology Dept.
am interested in participating in the study
Name. Age.
Please return to:- Sarah Willis 
Department of Biology 
The Open University 
Milton Keynes 
MK7 6AA
APPENDIX II
GENERAL HEALTH QUESTIONNAIRE -28
THE 
GENERAL HEALTH 
QUESTIONNAIRE
GHQ28
David Goldberg
Please read this carefully.
We should like to know if you have had any medical complaints and how your health has been In 
general, over the past few weeks. Please answer ALL the questions on the following pages simply by 
underlining the answer which you think m ost nearly applies to  you. Remember that w e  want to  know  
about present and recent complaints, not those that you had in the past.
it is important that you try to answer ALL the questions.
Thank you very much for your co-operation.
Have you recently
— been feeling perfectly well and in Better Same Worse Much worse
i good health? than usual as usual than usual than usual
A2 been feeling in need of a good Not No more Rather more Much more
tonic? atall than usual than usual than usual
A3 been feeling run down and out of Not No more Rather more Much more
sorts? atall than usual than usual than usual
A4 felt that you are ill? Not No more Rather more Much more
atall than usual than usual than usual
A5 been getting any pains in Not No more Rather more Much more
yourhead? atall than usual than usual than usual
A6 been getting a feeling of tightness Not No more Rather more Much more
or pressure in your head? atall than usual than usual than usual
A7 been having hot or cold spells? Not No more Rather more Much more
» atall than usual than usual than usual
B1 lost much sleep over worry? Not No more Rather more Much more
atall than usual than usual than usual
B2 had difficulty in staying asleep Not No more Rather more Much more
once you are off? atall than usual than usual than usual
B3 felt constantly under strain? Not No more Rather more Much more
atall than usual than usual than usual
B4 been getting edgy and Not No more Rather more Much more
bad-tempered? atall than usual than usual than usual
B5 been getting scared or panicky Not No more Rather more Much more
for no good reason? atall than usual than usual than usual
B6 found everything getting on Not No more Rather more Much more
top of you? atall than usual than usual than usual
B7 been feeling nervous arid Not No more Rather more Much more
strung-up all the time? atall than usual than usual than usual
Cl — been managing to keep yourself 
busy and occupied?
More so 
than usual
Same 
as usual
Rather less 
than usual
Much less 
than usual
02 - been taking longer over the things 
you do?
Quicker 
than usual
Same 
as usual
Longer 
than usual
Much longer 
than usual
03 - felt on the w hole you were doing 
things well?
Better 
than usual
About 
the sam e
Less well 
than usual
Much 
less well
0 4 - been satisfied with the way  
you've carried out your task?
More
satisfied
About sam e 
as usual
Less satisfied 
than usual
Much less 
satisfied
05 - felt that you are playing a useful 
part in things?
More so 
than usual
Sam e 
as usual
Less useful 
than usual
Much less 
useful
06 - felt capable of making decisions 
about things?
More so 
than usual
Sam e 
as usual
Less so 
than usual
Much less 
capable
07 - been able to  enjoy your normal 
day-to-day activities?
More so 
than usual
Same 
as usual
Less so 
than usual
Much less 
than usual
D1 -  been thinking of yourself as a Not No more Rather more Much more
worthless person? atall than usual than usual than usual
D2 -  felt that life is entirely hopeless? Not No more Rather more Much more
atall than usual than usual than usual
D3 -  felt that life isn't worth living? Not No more Rather more Much more
atall than usual than usual than usual
D4 -  thought of the possibility that you Definitely 1 don't Has crossed Definitely
might make away with yourself? not thinkso my mind have
D5 -  found at tim es you couldn't do Not No more Rather more Much more
anything because your nerves 
were too bad?
atall than usual than usual than usual
D6 -  found yourself wishing you were Not No more Rather more Much more
dead and away from it all? atall than usual than usual than usual
D7 -  found that the idea of taking your Definitely 1 don't Has crossed Definitely
own life kept coming into your mind? not thinkso my mind has
G
B 0 D TOTAL
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APPENDIX III
BECK DEPRESSION INVENTORY
NAME .(THIS WILL BE REMOVED LATER)
DATE
CODE .(PLEASE LEAVE THIS BLANK)
INSTRUCTIONS:
In each group of statements below, choose the one which best describes how you feel at 
the moment, and draw a circle round the number at the left of the statement.
A 0 I do not feel sad
1 I feel blue or sad
2a I am blue or sad all the time and I can't snap out of it
2b I am so sad of unhappy that it is very painful .
3 I am so sad or unhappy that I can't stand it
B 0 I am not particularly pessimistic or discouraged about the future
1 I feel discouraged about the future
2a I feel I have nothing to look forward to
2b I feel that I won't ever get over my troubles
3 I feel that the future is hopeless and that things cannot improve
C 0 I do not feel like a failure
1 I feel I have failed more than the average person
2a I feel that I have accomplished very litde that is worthwhile or that means anything
2b As I look back on my life all I can see is a lot of failures
3 I feel I am a complete failure as a person (parent, husband,wife)
D 0 I am not particularly dissatisfied
la I feel boied most of the time
lb I don’t enjoy things the way I used to
2 I don't get satisfaction out of anything any more
3 I am dissatisfied with everything
E . 0 I don't feel particularly guilty
1 I feel bad or unworthy a good part of the time
2a I feel quite guilty
2b I feel bad or unworthy practically all the time now
3 I feel as though I am bad or worthless
F O I  don't feel I am being punished
1 I have a feeling that something bad may happen to me
2 I feel I am being punished or will be punished
3a I feel I deserve to be punished
3b I want to be punished
G 0 I don't feel disappointed in myself
la I am disappointed in myself
lb I don't like myself
2 i am disgusted with myself
3 I hate myself
H O I  don't feel I am any worse than anybody else
1 I am very critical of myself for my wealmesses or mistakes
2a I blame myself for everything that goes wrong
2b I feel I have many bad faults
I 0 I don't have any thoughts of harming myself
1 I have thoughts of harming myself but I would not cany them out
2a . I feel I would be better off dead
2b I have derinite plans about committing suicide
2c I feel my family would be better off if I were dead
3 I would kill myself if I could
J 0 1 don't cry any more than usual
1 I cry more than I used to
2 I cry all the time now, I can't stop it
3 I used to be able to cry but now I can't cry at all even though I want to
K 0 I am no more irritated now than I ever am
1 I get annoyed or irritated more eaily than I used to
2 I feel irritated all the time
3 I don't get irritated at all at things that used to irritate me
L 0 I have not lost interest in other people
1 I am less interested in other people now than I used to be
2 I have lost most of my interest in other people and have little feeling for them
3 I have lost all my interest in other people anû don't care about them at all
M 0 I make decisions about as well as ever
1 I am less sure of myself now and try to put off making decisions
2 I can't make decisions any more without help
3 I can't niake decisions at all any more
N 0 I don't feel I look any worse than I used to
1 lain  worried that I am looking old or unattractive
2 I feel that there are permanent changes in my appearance and they make me look 
unattractive
3 I feel that I am ugly or repulsive looking
O 0 I can work about as well as before
1 a It takes extra effort to get started at doing something
1 b I don't work as well as I used to
2 I have to push myself very hard to do anything
3 I can't do any work at all
P 0 I can sleep as well as usual
1 I wake up more tired in the morning than I used to
2 I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
3 I wake up early every day and can't get more than 5 hours sleep
Q 0 I don't get any more tired than usual
1 I get tired more easily than I used to
2 . I get tired from doing nothing
3 I get too tired to do anything
R . 0 My appetite is no worse than usual
1 . My appetite is not as good as it used to be
2 My appetite is much worse now
3 I have no appetite at all any more
s 0 I haven’t lost much weight, if any, lately
1 I have lost more than 5 lbs
2 I have lost inore than 10 lbs
3 I have lost more than 15 lbs
T 0 I am no more concerned about my health than usual
. 1 I am concerned about aches and pains, or upset stomach, or constipation or other
unpleasant feelings in my body
2 I am so concerned with how I feel or what I feel that its hard to think of mlich else
3 I am completely absorbed in what I feei
U 0 1 have not noticed any mcent change in my interest in sex
1 I am less interested in sex than I used to be
2 I am much less interested in sex now
3 I have lost interest in sex completely
)
APPENDIX IV
MULTIPLE AFFECT ADJECTIVE CHECKLIST
»
»
MULTIPLE AFFECT ADJECTIVE CHEQK LIST
DIRECTIONS: On this sheet you will find words which describe differentkinds of 
moods & feelings. Mark an X in the boxes beside the words which describe hdW 
you feel at the present time. Some of the words may sound alike, but we want you to 
maik aU the words that describe your feelings. ^
Please work rapidly.
1 active 45 fit 89
2 adventurous • 46 forlom 90
3 affectionate 47 frank 91
4 afraid 48 free 92
5 agitated 49 friendly 93
6 agreeable 50 frightened 94
•7 aggressive
alive
51 funous 95
8 52 gay 96
9 alone 53 gentle 97
10 amiable 54 glad 98
11 amused 55 gloomy 99
12 angry 56 good 100
13
14
annoyed
awful
. 57 
58
good-natured 
gnm .
101
102
—
15 bashful 59 103
16 bitter 60 iealthv 104
17 blue 61 hopeless 105
18 bored 62 hostile 106
19 calm 63 impatient 107
20 cautious 64 incensed 108
21 cheerful 65 indignant 109
22 clean 66 inspired 110
23 . complaining 67 interested 111
24 contefated 68 irritated 112
25 contrary 69 jealous 113
26 cool 70 oyful . 114
27 cooperative 71 kindly 115
28 critical 72 lonely 116
29 cross 73 lost 117
30 cmel 74 loving 118
31 daring 75 low 119
32 desperate . 76 lucky 120
33 destroyed 77 mad 121
34 devoted 78 mean 122
35 disagreeable 79 meek 123
36 discontented . 80 merry 124
37 discouraged 81 mild 125
38 disgusted 82 miserable 126
-39 displeased -• ■ -  -  '83- nervous ‘ -127 : ■
40 energetic 84 obliging 128
41 enraged 85 offended 129
42 enthusiastic 86 outraged 130
43 feai^l 87 panicky 131
44 fine 88 patient 132
peaceful .
pleased
pleasant
polite
powerful
quiet
reckless
rejected '
rough
safe . 
satisfied 
secure : 
shaky 
shy
soothed
steady,
stubiiorn
stormy
strong
suffering
sullen
sunk
sympathetic
tame :
tender
tense
terrible
terrified.
thoughtful
timid
tormented
understanding
unhappy
unsociable
upset
vexed
warm
whole
wild
willful
wilted
worrying
young
APPENDIX V
THERAPISTS REPORT
THERAPISTS REPORT
CLIENT:
NUMBER OF WEEKS IN THERAPY: DATE:
1
DEPRESSION
11
not at all
1
depressed
depressed ''
Please mark the line above according to how depressed the client is,
in your opinion at the present time
ANXIETY
1 1
not at all
1
anxious
anxious
Please mark the line above according to how anxious the client is; in
your opinion at the present time
COMMENTS
If there are any other points you would like to make please list theg; below
